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ABSTRACT
DEFINING THE LET-7 MICRORNA-MEDIATED MOLECULAR
MECHANISMS REGULATING T CELL DIFFERENTIATION
MAY 2020
CONSTANCE ANGELOU, B.S., UNIVERSITÉ CATHOLIQUE DE LOUVAIN
M.S., UNIVERSITÉ CATHOLIQUE DE LOUVAIN
PH.D. UNIVERSITY OF MASSACHUSETTS, AMHERST
Directed by: Leonid A. Pobezinsky, Ph.D.
CD4+ and CD8+ T cells are lymphocytes of the adaptive immune system that play
essential roles in immunity. Both T cell subsets recognize their cognate antigen through
the T cell receptor (TCR), which induces the proliferation and differentiation of these
antigen-specific cells into effector T cells. CD4+ T cells have the potential to differentiate
into one of multiple lineages of helper T (Th) cells and participate indirectly in antigen
clearance by orchestrating the function of other cells. CD8+ T cells differentiate into
cytotoxic T lymphocytes (CTL), which directly contributes to the resolution of an
infection by killing cancerous or virally-infected cells. Upon antigen clearance, most
effector T cells die, but some survive and generate long-lived memory T cells that will
respond faster and more efficiently to subsequent encounters with the same antigen.
When antigen fails to be cleared, such as in chronic infections and cancer, effector T cells
are diverted into a hyporesponsive state, exhaustion, characterized by the upregulation of
co-inhibitory receptors that transmits inhibitory signals resulting in the loss of effector
function and memory potential. Moreover, when T cell differentiation is dysregulated, T
cell responses become aberrant, causing autoimmune diseases. Therefore, understanding
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the molecular mechanisms controlling T cell responses is important to develop innovative
treatments that can enhance T cell activity during infections and cancer, and dampen the
generation of disease-causing T cells in autoimmunity. We have uncovered a novel posttranscriptional mechanism regulating T cell differentiation. Particularly, we showed that
the let-7 family of miRNAs is highly expressed in naive T cells, but gets dramatically
downregulated upon antigen encounter, proportionally to both the strength and duration
of TCR stimulation. Specifically, let-7 downregulation was required for the
differentiation of pathogenic Th17 cells in experimental autoimmune encephalomyelitis
(EAE), a mouse model of the autoimmune disease multiple sclerosis (MS). In CD8+ T
cells, although let-7 inhibits CTL differentiation in vitro, let-7 was demonstrated both in
silico and in vivo to promote memory CD8+ T cell formation, while repressing the
differentiation of terminal effectors, which are susceptible to exhaustion. Thus, let-7
constitutes a promising tool for the therapeutic manipulation of T cell responses.
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CHAPTER 1
INTRODUCTION

1.1 The immune system
The immune system comprises numerous types of bone marrow-derived
(hematopoietic) cells that have evolved to recognize and react to foreign substances,
known as antigens (Janeway, 1992; Medzhitov, 2007). The immune system’s reaction, or
immunity, constitutes the body’s defense against diseases caused by infectious pathogens,
such as viruses, bacteria, protozoa, fungi, and parasites, as well as cancer (Janeway et al.,
2017). The immune system can be divided into two distinct, but intertwined, components
– the innate and adaptive immune systems (Figure 1.1) (Vivier & Malissen, 2005). The
innate immune system is a series of broad and immediate defense mechanisms that serve
as a first physical and chemical line of defense against pathogens that gets established
within minutes after the onset of infection. Innate defense mechanisms consist of physical
barriers or epithelia (e.g. skin, oral mucosa, respiratory epithelium, intestine), as well as
circulating antimicrobial proteins, and innate immune cells. Innate immune cells include
granulocytes, macrophages, dendritic cells, innate lymphoid cells, and natural killer cells,
which recognize a wide variety of pathogen- or damage-associated molecules (Akira et
al., 2006; Bird et al., 2018). The adaptive immune system is unique to vertebrates, and
encompasses B and T cells, which express surface receptors that specifically recognize
individual immune determinants, or epitopes, on antigens (Burnet, 1959; Pancer &
Cooper, 2007). Adaptive immunity gets activated by antigen-presenting cells, such as
dendritic cells, when pathogens resist to innate immune responses, and participates in
pathogen elimination by using processes that specifically target antigen-expressing
1

pathogens (Busso, 2008; Iwasaki & Medzhitov, 2015). B cells develop in the bone
marrow, and contribute to immune responses through the production of antibodies
(humoral immunity), while T cells mature in the thymus and secrete effector molecules
and cytokines which contribute either directly or indirectly to pathogen clearance (cellular
immunity) (Waksman et al., 1962; Ryser & Vassalli, 1974; Spits, 2002; Cooper, 2015).
Unlike the innate immune system, adaptive immune responses are slower, as adaptive
immune cells need to differentiate and acquire their function after responding to presented
antigen. However, the duration of these responses lasts longer and results, after the
resolution of an infection, in the formation of long-lived memory cells. These memory
cells respond faster, with higher affinity, and more efficiently upon subsequent exposures
to the same antigen (Figure 1.2) (Hammarlund et al., 2003).

1.2 T lymphocyte development in the thymus
T lymphocyte progenitors are generated following Notch signaling in common
lymphoid progenitors in the bone marrow and then migrate to the thymus where they
become thymocytes and develop into mature T cells (Figure 1.3) (Kondo et al., 1997;
Pui et al., 1999; Spits, 2002). The thymus is also the site where thymocytes acquire their
lineage identity, characterized by the mutually exclusive surface expression of the coreceptors CD4 and CD8, which will determine whether the generated mature T cells will
have the potential to differentiate into helper CD4+ T (Th) cells or CD8+ cytotoxic T
lymphocytes (CTLs) (Singer et al., 2008). At the beginning of thymic education,
thymocytes are double-negatives (DN), as they do not express any of these surface coreceptors, and undergo irreversible random genetic recombinations of T cell receptor
(TCR) gene segments, thereby generating a broad diversity (repertoire) of different
2

antigen-specific TCR from only a limited pool of gene segments (Davis & Bjorkman,
1988; Engel & Hedrick, 1988). Each thymocyte then expresses a unique TCR that is
transmitted to its progeny, or clone. After productive TCR rearrangement, thymocytes
upregulate both co-receptors, thereby becoming double-positives (DP), and are subjected
to repertoire (positive) selection (Nikolić-Žugić, 1991; Mombaerts et al., 1992; Starr et
al., 2003). During this process, thymocytes interact with thymic epithelial cells, which
express self-peptide antigens presented on major histocompatibility complex (MHC)
molecules (Scott et al., 1989; Anderson et al., 1996). Thymocytes that fail to recognize
self-MHC die “by neglect”, while cells that are able to do so are positively selected and
thus receive survival signals, thus establishing an MHC-restricted T cell repertoire (Klein
et al., 2014). Positively selected thymocytes subsequently go through the process of
negative selection, during which thymocytes that have too strong of an affinity for selfpeptides receive apoptotic signals, resulting in the deletion of these potentially harmful
autoreactive T cells (Ashton-Rickardt et al., 1994). During the same process, DP
thymocytes also transition to an intermediate stage during which CD8 gets
downregulated, and CD4 versus CD8 lineage commitment occurs following mutually
exclusive signaling events (Brugnera et al., 2000). Persistence of positively selecting
TCR signals induces the transient expression of the transcription factor ThPOK and
results in the generation of single-positive CD4+ T cells (He et al., 2005; Luckey et al.,
2014). In contrast, cessation of TCR signaling following positive selection allows
thymocytes to respond to the cytokine IL-7, the signaling of which drives the upregulation
of the transcription factor Runx3, leading to ThPOK repression, co-receptor reversal, and
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commitment of intermediate thymocytes to the CD8+ T cell lineage (Sato et al., 2005;
McCaughtry et al., 2012).
The goal of T cell development in the thymus is thus to produce a functional pool
of mature MHC-restricted and self-tolerant mature T cells with distinct differentiation
potentials. After thymic education, mature T cells exit the thymus and migrate to
secondary lymphoid organs, such as the spleen and lymph nodes (McCaughtry et al.,
2007).

1.3 T cell differentiation
1.3.1 Activation of naive T cells
Mature T lymphocytes that migrate to the secondary lymphoid organs after
developing in the thymus are naive and appear small and round, with a low cytoplasmto-nucleus ratio (Donnadieu et al., 1994). Naive T cells are antigen-inexperienced and
exist in an inactive, or quiescent, state defined by rare mitotic divisions, minor
transcriptional activity, and absence of any effector function (Hamilton & Jameson,
2012). Because of their low activity level, naive T cells have limited metabolic needs,
which they fulfill by using oxidative phosphorylation as the predominant metabolic
pathway (Chapman et al., 2020). Although devoid of any effector function, naive T cells
constitute a sustained homeostatic pool of potential effector cells that will only acquire
their function upon antigen recognition, thereby avoiding any spontaneous activity that
could become detrimental to the host and would result in the depletion of the naive T cell
reservoir (Tzachanis et al., 2004).
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Antigen presentation to antigen-specific naive T cells initiates effector T cell
differentiation with T cell activation, a process achieved by the combination of three
distinct, but synergistic signals (Figure 1.4) (Smith-Garvin et al., 2009). The first signal
directly derives from the recognition of the cognate antigen presented on MHC molecules
(Cone, 1981). MHC class I is recognized by CD8+ T cells and is expressed by all
nucleated cell types, while CD4+ T cells recognize MHC class II, which is expressed only
on antigen-presenting cells (APCs), such as dendritic cells, macrophages, and B cells, as
well as by thymic epithelial cells (Rudolph et al., 2006). Antigens recognized by CD4+ T
cells consist of exogenous peptides that get processed in acidified endocytic vesicles
(endocytic pathway) into fragments of up to 18 residues-long, whereas CD8+ T cells
recognize short, 8-10 residues-long endogenous peptides generated in the cytosol (Stern
& Wiley, 1994). The interaction between the TCR and peptide-antigen:MHC complex is
stabilized by co-receptor binding to constant domains on MHC molecules (Gao et al.,
2002). This interaction further induces conformation changes in the intracellular portion
of the co-receptor, which is connected to the kinase Lck, and brings Lck close to the
immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3 complex, which
constitutes the signaling component of the TCR (Samelson et al., 1986; Artyomov et al.,
2010). Lck phosphorylates the CD3 ITAMs, which trigger TCR signaling, a highly
complex series of signal transduction pathways that initiate T cell activation
(Glaichenhaus et al., 1991). These pathways promote the nuclear translocation and
subsequent activity of transcription factors that are already expressed in naive T cells, but
remain in the cytosol in an inactive state until they receive activating signals to translocate
into the nucleus and transcribe genes required for the initiation of T cell differentiation
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(Figure 1.5). For instance, calcium influx, triggered upon TCR stimulation, activates
calmodulin, which interacts with and thereby activates the phosphatase calcineurin (Jain
et al., 1993). In turn, calcineurin dephosphorylates the transcription factor NFAT, which
is initially sequestered in the cytoplasm, thereby enabling NFAT nuclear translocation
and transcriptional activity. Similarly, the MAPK pathway leads to c-Jun
phosphorylation, which interacts with phosphorylated c-Fos in the nucleus to form the
active transcriptional complex AP-1 (Maciàn et al., 2001). Notably, NFAT and AP-1, by
binding to common gene promoters, enhance the strength of TCR activation (Maciàn,
2005). On the other hand, the transcription factor NF-κB is kept in the cytoplasm when
bound to the inhibitor IκB. TCR signaling events induce the phosphorylation and
subsequent degradation of IκB, which enables the translocation of NF-κB to the nucleus,
where it drives the transcription of target genes (Schulze-Luehrmann & Ghosh, 2006).
Enabling the transcriptional activity of these three transcription factors thus initiates the
expression of genes required for effector T cell differentiation in a timely manner, which
is critical to achieve efficient T cell responses.
The second signal results from interactions between co-stimulatory ligands and
receptors, such as the CD28 receptor on the T cell and molecules of the B7 family on
APCs, and leads to the amplification of the TCR signal, and in the generation of
mitogenic, metabolic, and survival signals (Boise et al., 1995; Pagès et al., 1996, Vella et
al., 1998; Frauwirth et al., 2002). In fact, absence of co-stimulation during T cell
activation elicits a dysfunctional state known as anergy (Harding et al., 1992).
The third signal is mediated by cytokines, which are secreted by multiple immune
and non-immune cell types, including APCs, and differ in nature according to the type of
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pathogen detected by the host (Curtsinger et al., 1999). For instance, CD28-dependent
co-stimulation of activated T cells leads to the expression of IL-2 and the IL-2 receptor
high-affinity chain, IL-2Rα, also known as CD25. Binding of IL-2 to its high-affinity
receptor is critical during early T cell activation as it promotes T cell survival, growth,
and clonal expansion (Pape et al., 1997, Refaeli et al., 1998). Cytokine signaling also
plays a decisive role in the acquisition of effector T cell function, which will be discussed
later.

1.3.2 Metabolic reprogramming and proliferation
In response to these three stimulatory signals, activated T cells exit quiescence
and undergo dramatic transcriptional, morphological, and metabolic transitions, as they
prepare to rapidly proliferate in order to produce a large progeny of antigen-specific
effector T cells that will mount an efficient response against the antigen (Butz & Bevan,
1998; Frauwirth et al., 2002). The intensified rates of RNA and protein synthesis result
in the accumulation of newly produced molecules in the cytoplasm of activated T cells,
which leads to cell growth characterized by a greater cytoplasm-to-nucleus ratio
(Donnadieu et al., 1994). The exit of activated T cells from quiescence is also marked by
their entry into the cell cycle, which promotes the rapid expansion of antigen-specific T
cell clones (Butz & Bevan, 1998). This increased cellular activity requires greater
amounts of energy and biomacromolecules, which activated T cells satisfy by switching
their metabolism from oxidative phosphorylation to glycolysis. In addition to providing
ATP more rapidly, glycolysis also results in the production of a large variety of
metabolites necessary for the cellular processes needed for T cell proliferation and
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functional differentiation, including DNA replication and biomacromolecules synthesis
(Chapman et al. 2020).
The initiation of the metabolic switch and cell cycle entry requires the expression
of the transcription factor Myc, which is rapidly induced upon T cell activation by both
TCR and co-stimulatory signals, and enhanced by IL-2 signaling at later stages of T cell
activation (Reed et al., 1985; Wang et al., 2011). On the one hand, Myc drives the
expression of glucose transporters and glycolytic enzymes, which contributes to increased
glucose uptake and ATP production by glycolysis. On the other hand, Myc also directly
induces the expression of cyclins, cyclin-dependent kinases, and transcription factor of
the E2F family, while repressing cell cycle inhibitors, thereby promoting cell cycle
progression from the G1 to S phase (Grandori & Eisenman, 1997). However, because the
continuous expression of Myc is detrimental to T cell survival, Myc is only expressed in
a transient manner, but its activity is preserved by upregulation of the transcription factor
AP-4, a direct Myc target gene which maintains the metabolically active and proliferative
state of differentiating T cells after Myc downregulation (Butz & Bevan, 1998; Chang et
al., 2000; Hoffman & Liebermann, 2008; Jung et al., 2008; Chou et al., 2014).

1.3.3 The acquisition of effector T cell function
1.3.3.1 CD4+ helper T cells
As mentioned earlier, cytokine signaling plays an important role in the acquisition
of effector T cell function. In the case of CD4+ T cells, which have the potential to
differentiate into one of several helper T (Th) cell lineages, cytokines present during
CD4+ T cell activation play a central role in inducing specific Th differentiation programs
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(Zhu et al., 2010). Each Th cell subset is tailored to respond effectively to distinct types
of pathogens, as they each express a signature transcription factor which controls the
expression of specific cytokines (Figure 1.6) (Zhu & Paul, 2008). The cytokines IL-12
and IFNγ drive the Th1 differentiation program, which is characterized by the expression
of the transcription factor T-bet and secretion the cytokine IFNγ. Th1 cells contribute to
the clearance of intracellular pathogens and tumor cells by promoting the phagocytic
activity and antigen-presenting function of macrophages, as well as the function of CD8+
cytotoxic T lymphocytes (CTLs) (Hsieh et al., 1993; Szabo et al., 2000; Lighvani et al.,
2001). Th2 differentiation is induced by IL-4 signaling, which induces the expression of
the transcription factor GATA-3 and secretion of the cytokines IL-4, IL-5, and IL-13. Th2
cells activate eosinophils, basophils, and mast cells, and elicit mucus secretion in goblet
cells and smooth muscle contraction, all of which work towards the elimination of
extracellular pathogens (Swain et al., 1990; Zheng et al., 1997, Kishikawa et al., 2001;
Min et al., 2004). The Th17 lineage is promoted by IL-6 in combination with TGF-β,
which drives RORγt expression, secretion of IL-17, IL-21, and IL-22, and helps in the
clearance of mucosal bacteria and fungi by activating neutrophils and inducing
antimicrobial peptide secretion in epithelial cells (Aggarwal et al., 2003; Mangan et al.,
2006; Zhou et al., 2007; Yang et al., 2008). Follicualr T (TFH) cells are generated upon
exposure to IL-6 alone, express the transcription factor Bcl-6, and can secrete different
cytokines, depending on the type of immune response, including IL-21, IFNγ, IL-4, IL5, and TGF-β (Yu et al., 2009). The role of TFH cells is to specify the production of highaffinity antigen-specific antibodies of the appropriate isotype by B cells, phenomena
known as somatic hypermutation and immunoglobulin isotype switching, which are
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dependent on the interaction between the co-stimulatory molecules CD40 and CD40L
(Kawabe et al., 1994; Xu et al., 1994). Thus, through cytokine secretion and cell-cell
interactions, Th cells play a critical role in the establishment, coordination, and
potentiation of adaptive immune responses by enabling or enhancing the function of
immune and non-immune cells, as well as by attracting appropriate immune cells to the
site of infection, hence their “helper” appellation. A distinct type of effector CD4+ T cells,
regulatory T (Treg) cells, are induced upon exposure to TGF-β and IL-2, express FOXP3,
and secrete the immunosuppressive cytokines IL-10 and TGF-β to regulate the magnitude
and intensity of immune responses and prevent detrimental consequences on the host
(Sakaguchi et al., 1995; Chen et al., 2003; Fontenot et al., 2003; DiPaolo et al., 2007; Kim
et al., 2007). The regulation of Th cell responses is essential, as spontaneous or sustained
Th cell activity can result in the development of pathologies, such as hypersensitivities
and autoimmune disorders (Ohashi, 2002). However, despite undergoing negative
selection in the thymus and being kept in check by Tregs, some autoreactive T cell clones
are able to escape these regulatory mechanisms and drive autoimmune diseases upon
recognition of self-peptide antigens (Yui et al., 1990; Kariv et al., 1993).

1.3.3.2 CD8+ cytotoxic T lymphocytes
Following antigen encounter, CD8+ T cells differentiate into cytotoxic T
lymphocytes (CTLs) in the presence of the cytokine IL-2 (Andrus et al., 1984). As the
name suggests, CTLs are able to kill targets cells, specifically those infected by
intracellular pathogens, such as viruses, or that are cancerous, thus directly contributing
to infection clearance (Figure 1.7) (Sawamura et al., 1989; Dharakul et al., 1990; Harty
et al., 1992; Rodrigues et al., 2003). Differentiation of naive CD8+ T cells into CTLs
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requires a complex regulatory interplay between the transcription factors Notch, Runx3,
T-bet, Eomesodermin (Eomes), Blimp-1, Id2, and Zeb2 (Pearce et al., 2003; Sullivan et
al., 2003; Cannarile et al., 2006; Cho et al., 2009; Cruz-Guilloty et al., 2009; Kallies et
al., 2009; Backer et al., 2014; Dominguez et al., 2015). This differentiation program
induces the expression by CTLs of the effector molecules Perforin, Granzyme A, and
Granzyme B, as well as the death receptor ligand FasL, and the cytokines IFNγ and TNFα
(Ruby & Ramshaw, 1991; Suda & Nagata, 1994; Janas et al., 2005, Brehm et al., 2005).
Effector molecules are contained within lysosome-derived structures, called secretory
granules, and mediate direct cytolysis of target cells upon release, which is triggered upon
antigen recognition by CTLs on target cells through TCR:MHC I interactions, a process
known as degranulation (Peters et al., 1991). Degranulation involves the reorientation of
the Golgi apparatus towards the target cell, where perforin forms a pore in the target cell
membrane to enable the entry of the proteases Granzymes A and B (Masson & Tschopp,
1985). Granzyme A is a tryptase that can initiate caspase-independent cell death by
cleaving NDUFS3, a protein from complex I of the mitochondrial electron chain,
resulting in the disruption of the NADH oxidation process and reactive oxygen species
production (Martinvalet et al., 2008). Other identified substrates of Granzyme A are
histones and proteins involved in DNA repair pathways, which sensitizes target cells to
DNA damage and degradation upon Granzyme A-mediated cleavage (Lieberman, 2010).
Granzyme B is a serine-protease that induces apoptosis by cleaving inactive initiator procaspases-8 and -10, as well as inactive executioner pro-caspases-3 and -7 into their active
forms, which contributes to cell disassembly (Adrain et al., 2005). In human but not in
mouse, Granzyme B is also able to induce the intrinsic pathway of apoptosis by cleaving
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the pro-apoptotic protein BID, leading to cytochrome c release (Sutton et al., 2000,
Casciola-Rosen et al., 2007). Similarly to granule-mediated cytolysis, expression of FasL
on CTLs can trigger apoptosis of the target cell through the extrinsic apoptotic pathway
by binding to its cognate receptor Fas on the target cell (Rouvier et al., 1993; Suda &
Nagata, 1994). In contrast to effector molecules, cytokines secreted by CTLs do not
contribute directly to target cell killing. Rather, IFNγ promotes CTL proliferation,
motility, and cytotoxicity by stimulating perforin expression (Whitmire et al., 2005; Bhat
al., 2017), potentiates Th1 cell differentiation and function, and enhances antigen
presentation and Fas expression on target cells (Portnoy et al., 1989; Früh & Yang, 1999;
Müllbacher et al., 2002). CTLs are able to produce both soluble and membrane-bound
forms of TNFα. Soluble TNFα activates and recruits immune cells to the site of infection,
and enhances T cell survival and CTL cytotoxicity (Bancroft et al., 1989; McKenzie et
al., 2006; Calzascia et al., 2007; Allie et al., 2013). On the other hand, membrane-bound
TNFα has been suggested to participate in “slow lysis” of target cells upon interaction
with its receptor TNFR1 (Ratner & Clark, 1993).

1.4 T cell motility, homing and migration to tissues
Efficient immune responses require T cells to adopt appropriate trafficking
patterns throughout their lifetime. T cell motility arises from the combination of three
distinct processes: autonomous cell locomotion, physical guidance, and response to
chemical signals (Krummel et al., 2016). Autonomous cell locomotion depends on the
cell-intrinsic motility machinery, including the actin cytoskeleton and motor proteins,
while physical guidance is controlled by interactions with the extracellular matrix and
surrounding cells, and the response to chemical signals relies on the expression of
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chemokine receptors on the T cell surface (Figure 1.8). Depending on their stage of
differentiation, T cells express distinct chemokine receptors that sense specific
chemokines. The signaling events resulting from these interactions lead to the
rearrangement of the actin cytoskeleton, which enables the migration of T cells towards
peripheral tissues, where these cells participate in processes ranging from development
in the thymus, homing, antigen encounter, and ongoing immune responses at inflamed
sites (Griffith et al., 2014). For instance, mature naive T cells traveling in the bloodstream
express CCR7, the receptor that recognizes and guides these cells towards gradients of
the chemokines CCL19 and CCl21, which are secreted by stromal cells of the secondary
lymphoid organs, such as the spleen and lymph nodes, where antigen presentation occurs
(Gunn et al., 1998; Förster et al., 1999; Luther et al., 2000). T cells constantly interact
with endothelial cells through repeated bind-release events between adhesion molecules,
such as L-selectin (CD62L), and their ligands, a process termed “rolling” (Kishimoto et
al., 1990). T cells that respond to CCL19/CCL21 upregulate surface adhesion molecules
that will bind more strongly to the endothelium, and undergo rearrangement of their actin
cytoskeleton that promotes the transmigration of these cells from the bloodstream into
the secondary lymphoid organs through specialized blood vessels, high endothelial
venules (HEV) (Stein et al., 2000). Engagement of the TCR with peptide antigen:MHC
results in the transient upregulation of CD69, as well as the reciprocal downregulation of
S1PR1 on activated T cells, which results in their retention in secondary lymphoid organs
during activation and differentiation (Matloubian et al., 2004; Shiow et al., 2006). TCR
engagement is also accompanied by the reciprocal downregulation of CD62L and
upregulation of the adhesion molecule CD44 (DeGrendele et al., 1996). After
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differentiation, effector T cells downregulate CD69 expression and restore S1PR1
expression, which facilitates their exit from the secondary lymphoid organs and re-entry
into the circulation through diapedesis by following gradients of the S1P1R ligand S1P
(Pappu et al., 2007; Bankovich et al., 2010). Many cell types at sites of ongoing immune
responses secrete chemokines that will also generate gradients, and result in the
recruitment of the appropriate types of effector T cells, which will be specifically
responsive to these signals through the expression of the corresponding cognate
chemokine receptors (Kagnoff & Eckmann, 1997; Griffith et al., 2014). Once in the
inflamed tissue, effector T cells keep following chemokine gradients, and come to an
arrest upon antigen re-encounter.

1.5 Memory T cell formation
Upon entry into inflamed sites, large numbers of antigen-specific T cells, peaking
at about a week after antigen challenge, accomplish their effector function and participate
in antigen clearance (De Boer et al., 2003). After resolution of an infection, these cells
are no longer needed, and may even be detrimental to the host, due to the tissue toxicity
of the effector molecules and cytokines they secrete (Hutcheson et al., 2008).
Accordingly, antigen clearance is followed by the withdrawal of co-stimulatory signals
and cytokines, including the survival factor IL-2, which will cause approximately 90% of
expanded effector T cell clones to undergo apoptosis mediated by the pro-apoptotic factor
Bim, an event known as contraction (Badovinac et al., 2002; Pellegrini et al., 2003,
McKinstry et al., 2010). Because they express high levels of the chemokine receptor IL7α (CD127), Bcl-2, and other anti-apoptotic proteins, the remaining 10% are able to
survive and differentiate into long-lived memory T cells. These cells preserve the memory
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of the initial antigen exposure and respond more rapidly and efficiently to subsequent
challenges with the same antigen (Figure 1.9) (Akbar et al., 1993; Mueller et al., 1996,
Grayson et al., 2000; Wojciechowski et al., 2006; Whitmire et al., 2008). Memory CD4+
T cell differentiation remains poorly understood, but shares many similarities with the
mechanisms of CD8+ T cell memory formation, which have been more extensively
studied (Seder & Ahmed, 2003). In contrast to effector T cells, which are highly active
and glycolytic, memory T cells exist in a quiescent state characterized by the preferential
utilization of oxidative phosphorylation and fatty acid oxidation, but retain an intermittent
self-renewal capacity, and can survive in the absence of interaction with their cognate
antigen (Seder & Ahmed, 2003; Pearce et al., 2009; van der Windt et al., 2012).
Several models have proposed distinct explanations for the determination of this
terminal-effector (contraction-sensitive)-versus-memory (contraction-resistant) T cell
fate dichotomy (Kaech & Cui, 2012). In the asymmetric cell fate model, a single T cell
precursor gives rise to both a terminal effector and a memory T cell precursor at the time
of the first division during antigen presentation, which depends on APC-proximal versus
-distal T cell identity, respectively (Chang et al., 2007). The underlying uneven
acquisition of factors following cell division programs the daughter cells to adopt distinct
differentiation programs (Arsenio et al., 2014). For instance, the proximal daughter cell
obtains more of T-bet, as well as the high-affinity alpha chain of the IL-2 receptor (IL2Rα or CD25), the signaling of which negatively regulates IL-7Rα (CD127), and thus
contributes to inducing terminal effector differentiation (Xue et al., 2002; Kalia et al.,
2010; Chang et al., 2011). In contrast, the signal-strength model suggests that the strength
of signals 1, 2, and 3 initially received by a T cell during antigen presentation determines
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T cell fate. That is, a weak signal strength generates memory-like T cells, while strong
signals induce terminal effector-like T cells (Stemberger et al., 2007; Gerlach et al.,
2010). In the decreasing-potential model, the cumulative amounts of signals 1, 2, and 3
received throughout the effector T cell stage will similarly shape T cell fate (Kaech &
Ahmed, 2001; Harbertson et al., 2002; Williams et al., 2008; Plumlee et al., 2013).
Finally, the T memory stem cell model proposes the existence of a subset of memory T
cells with stem-like properties that can maintain the memory T cell pool, while being able
to give rise to effector T cells (Gattinoni et al., 2011; Graef et al., 2014).
T cells that will become terminal effectors or memory cells can already be
distinguished during the primary immune response by specific markers. Memory
precursor effector cells (MPECs) highly rely on IL-7 signaling for their maintenance, and
accordingly express high levels of its cognate receptor IL-7Rα (CD127), whereas shortlived effector cells (SLECs) express high levels of the terminal effector marker KLRG1
(Kaech et al., 2003; Kondrack et al., 2003; Seddon et al. 2003, al; Lenz et al., 2004; Joshi
et al., 2007). Memory T cell differentiation also requires the expression of transcription
factors, including Eomes, FOXO1, and Id3, as well as IL-15 and Wnt signaling, which
induces the expression of the transcription factors TCF-1 and LEF1 (Zhang et al., 1998;
Becker et al., 2002; Gattinoni et al., 2009; Zhou et al., 2010; Yang et al., 2011; Zhou &
Xue, 2012; Hess Michelini et al., 2013). However, the memory T cell pool is
heterogeneous, and as such exhibit distinct differentiation capacities, proliferative
potentials, effector function, and homing characteristics (Buchholz et al,. 2013). T
memory stem cells (TSCM) are multipotent and can give rise to all types of memory T cells
(Figure 1.10), and accordingly exhibit a high proliferative and self-renewal ability, but
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do not display any effector function, and reside in the secondary lymphoid organs
(Gattinoni et al., 2011; Lugli et al., 2013). On the contrary, tissue-resident memory T cells
(TRM) display the lowest differentiation capacity, but proliferate rapidly and exhibit strong
effector function upon recall, and accordingly occupy non-lymphoid organs, such as the
lung, liver, skin, and adipose tissue (Beura et al., 2019). In between TSCM and TRM are
central-memory (TCM) and effector-memory T (TEM) cells, TCM being less differentiated
than TEM, which can be distinguished by their level of CD62L expression (Sallusto et al.,
1999; Ahmadzadeh et al., 2001; Pepper & Jenkins, 2011). TCM exhibit high CD62L
expression, and accordingly reside in the secondary lymphoid organs. These cells also
have a higher proliferative potential and can give rise to TRM that populate the skin
(Osborn et al., 2019), but display weaker effector function upon antigen re-challenge
(Wherry et al., 2003). TEM express low levels of CD62L, and are found in the circulation
(Masopust et al., 2001). This memory T cell subset has a lower proliferation ability than
TCM, but elicits a more potent effector response upon antigen re-encounter (Sallusto et al.,
2004; Olson et al., 2013; Roberts et al., 2014). Despite their apparent more differentiated
phenotype, TRM and TEM have the capacity to give rise to TCM that populate the secondary
lymphoid organs (Wherry et al., 2003; Bromley et al., 2013; Beura et al., 2018).

1.6 T cell exhaustion
In distinction from acute infections during which antigen is effectively cleared by
functional effector T cells and memory T cells are formed following contraction, antigen
persists during chronic infections and cancer, resulting in an unresponsive state known as
exhaustion which has been more extensively studied in CD8+ T cells than in CD4+ T cells
(Moskophidis et al., 1993; Crawford et al.; 2014). The exhausted state is characterized by
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compromised effector T cell proliferation, cytotoxic function, and pro-inflammatory
cytokine production, as well as by the loss of memory T cell potential (Zajac et al., 1998;
Fuller et al., 2003; Wherry et al., 2004; Angelosanto et al., 2012). T cell exhaustion is
established progressively through continuous TCR signaling provoked by recurring
contacts with the lingering antigen, during which T cells upregulate co-inhibitory
receptors, such as PD-1, TIM-3, LAG-3, CD160, 2B4, and CTLA-4 (Figure 1.11) (Day
et al., 2006; Grosso et al., 2007; Wherry, 2007; Cai et al., 2008; Jones et al., 2008; Bucks
et al., 2009; Razziorrouh et al., 2010). During acute infections, these surface molecules
get expressed transiently on activated T cells following antigen encounter, and promote
self-tolerance by negatively regulating T cell activation and proliferation when bound to
their ligand, hence their designation as “immune checkpoints” (Brunet et al., 1987;
Triebel et al., 1990; Maïza et al., 1993; Valiante & Trinchieri, 1993; Agata et al., 1996;
Monney et al., 2002; Probst et al., 2005). In contrast, during chronic inflammation,
exhausted T cells continuously express high levels of these receptors, which can inhibit
T cell responses by transmitting negative signals or inducing cell death upon ligand
binding (Blackburn et al., 2009). Cognate ligands for these co-inhibitory receptors are
upregulated in response to immune signals, such as cytokines, on APCs, as well as on
non-hematopoietic cells, including endothelial cells, and are also abundantly expressed
in immunosuppressive environments typical of chronic infections and cancer (Mazanet
& Hughes, 2002; Liang et al., 2003; Rodig et al., 2003; Mühlbauer et al., 2006). For
instance, PD-1 suppresses effector T cell function after interaction with PD-L1 or PD-L2,
TIM-3 elicits calcium-dependent cell death when bound to Galectin-9, and CD160
inhibits T cell activation upon binding herpesvirus entry mediator (HVEM) (Freeman et
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al., 2000; Latchman et al., 2001; Iwai et al., 2002; Zhu et al., 2005; Mühlbauer et al.,
2006; Cai et al., 2008; Mengshol et al.; 2010; Malissen et al., 2019). Other co-inhibitory
receptors function by competing for co-stimulatory ligand binding (Blackburn et al.,
2009). Specifically, LAG-3 competes with its homolog CD4 for binding to MHC-II, 2B4
competes with CD2 for interacting with CD48, and CTLA-4 competes with CD28 for
binding to the B7-family molecules (Baixeras et al., 1992; Brown et al., 1998; Fallarino
et al, 1998). Suppression of T cell function following co-inhibitory receptor signaling
occurs in a sequential fashion, starting with compromised IL-2 production, proliferation,
motility, and cytotoxicity, followed by the loss of the ability to produce TNFα and IFNγ,
and eventually concluding with the death of the exhausted T cells (Wherry et al., 2003;
Zinselmeyer et al., 2013).
The establishment of the exhausted state in T cells is induced by a dysregulated
terminal effector differentiation program derived from persistent TCR stimulation that
results in aberrant expression of multiple transcription factors, including BATF, Blimp1, Eomes, Id2, IRF4, NFAT, TOX, as well as transcription factors from the NR4A family,
which in turn control the expression of some co-inhibitory receptors (Cannarile et al.,
2006; Wherry, 2007; Oestreich et al., 2008; Shin et al., 2009; Quigley et al., 2010;
Buggert et al., 2014; Martinez et al., 2015; Man et al., 2017; Li et al., 2019; Seo et al.,
2019). In recent years, the possibility of reverting exhausted T cells back to a functional
state has been demonstrated by inhibiting the interaction between co-inhibitory receptors
and their ligands using blocking antibodies, thereby preventing co-inhibitory receptor
signaling (Leach et al., 1996; Barber et al., 2006; Sakuishi et al,. 2010; Wolchok et al.,
2013). This strategy, termed “checkpoint blockade immunotherapy” (CBI), has since
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been developed for human therapeutic purposes, and many “checkpoint inhibitors”,
mainly targeting PD-1, PD-L1, and CTLA-4, have already been approved for the
treatment of various types of cancer (Hargadon et al., 2018). However, most patients are
resistant to CBI, and some of them experience detrimental effects due to the tissue toxicity
of these treatments, especially when used in combination (Topalian et al., 2012; Wolchok
et al., 2013; Topalian et al., 2014; Larkin et al., 2015). Studies investigating the possibility
of using CBI to treat chronic infectious diseases, such as HIV, hepatitis B, tuberculosis,
and malaria, are ongoing (Wykes & Lewin, 2018).
Aside from co-inhibitory receptors, anti-inflammatory cytokine signaling also
participates in the induction of T cell exhaustion, as these are abundant during chronic
infections and in the tumor microenvironment (Landskron et al., 2014; Beltra &
Decaluwe, 2016). Two potent immunosuppressive cytokines are IL-10 and TGFβ, which
are secreted by Tregs, but also other T cells, including exhausted T cells and APCs
(Tinoco et al., 2009; Ng & Oldstone, 2012; Parish et al., 2014). These cytokines
contribute to the suppression of effector T cell function both directly, by restraining T
cell proliferation, cytokine production, and cytotoxicity, as well as indirectly, by
preventing the upregulation of MHC molecules on APCs, and by suppressing the
response of other innate immune cells that normally support effector T cell function,
notably macrophages (Geiser et al., 1993; Lee et al., 1997; Corinti et al., 2001; Thomas
& Massagué, 2005; Wilson & Brooks, 2011; Stephen et al., 2014; Ip et al., 2017).
Similarly to CBI, blocking IL-10 signaling during chronic viral infection using
neutralizing antibodies has been shown to restore effector T cell function and result in
viral clearance (Brooks et al., 2006; Ejrnaes et al., 2006). However, TGFβ blockade alone
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fails to ameliorate effector T cell function in chronic disease, and needs to be combined
with CBI to enhance T cell-mediated anti-tumor responses (Garidou et al., 2012;
Mariathasan et al., 2018; Tauriello et al., 2018).

1.7 Regulation of T cell differentiation by microRNAs
1.7.1 Biogenesis and function of microRNAs
MicroRNA (miRNA)-mediated RNA interference is one of the most well-studied
post-transcriptional mechanisms that potently regulates gene expression (Elbashir et al.,
2001; Kim et al., 2008). MiRNAs are short, 20-22 nucleotide-long, non-coding RNAs
that bind target mRNAs in a sequence-specific manner to inhibit translation by inducing
target mRNA degradation or ribosome stalling (Lee et al., 1993; Lee & Ambros, 2001;
Bartel et al., 2009). Several hundreds of miRNAs have been identified in the mammalian
genome, and many of these are evolutionarily conserved (Lagos-Quintana et al., 2001;
Lewis et al., 2003). Single miRNAs have many target mRNAs, and individual mRNAs
can be directly regulated by multiple miRNAs (Lim et al., 2005; Friedman et al., 2009).
MiRNAs are involved in the control of a broad range of cellular functions, including cell
differentiation, cell cycle progression and apoptosis, which makes these an essential
component of the cellular machinery, as they confer robustness to a wide range of
biological processes, including development and immunity (Abbott et al., 2005; Farh et
al., 2005; Stark et al., 2005). It has been estimated that miRNAs control the expression of
approximately one third of the total human gene pool, including genes involved in
immune cell differentiation (Lewis et al., 2005). However, dysregulation of miRNAmediated RNA interference has been shown to result in pathologies, such as
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developmental defects, cancer, obesity, and autoimmune diseases (Zhao et al., 2007;
Wang et al., 2008; Frost & Olson, 2011; Xu et al., 2013).
MiRNAs can be encoded by genes located either in intergenic regions of the
genome, where they rely on their own promoter for transcription, or within gene introns,
in which case the transcription of these miRNAs is controlled by the promoter of the
neighboring gene (Rodriguez et al., 2004; Baskerville & Bartel, 2005). Because in this
situation both the adjoined gene and the miRNA are transcribed at the same time, mRNA
splicing and processing is needed to separate the miRNA from the gene mRNA (Kim &
Kim, 2007; Melamed et al., 2013; Ramalingam et al., 2014). In addition, miRNA genes
can include either a single miRNA (monocistronic) or a cluster of multiple miRNAs
(polycistronic), which all share the same promoter (Altuvia et al., 2005; Ozsolak et al.,
2008).
MiRNA gene transcription, mediated by RNA polymerases II and III, produces
long primary miRNA (pri-miRNA) transcripts, consisting of a succession of hairpin
structures (Figure 1.12) (Lee et al., 2004; Borchert et al., 2006). Pri-miRNAs are then
cleaved by the ribonuclease (RNase) III enzyme Drosha of the microprocessor complex
in the nucleus into precursor miRNAs (pre-miRNAs), which are composed of 60-70
nucleotide-long single hairpin structures (Lee et al., 2003). Pre-miRNAs are next
exported from the nucleus to the cytoplasm by Exporting 5, where they undergo cleavage
of their hairpin loop, mediated by the RNase III enzyme Dicer, which generates mature
miRNA duplexes (Knight & Bass, 2001; Yi et al., 2003). Only one strand of this doublestranded mature miRNA, the guide strand, will bind to the RNAse III enzyme Argonaute
(AGO) and other proteins to generate the RNA-induced silencing complex (RISC), while
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the other strand, the passenger strand, will be degraded (Williams & Rubin, 2002;
Kloosterman et al., 2004; Rand et al., 2004; Leuschner et al., 2006; Ameres et al., 2007;
MacRae et al., 2008).
MiRNAs recognize their target mRNAs through their seed region, located at their
5’ end at positions 2-8, and miRNAs with conserved seed regions are grouped into
families which share common mRNA targets (Lewis et al., 2005; Bartel, 2018). RISC
antagonizes protein translation by mediating the degradation of target mRNAs when the
loaded miRNA seed region is perfectly complementary to the mRNA, or by ribosome
stalling in cases of partial mRNA-miRNA seed region complementarity (Vella et al.,
2004; Bagga et al., 2005; Baek et al., 2008). MiRNA seed regions most commonly bind
sequences canonically located within the 3’ untranslated region (UTR) of mRNAs, but
some miRNAs binding sites can be found in non-canonical sites outside the 3’ UTR, such
as within the mRNA 5’ UTR or coding sequence (CDS) (Lai, 2002; Lytle et al., 2007;
Majoros & Ohler, 2007; Schnall-Levin et al., 2010). Interestingly, recent studies have
described a role for sequences outside the seed region in miRNA-mediated RNA
interference (Grimson et al., 2007; Brancati & Großhans, 2018).

1.7.2 Role of microRNAs in CD4+ T cell differentiation
The crucial regulatory functions of miRNAs in many aspects of T cell
development, homeostasis, and differentiation, have been extensively studied
(Baumjohann & Ansel, 2013; Wells et al., 2020). Pioneer studies using ectopic
overexpression of miRNAs demonstrated that miRNAs were able to direct hematopoietic
lineage differentiation (Chen et al., 2004). Moreover, T cell-specific deletion of factors
involved in miRNA biogenesis, such as Dicer and Drosha, led to diminished survival and
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proliferation of activated T cells (Cobb et al., 2005), but also resulted in enhanced Th1
cell differentiation and inflammatory disease with reduced Treg presence, which suggested
that miRNAs can control the quiescent state of naive T cells (Muljo et al., 2005; Cobb et
al., 2006; Chong et al., 2008). Subsequent studies identified regulatory roles for
individual miRNAs at distinct steps of CD4+ T cell differentiation (Baumjohann & Ansel,
2013). For instance, miR-155 and miR-181a enhance CD4+ T cell activation and clonal
selection (Banerjee et al., 2010; Palin et al., 2013), while miR-146a inhibits it (Yang et
al., 2012). Moreover, the miR-17-92 miRNA cluster promotes CD4+ T cell proliferation
and survival, ultimately resulting in lymphoproliferative disease and autoimmunity (Xiao
et al., 2008). Furthermore, Th1 cell differentiation is enhanced by the miR-17-92 cluster
and miR-155, but negatively regulated by miR-29, miR-125b, and miR-146a (O’Connell
et al., 2010; Jiang et al., 2011; Rossi et al., 2011; Steiner et al., 2011; Yang et al., 2012).
MiR-21 facilitates the differentiation of Th2 cells, while miR-27, miR-126, and miR128
prevents it (Mattes et al., 2009; Guerau-de-Arellano et al., 2011; Sawant et al., 2013).
Th17 cell differentiation is increased by miR-155, miR-301a, and miR-326, but
suppressed by miR-10a (Du et al., 2009; O’Connell et al., 2010; Mycko et al., 2012;
Takahashi et al., 2012). The differentiation of TFH cells is positively regulated by the miR17-92 cluster, whereas miR-10a prevents it (Baumjohann et al., 2013; Takahashi et al.,
2012). Finally, Treg cell differentiation is promoted by miR-10a, miR-146a and miR-155,
but repressed by the miR-17-92 cluster (Lu et al., 2009; Lu et al., 2010; Jiang et al., 2011;
Jeker et al., 2012; Takahashi et al., 2012).
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1.7.3 Role of microRNAs in CD8+ cytotoxic T lymphocyte differentiation
The importance of miRNA-mediated regulation of CD8+ T cell responses was
demonstrated through CD8-specific deletion of Dicer, which led to enhanced activation
and proliferation, but also diminished survival, effector function, and migratory potential
(Zhang & Bevan, 2010). A later study found that Dicer deletion at the naive stage, but
not at the activated stage, potentiated CD8+ T cell responses through upregulation of
Granzyme B, IFNγ, as well as Eomes and its direct transcriptional target Perforin, due to
the absence of mature miR-139 and miR-342 (Trifari et al., 2013). Other miRNAs, such
as miR-15a/16 and miR-150, were also identified as critical drivers and suppressors of
CTL differentiation, respectively (Smith et al., 2015; Yang et al., 2017). Interestingly,
some miRNAs that play a role in the regulation of Th1 cell differentiation also control
CTL differentiation, such as the miR-17-92 cluster, miR-29, and miR-155, which inhibit
the T-bet/IFNγ signaling axis that both CTL and Th1 differentiation programs rely on
(Ma et al., 2011; Wu et al., 2012; Gracias et al., 2013).
Although studies profiled the expression of a wide array of miRNAs at different
stages of CD8+ T cell differentiation, the molecular mechanisms underlying the miRNAmediated regulation of the CD8+ T cell memory versus terminal-effector fate
specification remain largely unknown (Wu et al., 2007). Some miRNAs, such as miR143, miR-155, and the miR-200 family, have been shown to promote memory CD8+ T
cell formation (Tsai et al., 2013; Guan et al., 2018; Zhang et al., 2018). In contrast, other
miRNAs, including miR-15/16, the miR-17-92 cluster, miR-23a, miR-31, and miR-150,
have been found to skew the CD8+ T cell fate towards terminal effectors and exhausted
cells (Wu et al., 2012; Khan et al., 2013; Lin et al., 2014; Ban et al., 2017; Chen et al.,
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2017; Moffett et al., 2017; Gagnon et al, 2019). Despite the fact that all these studies
significantly contributed to the understanding of the miRNA-mediated control of T cell
differentiation and fate determination, whether specific miRNAs consistently play
regulatory roles throughout T cell differentiation remains an outstanding question in the
field.

1.8 The lethal-7 (let-7) family of microRNAs
1.8.1 Phylogeny and genomic organization of let-7 microRNAs
Lethal-7 (let-7) miRNAs were discovered in the nematode Caenorhabditis
elegans and were initially described as critical regulators of larval development, in which
let-7 deficiency results in premature death (Meneely & Herman, 1984; Lee et al., 1993;
Reinhart et al., 2000; Slack et al., 2000). The let-7 family of miRNAs was later found to
be highly conserved across bilaterian animals, in which more let-7 isoforms, or members,
are found in comparison to C. elegans, due to multiple let-7 miRNA gene duplications
(Pasquinelli et al., 2000; Hertel et al., 2012). In the mouse, 14 paralog let-7 genes produce
8 mature let-7 members, while in humans 12 miRNA genes give rise to 10 mature let-7
members (Lagos-Quintana et al., 2002). Paralog let-7 miRNA genes are located on
distinct chromosomes and different members are identified by a unique letter (e.g. let-7a,
let-7b). In addition, identical mature let-7 miRNAs can be generated from distinct let-7
genes, which is indicated by a unique number after the let-7 member name (e.g. let-7a-1,
let-7a-2) (Ambros et al., 2003; Roush & Slack, 2008).
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1.8.2 Regulation of let-7 microRNA expression
Let-7 miRNAs are expressed in numerous different cell types and control many
biological processes, such as cell survival, metabolism, and differentiation (Büssing et
al., 2008; Zhu et al., 2011). Particularly, let-7 miRNAs were found to silence the mRNAs
of cell cycle progression regulator genes such as Cdc25a and Cdk6, as well as genes
involved in carcinogenesis, including HMGA2, Myc, and Ras, demonstrating their robust
tumor-suppressing function (Mayr et al, 2007; Büssing et al., 2008). The tight and
complex regulation of let-7 miRNAs is well illustrated by the differences in its expression
levels in distinct cell types (Reinhardt et al., 2000, Johnson et al., 2003). For instance, in
embryonic stem cells, mature let-7 miRNAs cannot be detected, but both pri- and pre-let7 forms are present, which indicates that let-7 expression is regulated at the posttranscriptional level, at different steps of let-7 biogenesis (Suh et al,. 2004; Thomson et
al., 2006). Well-studied factors that inhibit mature let-7 miRNA expression are the fetal
proteins Lin28 and Lin28B, which bind to a specific and conserved sequence in the stemloop region of pri- and pre-let7, thereby preventing Drosha- and Dicer-mediated
processing (Piskounova et al., 2008; Viswanathan et al., 2008). Moreover, binding of
Lin28 to pre-let-7 leads to the recruitment of the terminal uridylyl transferases (TUTases)
TUT4 and Zcchc11, which polyuridylate pre-let-7, thereby marking it for degradation by
the exoribonuclease Dis3l2 (Heo et al., 2008; Hagan et al., 2009; Heo et al., 2009;
Piskounova et al,. 2011; Chang et al., 2013). Lin28-mediated let-7 miRNA repression
therefore constitutes a potent regulatory mechanism during early embryonic
development, and has also been shown to play an important role in establishing neonatal
immunity (Wang et al., 2016).
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1.8.3 Let-7 microRNAs in immunity
In contrast to embryonic stem cells, let-7 miRNAs are highly expressed in lymphocytes
(Kuchen et al., 2010). As such, many lymphocyte subsets have been shown to be
dependent on let-7 miRNAs for their development, homeostasis, and differentiation. For
instance, the upregulation of let-7 miRNAs during natural killer T (NKT) cell
development in the thymus is necessary for the differentiation of IFNγ-producing
effectors (Pobezinsky et al., 2015). In the periphery, let-7 miRNA expression is required
for the survival and maintenance of the quiescent phenotype in naive T cells (Wells et al.,
2017; Pobezinskaya et al., 2019). During lymphocyte activation, let-7 miRNAs have been
shown to inhibit the metabolic reprogramming of both B cells and CD8+ T cells by
negatively regulating the expression of the transcription factor Myc and the glycolytic
enzyme hexokinase 2 (Wells et al., 2017; Jiang et al., 2018). Moreover, let-7 miRNAs
have been shown to play a regulatory role in CD8+ cytotoxic T lymphocyte (CTL)
function by directly targeting the transcription factor Eomes, as well as in CD4+ helper T
cell responses during HIV infection and airway inflammation by regulating the
expression of the cytokines IL-10 and IL-13, respectively (Polikepahad et al., 2010;
Kumar et al., 2011; Swaminathan et al., 2012; Wells et al., 2017). One study also
proposed a regulatory role for let-7f expression in Th17 cell function in women with
severe asthma (Newcomb et al., 2015). In addition, the exosome-mediated transfer of let7 miRNAs to various immune cells has been proposed as a suppressive mechanism used
by regulatory T (Treg) cells, and has also been reported to inhibit the generation and
function of Treg cells (Okoye et al., 2014; Kimura et al., 2018). Although many studies
have described regulatory roles for let-7 in T cells, the molecular mechanisms underlying
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the control of T cell differentiation and the determination of memory versus terminal
effector/exhausted T cell fate remains unclear.

1.9 Rationale, central hypothesis, specific aims, and significance
We have previously shown that all let-7 family members are abundantly expressed
in naive CD8+ T cells, but get dramatically downregulated upon antigen recognition,
which enables CTL differentiation and function (Wells et al., 2017). Based on these
findings, the central hypothesis of this dissertation is that let-7 acts as a central regulator
of effector T cell differentiation and fate specification. This main hypothesis will be
investigated through two specific aims. The first aim will be to determine the regulatory
role of let-7 miRNAs during CD4+ T helper cell differentiation. The second aim will
elucidate the signaling pathways controlled by let-7 miRNAs in memory versus terminaleffector/exhausted CD8+ T cell fate specification. Completion of the proposed aims will
identify let-7 miRNAs as key regulators of T cell responses. Determining the let-7mediated regulatory mechanisms governing the differentiation of CD4+ T helper cells and
specifying the differentiation of CD8+ T cells towards the memory or terminal
effector/exhausted fate will significantly advance our understanding of the posttranscriptional mechanisms controlling the function and fate of T cells. Moreover, this
research has the potential to establish let-7 miRNAs as a promising novel therapeutic
target or cargo that can adjust T cell responses in the contexts of infectious diseases,
cancer, and autoimmunity.
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Figure 1.1: Innate and adaptive immune cells and response kinetics. Innate processes
of the immune system constitute the first defenses against pathogens, while adaptive
mechanisms of immunity, which are mediated by activated lymphocytes, are slower to
appear. ILC, innate lymphoid cell; NK, natural killer. Adapted from Cellular and
Molecular Immunology, 8th edition, Figure 1-1.
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Figure 1.2: The innate and adaptive immune systems show distinct kinetics and
amplitudes in primary and secondary response to antigen. The primary adaptive
immune response to antigen is low in both duration and amplitude, while subsequent
exposure to the same antigen results in secondary responses. These secondary responses
recruit memory cells and are thus faster to appear, stronger in amplitude, and more
specific to the antigen than was the primary response (dark blue). In contrast, innate
immune responses, which do not form immunological memory, remain unchanged every
time the antigen is encountered (light blue). Adapted from Cellular and Molecular
Immunology, 8th edition, Figure 1-8.
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Figure 1.3: T cell selection in the thymus. T cell progenitors migrate from the barrow
to the thymus, where they become thymocytes and complete their development by
rearranging their T cell receptor genes and undergoing repertoire selection. (a & b)
During the process of positive selection, immature T cells that are able to bind self-MHC
receive survival signals, while those which fail to recognize self-MHC are eliminated
through the induction of apoptosis. (c) Next, the process of negative selection selects selftolerant thymocytes by providing survival signals, whereas those which react too strongly
with self-antigen are deleted from the repertoire by apoptosis.
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Figure 1.4: Efficient activation of naive T cells by antigen-presenting cells require
three types of signals. Upon antigen recognition in the context of peptide:self-MHC
complex by the T cell receptor (TCR) on the surface of an antigen-presenting cell
(APC), the CD3 complex of the TCR and the co-receptor (CD4 in this example) send
signal 1 to the activated T cell (arrow 1). Signal 2 is transmitted by ligation of costimulatory receptors, expressed on T cells (CD28 in this example), to their ligand
expressed by the APC (molecules of the B7 family in this example) and provide
survival, metabolic, and mitogenic signals (arrow 2). Signal 3 is mediated by cytokine
signaling, which is important for directing the differentiation of T cells, particularly in
the case of CD4+ T cells which can differentiate into multiple distinct lineages,
depending on the nature of signal 3. Adapted from Owen Kuby Immunology, 7th
edition, Figure 11-3.
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Figure 1.5: Engagement of the T cell receptor results in the activation of
transcription factors that initiate the differentiation process. Model representing
signaling events occurring upon T cell receptor (TCR) engagement. Recognition of
cognate antigen by TCR, which is associated to the CD3 complex, elicits a cascade of
phosphorylation events eventually leading to the activation and nuclear translocation of
the transcription factors NFκB, NFAT, and AP-1, the latter being a complex comprising
c-Fos and c-Jun. Adapted from Cellular and Molecular Immunology, 8th edition,
Overview Figure 3-5.
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Figure 1.6: CD4+ T cells can differentiate into multiple subsets of helper T cells. Each
helper T cell lineage is induced by distinct cytokines and specialize in enhancing the
function of or recruiting other cells that will directly participate in the elimination of
different types of pathogens. Adapted from Janeway’s Immunobiology, 9th edition,
Figure 9.30.
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Figure 1.7: CD8+ T cells differentiate into cytotoxic T lymphocytes that can directly
kill target cells. Differentiated cytotoxic CD8+ T lymphocytes (CTLs) specialize in
lysing cancerous cells and cells infected with intracellular pathogens upon recognition of
pathogen fragments presented on MHC class I molecules on the surface of target cells.
Adapted from Janeway’s Immunobiology, 9th edition, Figure 9.22.
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Figure 1.8: Effector T cells reach sites of ongoing immune responses by following
physical and chemical cues that induce rearrangements in their actin cytoskeleton.
Effector T cells express surface receptors for cell-adhesion molecules such as selectins
and integrins, as well as chemokine receptors. Interactions with cells expressing ligands
for selectins and integrins, as well as chemokine gradients, direct the migration of these
cells to inflames tissues. Adapted from Cellular and Molecular Immunology, 8th edition,
Figure 3-3.
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Figure 1.9: Phases of a T cell response in the context of acute infections. Antigenspecific T cells undergo massive clonal expansion upon activation, but most effector T
cells undergo apoptosis upon antigen clearance during the contraction phase, while only
a small T cell population remains and form long-lasting immunological memory. Adapted
from Kaech & Cui, 2012.
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Figure 1.10 Heterogeneity of the memory T cell pool. Multiple memory T cell subsets
can differentiate from naïve T cells and exhibit distinct differentiation potential and
preferential anatomic location. T memory stem cells (TSCM) are multipotent, reside in the
secondary lymphoid organs, and have the greatest proliferative, self-renewal and
differentiation capacity. On the other hand, tissue-resident memory T (TRM) cells show
the lowest differentiation ability and populate peripheral tissues. In between TSCM and
TRM are central (TCM) and effector (TEM) memory T cells, which can be distinguished by
differential expression of CD62L. TCM express high levels of CD62L and thus reside in
the secondary lymphoid organs, while TEM exhibit low expression of CD62L and are
found in the circulation. Despite their apparent more differentiated phenotype, TRM and
TEM can give rise to TCM that migrate to the lymphoid organs. Effector T cells (TEff) cells
represent terminally-differentiated cells, which eventually undergo cell death. is one
outcome of increased antigen exposure and proliferation. Adapted from Farber et al.,
2014.
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Figure 1.11: Chronic inflammation induces T cell exhaustion. In contrast to acute
infection, during which antigen gets cleared efficiently, antigen lingers during persistent
viral infection and in the tumor microenvironment, which recurrently signals to the T cell
receptor, resulting in the upregulation of co-inhibitory receptors, such as PD-1, LAG-3,
2B4, and CD160. In turn, ligation of these receptors to their cognate ligands present in
these immunosuppressive environments transmits negative signals to the T cell, leading
to the loss of effector function and memory potential. Adapted from Wherry, 2007.
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Figure 1.12: MicroRNA biogenesis and function. MicroRNAs (miRNAs) are encoded
as genes in the genome and are transcribed by RNA polymerase II into long primary
miRNAs (pri-miRNAs), which undergo a first cleavage by the endonuclease Drosha in
the nucleus, resulting in the generation of precursor miRNAs (pre-miRNAs.) These premiRNAs then get exported by Exportin 5 into the cytoplasm , where the endonuclease
Dicer will cleave the loop region to produce mature miRNA duplexes. Only the guide
strand will be incorporated into the RNA-induced silencing complex (RISC) and
participate in the silencing of messenger RNA (mRNA) targets, while the passenger
strand will undergo degradation. Adapted from Baumjohann & Ansel, 2013.
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CHAPTER 2
DIFFERENTIATION OF PATHOGENIC TH17 CELLS IS NEGATIVELY
REGULATED BY LET-7 MICRORNAS IN A MOUSE MODEL OF MULTIPLE
SCLEROSIS

2.1 Introduction
CD4+ helper T cells play essential roles in the function of the immune system by
orchestrating immune responses against a broad range of pathogens, supporting the
function of CD8+ T cells, helping B cells produce antibodies, activating macrophages and
granulocytes, eliciting memory responses, as well as by regulating the magnitude and
persistence of immune responses (Zhu & Paul, 2008). However, the dysregulation of
CD4+ T cell responses causes aberrant effector CD4+ T cell activity, including
overproduction of pro-inflammatory cytokines, eventually resulting in the manifestation
of autoimmune disorders, such as multiple sclerosis (MS) and related diseases
(Wucherpfennig, 2001; Goodnow, 2007). MS is a chronic inflammatory disease of the
central nervous system (CNS) that affects approximately 2.5 million people worldwide,
with a strong predominance in women (Compston & Coles, 2008). The animal model of
neuroinflammation, experimental autoimmune encephalomyelitis (EAE), recapitulates
the pathological and clinical symptoms of MS and has been extensively used to study this
disorder (Rangachari & Kuchroo, 2013). In both MS and EAE, autoreactive CD4+ type17 helper T (Th17) cells that are generated by exposure to IL-23 and IL-1β (Langrish et
al., 2005; Sutton et al., 2006, Komuczki et al., 2019) migrate to the CNS and cross the
blood-brain barrier by following gradients of chemokines secreted by CNS-resident
innate lymphoid cells (Kwong et al., 2017). The transcription factor Bhlhe40, which is
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induced in encephalitogenic Th17 by IL-1β signaling, positively regulates the secretion
of granulocyte-macrophage colony-stimulating factor (GM-CSF) (Martínez-Llordella et
al., 2013; Lin et al., 2014; Lin et al., 2016). GM-CSF is a proinflammatory cytokine
essential for disease induction as it promotes the activation, differentiation, and
recruitment of monocytes and dendritic cells to the CNS, as well as the mobilization of
the local microglia (McQualter et al., 2001; Ponomarev et al., 2007; Codarri et al., 2011;
El-Behi et al., 2011; Spath et al., 2017; Komuczki et al., 2019). In turn, GM-CSFstimulated glial and dendritic cells secrete IL-6 and IL-23, thereby reinforcing the
differentiation and maintenance of pathogenic Th17 cells (Sonderegger et al., 2008).
Inflammatory myeloid cells produce reactive oxygen species and cytokines that cause
neuron demyelination and axonal damage, which leads to the disruption of neuronal
signaling, eventually resulting in disabling physical symptoms, including progressive loss
of motor function, which reflect the extent of neurodegeneration (Compston & Coles,
2008).
About a third of the total risk factors for MS development can be attributed to
genetic variation, and genome-wide association studies have identified more than 100
different genetic variants associated with MS and related autoimmune disorders (Lock et
al., 2002; Duerr et al., 2006; Stuart et al., 2010; International Multiple Sclerosis Genetics
Consortium et al., 2013). Many of these susceptibility factors consist of variants of genes
which are involved in Th17 pathways and contain single nucleotide polymorphisms
within the untranslated regions (UTRs) of their mRNA. Given that UTR sequences are
targeted by factors controlling mRNA translation and stability (Barrett et al., 2012), the
post-transcriptional dysregulation of these genes, particularly by miRNAs, may be
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responsible for the aberrant cytokine responsiveness and effector function observed in
autoreactive Th17 cells. In fact, altered miRNA expression has been shown in
encephalitogenic Th17 cells from active MS lesions, and specific upregulated miRNAs,
such as miR-155 and miR-326, were demonstrated to promote the pathogenic Th17
phenotype (Du et al., 2009; Junker et al., 2009; O’Connell et al., 2010; Ma et al., 2014).
Although regulatory roles have been described for let-7 miRNAs in the control of
the differentiation of cytotoxic CD8+ T cells and various subsets of effector CD4+ T cells
(Polikepahad et al., 2010; Kumar et al., 2011; Swaminathan et al., 2012; Okoye et al.,
2014; Wells et al., 2017; Kimura et al., 2018), the precise contribution of let-7 miRNAs
in autoreactive Th17 cell differentiation and MS pathogenesis has been controversial (Ma
et al., 2014). Disease-promoting roles have been proposed for individual let-7 miRNA
family members (Junker et al., 2009; Guan et al., 2013; Kimura et al., 2018), but other
reports have suggested that let-7 miRNA expression may confer protection against MS
(Cox et al., 2010; Martinelli-Boneschi et al., 2012). Therefore, the objective of this project
was to investigate the role of let-7 miRNAs in the regulation of pathogenic Th17 cell
generation and identify the underlying molecular mechanisms.
We demonstrated that the differentiation of pathogenic Th17 cells in EAE requires
the downregulation of let-7 miRNAs in naive CD4+ T cells upon antigen stimulation.
Specifically, we found that high let-7 miRNA expression in activated CD4+ T cells
prevents EAE development by inhibiting the clonal expansion, IL23R/IL-1R1-dependent
acquisition of pathogenic function, and CCR2/CCR5-dependent chemokine-mediated
migration of Th17 cells to the CNS, while depletion of let-7 miRNAs enhances Th17 cell
pathogenicity and aggravates EAE. Therefore, let-7 miRNA delivery to pathogenic Th17
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cells may be a promising therapeutic strategy for the treatment of autoimmune diseases
such as MS.

2.2 Results
2.2.1 Let-7 expression in CD4+ T cells inhibits EAE development
The role of let-7 miRNAs in the differentiation of pathogenic CD4+ T cells
remains unclear (Junker et al., 2009; Cox et al., 2010; Martinelli-Boneschi et al., 2012;
Guan et al., 2013; Ma et al., 2014; Kimura et al., 2018). Previously, we have shown that
let-7 miRNA expression in CD8+ T cells prevents the differentiation of CTLs and must
be downregulated during antigen stimulation (Wells et al., 2017). Here, we found that,
similarly to CD8+ T cells, naive CD4+ T cells expressed high levels of let-7, which were
rapidly downregulated upon activation, proportionally to both the duration (Figure 2.1A)
and strength of TCR stimulation (Figure 2.1B). Based on these observations, we
hypothesized that let-7 miRNAs inhibit the differentiation of CD4+ T cells and may
therefore compromise the generation of pathogenic Th17 cells, thereby suppressing the
development of autoimmune disorders.
To test our hypothesis in vivo, we acquired mice with a doxycycline-inducible let7g transgene (Let-7Tg) in order to maintain high let-7g expression in activated CD4+ T
cells (Zhu et al., 2011). We used EAE susceptibility as a readout of CD4+ T cell
differentiation in doxycycline- or vehicle-treated Let-7Tg and WT control mice
immunized with the peptide antigen myelin oligodendrocyte glycoprotein, residues 3555 (MOG35-55), in complete Freund’s adjuvant (CFA). Only doxycycline-treated Let-7Tg
mice developed a significantly milder disease in comparison to control mice (Figure
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2.2A). Strikingly, the number of mononuclear cells (Figure 2.2B) and CD4+ T
lymphocytes (Figure 2.2C) that infiltrated the CNS was strongly diminished in these
mice. Overall, the frequencies and numbers of cytokine-producing CD4+ T cells were
greatly reduced in the CNS of doxycycline-treated Let-7Tg mice (Figure 2.2D). In
addition, in vitro MOG35-55-restimulated splenocytes from the same mice secreted less
IL-17, IFNγ, and GM-CSF in comparison to that of control mice (Figure 2.2E). We
obtained similar results using WT and Let-7Tg mice on a 2D2 RAG2-deficient
(2D2Rag2KO) background, in which all CD4+ T cells express the 2D2 transgenic T cell
receptor that recognizes the MOG35-55 peptide (Bettelli et al., 2003) (Figure 2.3). To
assess whether the absence of let-7 miRNAs in CD4+ T cells leads to aggravated EAE,
we used Lin28 transgenic mice (Lin28Tg) with T-cell specific ectopic overexpression of
the fetal protein Lin28B, which blocks let-7 miRNA biogenesis (Heo et al., 2008;
Piskounova et al., 2008; Newman et al., 2008; Heo et al., 2009; Piskounova et al., 2011;
Pobezinsky et al., 2015). 2D2Rag2KO Lin28Tg mice developed stronger symptoms of
EAE, during which the phenotype of cytokine-producing pathogenic CD4+ T cells was
enhanced, even though the extent of CD4+ T cell infiltration into the CNS was unchanged
in comparison to controls (Figure 2.3), suggesting that let-7 miRNAs inhibit EAE
development.
To determine whether the let-7 miRNA-mediated protection against EAE is CD4+
T cell-intrinsic, we adoptively transferred naive 2D2Rag2KO CD4+ T cells from Let-7Tg,
Lin28Tg and control mice, into Rag2KO recipient mice that were subsequently
immunized with MOG35-55 in CFA. At day 9 post-EAE induction, disease outcome
(Figure 2.4A), CNS infiltration (Figure 2.4B), as well as frequencies and numbers of
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cytokine-producing donor 2D2Rag2KO CD4+ T cells that had differentiated into
pathogenic CD4+ T cells (Figures 2.4C and 2.4D) recapitulated the results from our
previous EAE experiments (Figures 2.2 and 2.3). These results demonstrate that let-7
abolishes the development of EAE in a CD4+ T cell-intrinsic manner.
Although Let-7Tg CD4+ T cells were largely absent in the CNS of EAE-induced
mice, they were found in the spleen, albeit at lower numbers than control cells (Figure
2.4E). To explain this phenotype, we proposed four potential mechanisms: 1) poor cell
survival, 2) reduced proliferation, 3) compromised differentiation, or 4) impaired
trafficking.

2.2.2 Let-7 promotes survival but restricts the proliferation of activated CD4+ T
lymphocytes
To examine whether let-7 miRNAs negatively regulate the survival of activated
CD4+ T cells during EAE, we measured the survival rate of Let-7Tg, Lin28Tg and WT
control CD4+ T cells activated in vitro for 3 days. Interestingly, Let-7Tg cells survived
better than their WT counterparts, while the recovery of Lin28Tg lymphocytes was
significantly lower (Figure 2.5A). In fact, these results are in agreement with our recently
published findings in naive CD4+ and CD8+ T cells (Pobezinskaya et al., 2019),
suggesting that let-7 expression also supports the survival of activated CD4+ T cells.
Thus, the reduced numbers of CNS-infiltrated Let-7Tg CD4+ T cells recovered during
EAE cannot be explained by increased cell death.
Based on our data in CD8+ T cells (Wells et al., 2017), we tested whether let-7
miRNAs suppress CD4+ T cell proliferation as well. To address this question, Let-7Tg,
Lin28Tg and WT control naive CD4+ T cells were labeled with CellTrace Violet (CTV)
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and activated in vitro. We observed that Let-7Tg CD4+ T cells proliferated less than
activated control T cells, while Lin28Tg CD4+ T lymphocytes proliferated more (Figure
2.5B), even though this effect was less pronounced than in CD8+ T cells. These findings
suggest that let-7 restricts CD4+ T cell proliferation, which, in turn, can contribute to the
diminished numbers of CNS-infiltrated Let-7Tg CD4+ T cells observed in EAE.
Given that Let-7Tg CD4+ T cells exhibit a lower proliferative potential, we
investigated whether let-7 inhibits the expression of genes that regulate cell cycle
progression and the metabolic switch in antigen-stimulated CD4+ T cells. Similarly to the
results observed in CD8+ T cells, activated Let-7Tg CD4+ T cells expressed low levels of
cyclin D2 (Ccnd2), cyclin-dependent kinase 6 (Cdk6), phosphatase Cdc25a (Cdc25a),
and ubiquitin-conjugating enzyme Cdc34 (Cdc34), as well as the transcription factor Myc
and several Myc target genes involved in glycolysis and protein synthesis (Tfap4, Glut3,
Hk2, Ldha, Qars, Yars), while in Lin28Tg cells those genes were derepressed
(Galaktionov et al., 1996; Johnson et al., 2007; Legesse-Miller et al., 2009; Wells et al.,
2017) (Figures 2.5C and 2.5D). These results indicate that let-7 miRNAs may restrain
CD4+ T cell proliferation by suppressing the metabolic switch and cell cycle progression.
These data also suggest that Lin28Tg CD4+ T cells are able to elicit aggravated EAE
because of their proliferative and metabolic advantage over WT CD4+ T cells, despite a
survival defect.

2.2.3 Let-7 negatively regulates the differentiation of pathogenic Th17 cells
Alternatively, the low frequency of effector CD4+ T cells in the CNS of Let-7Tg
mice during EAE could be due to a defect in autoreactive CD4+ T cell differentiation.
Therefore, we tested the ability of let-7 miRNAs to influence the differentiation of
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pathogenic Th17 cells. Naive 2D2Rag2KO CD4+ T cells with different levels of let-7
expression were polarized in vitro towards the TGFβ-independent pathogenic Th17
lineage in the presence of the cytokines IL-1β, IL-6, and IL-23 (Chung et al., 2009;
Ghoreschi et al., 2010). We confirmed that, while the expression of let-7 miRNAs was
downregulated over time in 2D2Rag2KO WT cells (Figure 2.6A), the expression of the
let-7g transgene remained high in 2D2Rag2KO Let-7Tg cells before and after
differentiation (Figure 2.6B), and Lin28 expression could only be detected at substantial
levels in 2D2Rag2KO Lin28Tg cells (Figure 2.6C). Notably, very low frequencies of
Let-7Tg pathogenic Th17 cells expressed IL-17 and GM-CSF as compared to WT
controls, whereas Lin28Tg cells had increased percentages of cells that expressed these
cytokines (Figure 2.7A). This trend was also observed in the frequencies of IL-17+GMCSF+ double positive cells, suggested to be the most pathogenic Th17 cells in EAE
(Ponomarev et al., 2007; Sonderegger et al., 2008; Codarri et al., 2011; El-Behi et al.,
2011; Spath et al., 2017). Furthermore, the extent of Il17a and Csf2 mRNA expression
correlated with the percentage range of IL-17A- and GM-CSF-producing cells (Figure
2.7B). These results suggest that let-7 expression in CD4+ T lymphocytes prevents the
differentiation of pathogenic Th17 cells.
We observed that the expression of the cytokine receptors Il1r1 and Il23r, both
previously described as essential for the differentiation of pathogenic Th17 cells in EAE
(Langrish et al., 2005; Matsuki et al., 2006; McGeachy et al., 2009; El-Behi et al., 2011;
Komuczki et al., 2019), was profoundly inhibited in Let-7Tg and derepressed in Lin28Tg
pathogenic Th17-polarized cells. Analysis of Il1r1 and Il23r mRNA sequences revealed
multiple potential let-7 binding motifs which can be directly targeted by let-7 (Figure
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2.7C). In fact, such regulation was previously proposed for the mRNA of IL23R in human
memory CD4+ T cells (Li et al., 2011). Interestingly, although miRNA binding sites are
most commonly found within the 3’ UTRs of mRNAs, some let-7 binding sites were
located within the coding sequence of mouse and human Il1r1 and Il23r mRNAs. On the
other hand, the expression of the transcription factor Bhlhe40, shown to be induced by
IL-1R signaling (Lin et al., 2016) and essential for the pathogenicity of Th17 cells in EAE
(Martínez-Llordella et al., 2013; Lin et al., 2014), was only slightly reduced in Let-7Tg
pathogenic Th17-polarized cells, but drastically enhanced in Lin28Tg lymphocytes
(Figure 2.7B). Let-7 miRNAs did not repress the expression of other genes controlling
the Th17 cell fate, such as Il6ra, Il6st, Irf4 and Rorc, and had little impact on Stat3
expression (Figure 2.7D), even though Il6ra, Stat3, and Rorc are predicted direct let-7
targets (Agarwal et a;., 2015). Thus, these results suggest that let-7 miRNAs negatively
regulate the acquisition of pathogenic Th17 phenotype and may act through directly
targeting Il1r1 and Il23r transcripts.
Of note, in agreement with previously published reports (Polikepahad et al., 2010;
Kumar et al., 2011; Swaminathan et al., 2012), we confirmed that let-7 expression also
blocks the differentiation of Th0, Th1, and Th2 cells. Surprisingly, let-7 did not suppress
the differentiation of non-pathogenic Th17 cells generated in the presence of IL-6 and
TGF-β (Figures 2.8A and 2.8B) (McGeachy et al., 2007). Moreover, there was no
obvious effect of let-7 on the generation of iTregs in polyclonal polarization cultures, but
in monoclonal 2D2Rag2KO cells iTreg differentiation was quite substantially inhibited
by let-7 (Figures 2.8A and 2.8B). The expression level of Ifng, Il4, and Csf2 mRNAs
was consistent with the range of frequencies of IFNγ+, IL-4+ and GM-CSF+ cells in Th0,
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Th1, and Th2 cultures (Figures 2.9). The expression of genes encoding lineage-specific
cytokine receptors, such as Il12rb2 (Th1) and Il4ra (Th2), as well as lineage-specific
transcription factors, including Tbx21 (Th1) and Gata3 (Th2), and the transcription factor
Bhlhe40, which has been shown to promote a proinflammatory phenotype in Th1 cells
(Yu et al., 2018), was also repressed in Let-7Tg Th0, Th1, and Th2 cells, but increased
in Lin28Tg cells. Thus, these results suggest a broader suppressive role for let-7 miRNAs
in the regulation of effector CD4+ T cell differentiation.

2.2.4 Let-7 prevents the chemokine-mediated migration of pathogenic Th17 cells
In addition to reduced proliferation potential and compromised differentiation, the
lower number of effector Let-7Tg CD4+ T cells in the CNS may be due to impaired cell
trafficking. Antigen-stimulated T cells upregulate chemokine receptors to sense, migrate,
and home to the location of inflammatory sites by following gradients of chemokines
(Griffith et al., 2014). Two chemokine receptors, CCR2 and CCR5, have been shown to
be critical for the migration of pathogenic T cells to the CNS and subsequently for EAE
development (Fife et al., 2000; Szczuciński & Losy, 2007; Kara et al., 2015; Gu et al.,
2016). To determine whether let-7 regulates CCR2 and CCR5 expression, we measured
Ccr2 and Ccr5 mRNA levels in in vitro-generated 2D2Rag2KO pathogenic Th17 cells
from WT, Let-7Tg and Lin28Tg mice. Surprisingly, the expression of both Ccr2 and Ccr5
was very low in Let-7Tg cells, while in Lin28Tg cells it was enhanced (Figures 2.10A).
Interestingly, we found potential let-7 binding sites within the mRNA of both Ccr2 and
Ccr5 (Figures 2.10B). To test whether these binding sites were functional, we transfected
NIH3T3 fibroblasts, which have high endogenous expression of let-7 miRNAs, with dual
luciferase vectors containing the wild-type sequence of these binding motifs. An ability
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for let-7 to bind to both sites in the Ccr2 mRNA, and one site in Ccr5 mRNA was
demonstrated by a significant reduction in luciferase activity (Figures 2.10C). Mutation
of these binding sites restored luciferase activity, confirming direct let-7 targeting. To test
whether the let-7-mediated suppression of CCR2 and CCR5 expression is sufficient to
prevent chemokine-mediated migration of Th17 cells towards their specific ligands,
CCL2 and CCL4, we subjected in vitro-generated 2D2Rag2KO WT, Let-7Tg and
Lin28Tg pathogenic Th17 cells to chemokine-mediated migration assays. Indeed,
2D2Rag2KO Let-7Tg cells exhibited compromised trafficking in response to both
chemokines alone and in combination, while Lin28Tg cells migrated more efficiently
than WT cells (Figures 2.10D). Even though changes in cell motility can contribute to
the difference in trafficking of Th17 cells, neither speed nor other intrinsic motility
variables (track length, track straightness, and cell displacement) were negatively affected
by let-7 expression (Figures 2.11). To test whether let-7 miRNAs prevent the migration
of pathogenic Th17 cells by inhibiting CCR2 and CCR5 expression, we overexpressed
Ccr2 or Ccr5 in in vitro-generated 2D2Rag2KO WT and 2D2Rag2KO Let-7Tg
pathogenic Th17 cells (Figures 2.10E) and tested the migratory potential of these cells
using chemokine-mediated migration assays. Surprisingly, only overexpression of Ccr5,
but not Ccr2, partially rescued the chemotaxis of 2D2Rag2KO Let-7Tg pathogenic Th17
cells towards CCL4, and enhanced the migration of 2D2Rag2KO WT pathogenic Th17
cells (Figures 2.10F). These results strongly suggest that let-7 miRNAs restrict the
CCR5-mediated migration of pathogenic Th17 cells by directly binding to Ccr5 mRNA
and inhibiting CCR5 expression, and additional let-7-mediated regulatory mechanisms
are involved in the CCR2-mediated migration of these cells.
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Altogether, our data show that let-7 miRNAs control the pathogenicity of Th17
cell in EAE by restricting their clonal expansion, inhibiting IL-1R1/IL-23R-dependent
differentiation and preventing CCR2/CCR5-mediated migration to the CNS. As such, we
propose that let-7 miRNAs may constitute a promising therapeutic target for the treatment
of autoimmune diseases such as MS.

2.3 Discussion
In the present study, we have identified let-7 miRNAs as critical negative
regulators of pathogenic Th17 cell differentiation and EAE development. Specifically,
we found that, similarly to CD8+ T cells (Wells et al., 2017), the expression of let-7
miRNAs in naive CD4+ T cells is downregulated upon activation, which is essential for
the clonal expansion, acquisition of pathogenic Th17 phenotype, and migration to the
CNS. We demonstrate that high let-7 miRNA expression in activated CD4+ T cells
confers almost complete protection against EAE by preventing CD4+ T cell pathogenicity
and infiltration in the CNS, while in the absence of let-7 miRNAs the development of
EAE is exacerbated.
The role of miRNAs in the regulation of T cell differentiation and function has
been extensively studied (Baumjohann & Ansel, 2013). However, despite the growing
number of reports describing miRNA dysregulation in MS patients (Ma et al., 2014), their
contribution to MS pathogenesis remains largely unknown. Although let-7 is one of the
most highly expressed miRNA families in CD4+ T cells (Kuchen et al., 2010) and it has
been shown to play regulatory roles in helper T cell responses (Polikepahad et al., 2010;
Kumar et al., 2011; Swaminathan et al., 2012; Okoye et al., 2014; Kimura et al., 2018),
published reports have yielded conflicting conclusions regarding the contribution of let53

7 miRNAs to Th17 cell pathogenicity during MS and EAE, and have remained
unresolved (Ma et al., 2014). For example, Junker et al., 2009 found an upregulation of
let-7c in MS lesions, while Kimura et al., 2018 described an increase in exosomal let-7i
in MS patients and proposed a disease-promoting role for let-7i. On the other hand, Cox
et al., 2010 showed a downregulation of let-7d, f, i, and, together with MartinelliBoneschi et al., 2012, let-7g, in peripheral blood samples of MS patients, whereas Guan
et al., 2013 reported a decrease in let-7g and let-7i in pathogenic CD4+ T cells in EAE,
but at the same time let-7b, c, d, f and especially let-7e, were upregulated. Moreover,
overexpression of let-7e in CD4+ T cells led to aggravated EAE, while knockdown of this
miRNA attenuated the disease. Our findings are in discordance with Guan et al., 2013,
since we show that EAE is aggravated upon adoptive transfer of Lin28Tg naive CD4+ T
cells, in which all let-7 members are suppressed, into Rag2KO recipients. These
disparities could be due to the use of different mouse models and treatments, as the cited
study employed CD44 KO CD4+ T cells and lentivirus-mediated overexpression or
silencing of let-7e expression, while we used transgenic mice with specific modulation
of let-7 miRNA expression.
Our most striking finding is that let-7 miRNAs keep pathogenic CD4+ T cells
from infiltrating the CNS. This effect was not due to a detrimental impact of let-7
miRNAs on the survival of activated CD4+ T cells, as maintenance of high let-7 miRNA
expression improved the survival rate of activated CD4+ T cells, while let-7 deficiency
caused an increase in cell death, which is consistent with our recently published
observations in both naive CD4+ and CD8+ T cells that let-7 miRNAs promote
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homeostatic survival through IL-7-independent stabilization of Bcl2 expression
(Pobezinskaya et al., 2019).
In comparison to CD8+ T cells (Wells et al., 2017), we observed only an
incremental contribution of let-7 to the proliferation of CD4+ T cells, despite the fact that
we found let-7-mediated suppression of Myc and Myc target genes involved in glycolysis
and protein synthesis. Furthermore, we demonstrate that let-7 miRNAs inhibit the
expression of Cdc25 and Cdc34, both of which are involved in the positive regulation of
cell cycle progression and are also documented direct Myc and let-7 miRNA target genes
(Gakationov et al., 1996; Johnson et al., 2007; Legesse-Miller et al., 2009). Thus, our
results indicate that let-7 miRNAs may regulate cell cycle progression in CD4+ T cells
both directly by inhibiting Cdc25a and Cdc34, as well as indirectly through Myc.
It is well-known that regulatory T cells play an indispensable role in preventing
autoimmunity (Wing & Sakaguchi, 2010). Based on our EAE experiments, it was
reasonable to hypothesize that let-7 miRNA expression may enhance the development or
function of Tregs while let-7 deficiency may compromise it. Surprisingly, our data show
the opposite results, in which let-7 miRNAs inhibited the differentiation of monoclonal
(2D2Rag2KO) iTregs in vitro. Furthermore, we noticed that, even though Lin28Tg CD4+
T cells have an enhanced potential to differentiate into pathogenic Th17 cells, Lin28Tg
mice are healthy and do not show any sign of autoimmunity, suggesting unaltered Treg
function in the absence of let-7 miRNAs. Based on these observations we can conclude
that let-7 expression does not enhance Treg differentiation or function. Therefore, in order
to understand the observed phenotype, we focused our research on the role of let-7
miRNAs in the differentiation and function of pathogenic Th17 cells.
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We show that let-7 miRNAs prevent the in vitro differentiation of naive CD4+ T
cells towards the pathogenic Th17 lineage, as reflected by the reduced frequencies of IL17A+, GM-CSF+, and IL-17A+GM-CSF+ cells, and the downregulation of the cytokine
genes Il17a and Csf2 (encoding GM-CSF), as well as the cytokine receptor genes Il1r1,
and Il23r. Both IL-1R1 and IL-23R signaling play critical roles in Th17 cell
differentiation, as mice deficient in either cytokine receptor or their respective ligand are
completely resistant to EAE development (Cua et al., 2003; Matsuki et al., 2006; Sutton
et al., 2006; McGeachy et al., 2009). It was later found that IL-23R signaling, as well as
IL-1R-mediated expression of the transcription factor Bhlhe40, induces the expression of
the cytokine GM-CSF, which stimulates peripheral inflammatory macrophages and
promotes their migration to the CNS, where they are responsible for demyelination and
neuroaxonal damage (El-Behi et al., 2011; Lin et al., 2016; Spath et al., 2017; Komuczki
et al., 2019). Both Bhlhe40 and GM-CSF have been shown to be indispensable for EAE
induction, since deficiency in either factor confers protection against EAE (McQualter et
al., 2001; Ponomarev et al., 2007; Codarri et al., 2011; Martínez-Llordella et al., 2013;
Lin et al., 2014), and elevated GM-CSF levels have been correlated with the active phase
of MS (Carrieri et al., 1998). In addition, two earlier reports proposed a role for specific
members of the let-7 family in the regulation of Il23r expression. Specifically, potential
let-7f binding sites were identified in IL23R mRNA in human memory CD4+ T cells (Li
et al., 2011), and loss of let-7e- and let-7f-mediated regulation of a human IL23R gene
variant was shown to be associated with inflammatory bowel disease, due to a
polymorphism in the 3’ UTR of IL-23R mRNA sequence (Zwiers et al., 2012). In our
study, we found additional let-7 binding sites within the mRNA sequence of Il23r and
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described the regulatory role of let-7 miRNAs in the context of pathogenic Th17 cell
differentiation. Furthermore, we identified potential let-7 binding sites within the mRNA
sequence of Il1r1, which has never been suggested to be a direct let-7 miRNA target.
Therefore, we propose a novel let-7 miRNA-mediated regulatory mechanism in which
let-7 miRNAs prevent both IL-1R1 and IL-23R expression in CD4+ T cells by directly
targeting their respective transcripts. Consistent with knock-out studies, CD4+ T cells that
do not express these cytokine receptors are unable to receive the necessary signals for the
induction of Bhlhe40 and GM-CSF, thereby aborting the differentiation of
encephalitogenic Th17 cells and EAE development.
We also tested whether the let-7 miRNA-mediated restriction of CNS infiltration
by pathogenic CD4+ T cells in EAE was due to the inhibition of cell migration to the
CNS. Even though there was no difference in intrinsic motility of in vitro-generated
pathogenic Th17 cells, we demonstrated, using transwell assays, that let-7 repressed the
chemokine-mediated migration of these cells in response to the chemokines CCL2 and
CCL4 by suppressing the expression of their cognate receptors CCR2 and CCR5.
Although chemokine receptors are normally upregulated in differentiating T cells,
enabling them to migrate and home to the location of ongoing immune responses, CCL2
and CCL4 have been detected at high levels in the cerebrospinal fluid, brain tissue, and
active lesions of patients with MS, and elevated expression of both chemokine receptors
on pathogenic CD4+ T cells has been correlated with the active phase of MS (Sørensen
& Sellebjerg, 2011; Teleshova et al., 2002; Szczuciński & Losy, 2007). In fact, the role
of CCR2 and CCR5 in pathogenic CD4+ T cell trafficking to the CNS in MS has been
confirmed in EAE using receptor-deficient mice (Fife et al., 2000; Gu et al., 2016).

57

Despite the fact that the observed dysregulation of these receptors could be indirectly
resulting from the let-7-mediated inhibition of pathogenic Th17 differentiation, we found
that the mRNA sequences of both chemokine receptors contain potential let-7 miRNA
binding sites. We showed, using luciferase reporter assays, that both sites identified in
Ccr2 mRNA, but only one site in Ccr5 mRNA, are functional let-7-binding sites.
Furthermore, we showed, in transwell assays using Ccr2- and Ccr5-overexpressing cells,
that let-7 can inhibit the CCR5-, but not the CCR2-mediated migration of pathogenic
Th17 cells. Therefore, we propose that let-7 miRNAs, in addition to possibly targeting
Il1r1 and Il23r transcripts, also inhibit CCR5-mediated chemotaxis by directly targeting
Ccr5 mRNA in pathogenic CD4+ T cells. The repression of CCR2-mediated chemotaxis
appears to be controlled by unknown let-7-mediated regulatory mechanisms, as it is not
rescued upon CCR2 overexpression. In accordance with chemokine receptor deficiency
studies in EAE, we can conclude that the inability to express the adequate levels of CCR5
suppresses the responsiveness of pathogenic Th17 cells to their respective ligands,
thereby preventing their migration to the CNS and EAE induction.
Our study strongly highlights a potential therapeutic application for let-7 miRNAs
in the treatment of autoimmune diseases such as MS. Besides, we show that let-7
expression did not interfere with the differentiation of non-pathogenic Th17 cells, which
are generated with IL-6 and TGF-β (McGeachy et al., 2007). This was consistent with
our findings that let-7 expression does not inhibit the expression of genes expressed in
both Th17 subsets, such as the transcription factors Rorc and Irf4, as well as the IL-6
receptor components Il6ra and Il6st. In contrast to their pathogenic counterparts, these
cells are not able to induce EAE, likely due to their inability to secrete GM-CSF in the
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absence of IL-1β and IL-23 signaling. Instead, non-pathogenic Th17 cells secrete the antiinflammatory cytokine IL-10, which antagonizes autoimmune responses (Kühn et al.,
1993). Therefore, it would be interesting to test whether let-7 affects the normal function
of these cells, the preservation of which would be important in the context of the proposed
therapeutic strategy. Furthermore, because the phenotypic plasticity of the Th17 subset is
well known, assessing whether the let-7-mediated inhibition of pathogenic Th17
differentiation can contribute to the conversion of these cells towards the non-pathogenic
Th17 lineage in the presence of the adequate signals would also have significant
implications for this therapy (McGeachy et al., 2007; McGeachy et al., 2009).
Altogether, our data demonstrate that let-7 miRNAs have a protective effect in
EAE rather than a role in promoting disease pathogenesis. Therefore, delivering let-7
miRNAs to pathogenic Th17 cells may constitute a promising therapeutic strategy for the
treatment of MS and related autoimmune diseases.
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Figure 2.1 Let-7 miRNAs are highly expressed in naive CD4+ T cells, but get
downregulated upon activation, proportionally to the duration and strength of TCR
stimulation. (A) Quantitative RT-PCR analysis of individual let-7 miRNA expression in
naive CD4+ T cells activated with plate-bound α-CD3 mAbs (5 µg/mL) and α-CD28
mAbs (5 µg/mL) for increasing time periods as indicated, presented relative to results
obtained for the small nuclear RNA U6 (control) and normalized to the unstimulated (0
hours) control. (B) Quantitative RT-PCR analysis of individual let-7 miRNA expression
in naive CD4+ T cells activated for 24 hours with plate-bound α-TCR mAbs (as indicated)
and α-CD28 mAbs (5 µg/mL), presented relative to results obtained for the small nuclear
RNA U6 (control) and normalized to the unstimulated (0 hours) control. Data are from
one experiment representative of two independent experiments (A, B; mean ± S.E.M. of
technical triplicates).
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Figure 2.2 Downregulation of let-7 miRNAs upon activation is required for CD4+ T
cell pathogenicity in EAE. (A) Mean clinical scores in vehicle- (no dox) treated wildtype (WT) (n=3) and Let-7Tg (n=4) mice or doxycycline- (+ dox) treated WT (n=7) and
Let-7Tg (n=7) mice immunized with MOG35-55 in complete Freund’s adjuvant (CFA) and
pertussis toxin (60 ng). (B) Number of total mononuclear cells at the peak of the disease
(day 9-15 post-immunization) in the CNS of vehicle- (no dox) or doxycycline- (+ dox)
treated WT versus Let-7Tg mice. (C) Number of CNS-infiltrated CD4+ T cells at the peak
of the disease (day 9-15 post-immunization) in vehicle- (no dox) or doxycycline- (+ dox)
treated WT versus Let-7Tg mice as analyzed by flow cytometry. (D) Intracellular staining
of CD4+ T cells from the CNS of vehicle- (no dox) or doxycycline- (+ dox) treated WT
versus Let-7Tg mice (left). Numbers indicate the frequencies of cytokine-positive cells
within the indicated gates. Quantification of the numbers of cytokine-positive cells as
assessed by flow cytometry for each staining strategy (right). (E) ELISA analysis of IL17, IFNγ and GM-CSF concentration in the supernatants of splenocytes from vehicle- (no
dox) or doxycycline- (+ dox) treated WT versus Let-7Tg mice harvested at the peak of
disease (day 9-15 post-immunization) and restimulated for 5 days in vitro with 20 µg/mL
MOG35-55. * p < 0.05, ** p < 0.01; *** p < 0.001, **** p < 0.0001 (A, B, C, D, E),
employing two-way ANOVA (A) or compared with WT using two-tailed Student’s t test
(B, C, D, E). Data are from two combined independent experiments (A, B, C; mean ±
S.E.M. of each population from all mice), from one experiment representative of two
independent experiments (D; mean ± S.E.M. of each population from all mice), or from
one experiment (C; mean ± S.E.M. of technical triplicates of each population from all
mice).
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Figure 2.3 Let-7 miRNAs control the development of active EAE by negatively
regulating the pathogenicity of monoclonal CD4+ T cells. (A) Mean clinical scores in
2D2Rag2KO WT (n=4), 2D2Rag2KO Let-7Tg (n=5) and 2D2Rag2KO Lin28Tg (n=3)
mice immunized with MOG35-55 in complete Freund’s adjuvant (CFA) and pertussis toxin
(60 ng). (B) Number of total mononuclear cells at the peak of the disease (day 9 postimmunization) in the CNS of 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO
Lin28Tg mice. (C) Number of CNS-infiltrated CD4+ T cells at the peak of the disease
(day 9-15 post-immunization) in 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and
2D2Rag2KO Lin28Tg mice as analyzed by flow cytometry. (D) Intracellular staining of
CD4+ T cells from the CNS of 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO
Lin28Tg mice (left). Numbers indicate the frequencies of cytokine-positive cells within
the indicated gates. * p < 0.05, ** p < 0.01; *** p < 0.001, **** p < 0.0001 (A, B, C, D),
compared with WT employing two-way ANOVA (A) or using two-tailed Student’s t test
(B, C, D). Data are from two combined independent experiments (A, B, C; mean ± S.E.M.
of each population from all mice) or one experiment representative of two independent
experiments (D).
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Figure 2.4 Let-7 miRNAs negatively regulate CD4+ T cell pathogenicity in a cellintrinsic manner in EAE. (A) Mean clinical scores in Rag2KO recipient mice that
received 2D2Rag2KO WT (n=7), 2D2Rag2KO Let-7Tg (n=7) or 2D2Rag2KO Lin28Tg
(n=8) naive CD4+ T cells (2-2.5 x 106 cells/recipient) and that were subsequently
immunized with MOG35-55 in complete Freund’s adjuvant (CFA) and pertussis toxin (60
ng). (B) Number of total mononuclear cells at the peak of the disease (day 9 postimmunization) in the CNS of Rag2KO recipients that received 2D2Rag2KO WT,
2D2Rag2KO Let-7Tg, and 2D2Rag2KO Lin28Tg cells. (C) Number of CNS-infiltrated
2D2Rag2KO CD4+ T cells at the peak of the disease (day 9 post-immunization) in
Rag2KO recipients transferred with 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg, and
2D2Rag2KO Lin28Tg cells as analyzed by flow cytometry. (D) Intracellular staining of
donor CD4+ T cells from the CNS of Rag2KO recipients that received 2D2Rag2KO WT,
2D2Rag2KO Let-7Tg, and 2D2Rag2KO Lin28Tg cells (left). Numbers indicate the
frequencies of cytokine-positive cells within the indicated gates. (E) Quantification of
total cell numbers and CD4+ T cell numbers in the spleens of Rag2KO recipient mice that
received 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg, and 2D2Rag2KO Lin28Tg cells.
* p < 0.05, ** p < 0.01; *** p < 0.001, **** p < 0.0001 (A, B, C, D, E), compared with
WT employing two-way ANOVA (A) or using two-tailed Student’s t test (B, C, D, E).
Data are from two combined independent experiments (A, B, C; mean ± S.E.M. of each
population from all mice), from one experiment representative of two independent
experiments (D), or from one experiment (E; mean ± S.E.M. of each population from all
mice).
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Figure 2.5 Let-7 miRNAs control the proliferation of CD4+ T cells by negatively
regulating metabolic reprogramming and cell cycle progression. (A) Survival rate of
WT, Let-7Tg and Lin28Tg CD4+ T cells activated in vitro for 3 days with α-CD3 and αCD28 mAbs (5 µg/mL each) as analyzed by trypan blue exclusion. (B) Proliferation of
Cell-Trace Violet-labeled WT, Let-7Tg and Lin28Tg CD4+ T cells activated in vitro for
3 days α-CD3 and α-CD28 mAbs (5 µg/mL each) as analyzed by flow cytometry.
Numbers indicate the cell frequencies within the indicated gates for each genotype. (C)
Quantitative RT-PCR analysis of the cell cycle regulators, cyclin D2 (Ccnd2), cyclindependent kinase 6 (Cdk6), cell division cycle 25a phosphatase (Cdc25a), and ubiquitinconjugating enzyme E2 Cdc34 (Cdc34) in naive CD4+ T cells activated with plate-bound
α-CD3 and α-CD28 mAbs (5 µg/mL each) for increasing time periods as indicated,
presented relative to results obtained for the ribosomal protein Rpl13a (control). (D)
Quantitative RT-PCR analysis of the transcription factors Myc (Myc) and AP-4 (Tfap4),
as well as Myc direct target genes involved in glycolysis and protein synthesis, glucose
transporter 3 (Glut3), hexokinase 2 (Hk2), lactate dehydrogenase A (Ldha), glutamyltRNA synthetase (Qars) and tyrosyl-tRNA synthetase (Yars) in naive CD4+ T cells
activated with plate-bound α-CD3 mAbs and α-CD28 mAbs (5 µg/mL each) for 48 hours,
presented relative to results obtained for the ribosomal protein Rpl13a (control).
* p < 0.05, ** p < 0.01; *** p < 0.001, **** p < 0.0001 (A, C, D), compared with WT
using two-tailed Student’s t test. Data are from one experiment representative of two
independent experiments (A, C, D; mean ± S.E.M. of technical triplicates of each
population from all mice) or from two independent experiments (B).
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Figure 2.6 Let-7 miRNAs also get downregulated over time during pathogenic Th17
differentiation. (A) Quantitative RT-PCR analysis of individual let-7 miRNA expression
in naive 2D2Rag2KO WT CD4+ T cells and during in-vitro-generation of 2D2RagKO
WT pathogenic Th17 cells at the indicated time points, presented relative to results
obtained for the small nuclear RNA U6 (control), and normalized to results obtained for
naive 2D2Rag2KO WT CD4+ T cells. (B) Quantitative RT-PCR analysis of individual
let-7 miRNA expression in naive CD4+ T cells and day-5 in-vitro-generated pathogenic
Th17 cells from 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg, and 2D2Rag2KO Lin28Tg
mice, presented relative to results obtained for the small nuclear RNA U6 (control), and
normalized to results obtained for naive 2D2Rag2KO WT CD4+ T cells. (C) Quantitative
RT-PCR analysis of Lin28a and Lin28b in naive 2D2Rag2KO WT and 2D2Rag2KO
Lin28Tg CD4+ T cells, as well as during in-vitro-generation of 2D2RagKO WT
pathogenic Th17 cells at the indicated time points presented relative to results obtained
for the small nuclear RNA U6 (control), and normalized to results obtained for naive
2D2Rag2KO WT CD4+ T cells. . * p < 0.05, *** p < 0.001, **** p < 0.0001, compared
with WT using two-tailed Student’s t test. Data are from one experiment representative
of at least two experiments (A, B, C; mean ± S.E.M. of technical replicates).
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Figure 2.7 Let-7 miRNAs specifically inhibit the acquisition of the pathogenic Th17
phenotype. (A) Intracellular staining of CD4+ T cells from 2D2Rag2KO WT,
2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice polarized in vitro towards the
pathogenic Th17 lineage with IL-6, IL-1β, and IL-23. Numbers indicate the frequencies
of cytokine-positive cells within the indicated gates. (B) Quantitative RT-PCR analysis
of the cytokines IL-17A (Il17a) and GM-CSF (Csf2), the cytokine receptors IL-1R1
(Il1r1) and IL-23R (Il23r), and the transcription factor Bhlhe40 (Bhlhe40) in in vitrogenerated pathogenic Th17 cells from 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and
2D2Rag2KO Lin28Tg mice from (A), presented relative to results obtained for the
ribosomal protein Rpl13a (control). (C) Diagram positioning in silico-identified let-7
binding sites (black vertical lines) within the mouse and human mRNA sequences of the
cytokine receptors IL1-R1 (Il1r1 and IL1R1, respectively) and IL-23R (Il23r and IL-23R,
respectively). (D) Quantitative RT-PCR analysis of the IL-6 cytokine receptor
components IL-6Rα (Il6ra) and IL-6ST (Il6st), and the transcription factors STAT3
(Stat3), IRF4 (Irf4), and RORγt (Rorc) in in vitro-generated pathogenic Th17 cells from
2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice.* p < 0.05,
*** p<0.001, **** p < 0.0001 (B, D), compared with WT using two-tailed Student’s t
test. Data are from one experiment representative of two independent experiments (A) or
from two independent experiments (B, D; mean ± S.E.M. of technical triplicates of each
population from all mice).
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Figure 2.8 Let-7 miRNAs inhibit the differentiation of several helper T cell subsets
generated from both polyclonal and monoclonal naive CD4+ T cells in vitro.
Intracellular staining of CD4+ T cells from polyclonal (A) or monoclonal 2D2Rag2KO
(B) WT, Let-7Tg and Lin28Tg mice polarized in vitro towards the Th0, Th1, Th2, nonpathogenic Th17 and iTreg lineages. Numbers indicate the frequencies of cytokinepositive cells within the indicated gates. Data are from one experiment representative of
seven (A) or six (B) independent experiments.
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Figure 2.9 Let-7 miRNAs negatively regulate the expression of genes controlling the
differentiation of Th0, Th1 and Th2 cells generated in vitro. Quantitative RT-PCR
analysis of the cytokines IFNγ (Ifng), GM-CSF (Csf2), and IL-4 (Il4), the cytokine
receptors IL12Rβ2 (Il12rb2) and IL4Rα (Il4ra), as well as the transcription factors T-bet
(Tbx21), Bhlhe40 (Bhlhe40) and GATA3 (Gata3) in naive CD4+ T cells and in vitrogenerated Th0, Th1 and Th2 cells from WT, Let-7Tg and Lin28Tg mice, presented
relative to results obtained for the ribosomal protein Rpl13a (control). Data are from one
experiment representative of two independent experiments (mean ± S.E.M. of technical
triplicates of each population from all mice).
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Figure 2.10 Let-7 miRNAs prevent the chemokine-dependent migration of in vitrogenerated pathogenic Th17 cells by suppressing the expression of the chemokine
receptors CCR2 and CCR5. (A) Quantitative RT-PCR analysis of the chemokine
receptors CCR2 (Ccr2) and CCR5 (Ccr5) in in vitro-generated pathogenic Th17 cells
from 2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice,
presented relative to results obtained for the ribosomal protein Rpl13a (control). (B)
Diagram positioning in silico-identified conserved (red vertical lines) and non-conserved
(black vertical lines) let-7 binding sites within the mouse and human mRNA sequences
of the chemokine receptors CCR2 (Ccr2 and CCR2, respectively) and CCR5 (Ccr5 and
CCR5, respectively). (C) Luciferase reporter assay of let-7 targeting in-silico-identified
let-7-binding sites in mouse Ccr2 or Ccr5 mRNA, in NIH/3T3 cells transfected with a
luciferase reporter vector containing either the wild-type or mutated variants of these
binding sites, or either the wild-type or a mutated variant of the antisense seed sequence
of let-7g (controls). Results are presented as relative luminescence units (RLU),
calculated by normalization of Firefly luciferase activity to Renilla luciferase activity
(control). (D) Transwell migration assay of in vitro-generated pathogenic Th17 cells from
2D2Rag2KO WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice from (A) in
response to the chemokines CCL2 (50 ng/mL) and CCL4 (50 ng/mL) alone or in
combination (50 ng/mL or 10 ng/mL each). Results are presented as percentage of cell
migration in media only control, defined as 100%. (E) Quantitative RT-PCR analysis of
the chemokine receptors CCR2 (Ccr2) and CCR5 (Ccr5) in in vitro-generated pathogenic
Th17 cells from 2D2Rag2KO WT and 2D2Rag2KO Let-7Tg mice, transduced with
empty vector (solid bars), Ccr2-overexpression vector (horizontally-striped bars), and
Ccr5-overexpression vector (diagonally-striped bars), presented relative to results
obtained for the ribosomal protein Rpl13a (control). (F) Transwell migration assay of in
vitro-generated pathogenic Th17 cells from 2D2Rag2KO WT and 2D2Rag2KO Let-7Tg
mice, transduced with empty vector (solid bars), Ccr2-overexpression vector
(horizontally-striped bars), and Ccr5-overexpression vector (diagonally-striped bars) in
response to the chemokines CCL2 (50 ng/mL) and CCL4 (50 ng/mL) alone. Results are
presented as percentage of cell migration in media only control, defined as 100%.
* p < 0.05, ** p < 0.01; *** p < 0.001, **** p < 0.0001 (A, C, D, F), compared with WT
using two-tailed Student’s t test. Data are from one experiment representative two
independent experiments (A, C, D, F; mean ± S.E.M. of technical triplicates).
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Figure 2.11 Let-7 miRNAs do not control the intrinsic motility of in vitro-generated
pathogenic Th17 cells. Speed, track length, track straightness, and displacement of
migrating CFSE-labeled in vitro-generated pathogenic Th17 cells from 2D2Rag2KO
WT, 2D2Rag2KO Let-7Tg and 2D2Rag2KO Lin28Tg mice embedded in collagen
matrices. * p < 0.05, ** p < 0.01, **** p < 0.0001, compared with WT using two-tailed
Student’s t test. Data are from one experiment (mean ± S.E.M. of at least 175 analyzed
cells of each population from all mice).
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CHAPTER 3
COMPUTATIONAL ANALYSES PREDICT THE REGULATORY ROLE OF
LET-7 MICRORNAS IN SHAPING THE FATE OF CD8+ T CELLS TOWARDS
MEMORY FORMATION WHILE SUPPRESSING TERMINAL EFFECTOR
DIFFERENTIATION/EXHAUSTION

3.1 Introduction
Cytotoxic CD8+ T lymphocytes (CTLs) are critical players of the immune response,
as they are able to directly contribute to antigen clearance by recognizing and killing cells
infected by intracellular pathogens, as wells as tumor cells (Sawamura et al., 1989;
Dharakul et al., 1990; Harty et al., 1992; Rodrigues et al., 2003). Upon antigen encounter,
antigen-specific CD8+ T cells proliferate and generate a large pool of CTLs that migrate
to the inflamed sites and execute their effector function to participate in the resolution of
the infection (Butz & Bevan, 1998). After antigen elimination, the majority of CTLs
undergo apoptosis during a contraction phase, as they are terminally differentiated, but a
small proportion survives and generates long-lived memory CD8+ T cells that will
respond faster and more effectively to subsequent challenges with the same antigen
(Grayson et al, 2000; Badovinac et al., 2002). This terminal-effector versus memory fate
specification depends on the strength of signals 1, 2, and 3, received by CD8+ T cells
upon activation, with stronger signals leading to a decrease in memory potential
(Stemberger et al., 2007; Gerlach et al., 2010; Angelosanto et al., 2012). These signals
also result in the upregulation of co-inhibitory receptors or “immune checkpoints”, such
as PD-1, TIM-3, LAG-3, 2B4, CD160, and CTLA-4 (Wherry, 2007). During acute
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infections, these receptors are only expressed in a transient manner, and contribute to the
adjustment of the strength and duration of the CTL response to prevent toxicity towards
host tissues (Agata et al., 1996; Monney et al., 2002; Probst et al., 2005). However, when
antigen fails to be efficiently cleared, such as during chronic infections and cancer, the
persistence of TCR signals on CD8+ T cells results in a more abundant, permanent, and
joint expression of these receptors (Blackburn et al., 2009). Following the interaction of
these receptors with their specific ligands that are upregulated in immunosuppressive
environments, such as the tumor microenvironment, CTLs are diverted towards a
dysfunctional state known as exhaustion. Exhausted CTLs are unable to clear the
infection and to differentiate into long-lasting memory cells (Moskophidis et al., 1993;
Zajac et al., 1998; Wherry et al., 2004).
Although memory CD8+ T cell formation is compromised during chronic
inflammation, memory CD8+ T cells introduced under these pathological conditions have
the capacity to elicit highly protective responses (Shoukry et al., 2003; Malik et al., 2017).
These efficient responses may be due to the high survival capacity of memory cells,
coupled to low immune checkpoint expression that may confer resistance to exhaustion
(Shoukry et al., 2003; Wirth et al., 2010). In addition, the generation of memory CD8+ T
cells by vaccination possess outstanding potential for preventing infectious diseases
(Lauvau et al., 2001; Akondy et al., 2017). However, the molecular mechanisms
promoting memory formation while inhibiting terminal effector differentiation and
restraining exhaustion are still incompletely understood.
RNA interference mediated by miRNAs is a potent and well-conserved posttranscriptional mechanism that regulates gene expression in a sequence-specific manner
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(Elbashir et al., 2001; Kim et al., 2008). Many individual miRNAs have been shown to
play a role in the control of terminal-effector versus memory CD8+ T cell fate
determination. For instance, miR-143, miR-155, and miRNAs of the miR-200 family
promote memory CD8+ T cell differentiation (Tsai et al., 2013; Guan et al., 2018; Zhang
et al., 2018), while miR-15/16, the miR-17-92 cluster, miR-23a, miR-31, and miR-150,
direct terminal-effector specification (Wu et al., 2012; Khan et al., 2013; Lin et al., 2014;
Ban et al., 2017; Chen et al., 2017; Moffett et al., 2017; Gagnon et al, 2019).
We previously showed that the let-7 miRNA family is highly expressed in naive CD8+
T cells, thereby keeping these cells in a quiescent state and promoting their survival
(Wells et al., 2017; Pobezinskaya et al., 2019). Moreover, we demonstrated that let-7 gets
substantially downregulated upon antigen encounter, as these miRNAs negatively
regulate CTL differentiation (Wells et al., 2017). Surprisingly, follow-up studies in our
lab have found that, even though cytotoxic function is diminished upon let-7
overexpression in in vitro-generated CTLs, these cells confer superb anti-cancer
protection upon adoptive transfer into tumor-bearing mice. Conversely, although in vitrodifferentiated let-7-deficient CTLs exhibit enhanced cytotoxic function, these cells failed
to control the same tumors, leading to poor recipient survival. Because the CTL response
observed in vitro is not reflective of the in-vivo outcome, the purpose of the research
described here was to elucidate this paradox.
RNA sequencing (RNA-Seq) is a well-established quantitative method that measures
the expression of all genes in a tissue sample at a given time using next-generation
sequencing of the transcriptome (Wang et al., 2009). In addition, bioinformatics has
emerged as a powerful tool to understand this type of big biological data by executing in
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silico analyses that use mathematical and statistical methods embedded in specific
analysis pipelines (Van den Berge et al., 2019). Thus, we sought to apply RNA-Seq and
bioinformatics analyses in order to explain this in-vitro versus in-vivo discrepancy in the
let-7-mediated regulation of CTL function in an unbiased manner.
We found that the modulation of let-7 expression in CD8+ T cells results in
transcriptional changes that shape the terminal-effector versus memory fate. Specifically,
we showed that maintaining high let-7 expression during the early stages of CTL
differentiation led to the upregulation of a memory-like gene signature, whereas absence
of let-7 during the differentiation of CTLs led to the upregulation of a gene signature
associated with terminally-differentiated effectors and exhaustion. This was consistent
with the identification of multiple early T cell activation-associated pathways inhibited
by let-7, including ERK1/2 and Notch. Finally, we identified multiple direct let-7 target
genes that were negatively regulated throughout CD8+ T cell differentiation, among
which we found that Hk2 and Mycn functionally contribute to the control of terminaleffector versus memory fate. Altogether, this study has solved the paradoxical outcomes
in the let-7-regulated CTL function in-vitro versus in-vivo using an unbiased approach
that uncovered a novel regulatory role for let-7 in promoting the generation of memory
CD8+ T cells differentiation while preventing terminal-effector differentiation. Thus, let7 miRNAs exhibit an utmost encouraging therapeutic potential as an innovative treatment
against chronic infections and cancer.
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3.2 Results
3.2.1 Modulation of let-7 expression in CTLs results in transcriptional changes
To understand the discrepancy between the in-vitro and in-vivo performance of
CTLs expressing different levels of let-7 (Figure 3.1), we isolated naive CD8+ T cells
from P14Rag2KO WT, Let-7Tg, and Lin28Tg mice, where P14 is a transgenic TCR
which recognizes the gp33-41 epitope from the lymphocytic choriomeningitis virus
(LCMV) glycoprotein (Pircher et al., 1987). We differentiated these cells into CTLs in
vitro in the presence of the cytokine IL-2, and we performed RNA-Seq on these CTLs at
day 5 of culture to analyze their transcriptome.
To assess whether let-7 regulates the transcriptome of CTLs, we used Principal
Component Analysis (PCA) to reduce the complexity of all 35,276 transcripts examined
to only ranked 9 variables, or principal components (PCs), which reflect the overall
variance between all samples analyzed in a small range of dimensions (Abdi & Williams,
2010). We chose to project our experimental samples along PC1 and PC2, which together
accounted for most of the total variance (74% and 13%, respectively). Notably, PCA
analysis revealed that WT, Let-7Tg, and Lin28Tg CTLs exhibited transcriptionally
distinct gene signatures, as all samples from the same genotype were clustered together,
but separated from those with distinct genotypes (Figure 3.2A). This genetic distance
was statistically significant between all groups, as represented by the non-overlapping
95% confidence ellipses from each cluster. These results show that let-7 expression alters
the transcriptome of CTLs.
To examine the extent to which let-7 modulates the CTL transcriptome, we
performed differential gene expression analysis on Let-7Tg-versus-WT, and Lin28Tg81

versus-WT CTLs. The output data showed that, in comparison to WT CTLs, 216 genes
were downregulated and 286 genes were upregulated in Let-7Tg CTLs, while in Lin28Tg
CTLs 448 genes were downregulated and 428 genes were upregulated, as compared to
WT CTLs (Figures 3.2B). Moreover, we found that several genes involved in memory T
cell differentiation and terminal-effector differentiation/exhaustion were differentially
expressed in a reversed manner in Let-7Tg and Lin28Tg CTLs, when compared to WT
CTLs. For instance, memory markers, such as Ccr7, Id3, Il7ra, Lef1, Sell (CD62L) and
Tcf7 (TCF-1), were upregulated in Let-7Tg CTLs, but downregulated in Lin28Tg CTLs,
whereas terminal-effector/exhaustion markers, including Cd244a (2B4), Entpd1 (CD39),
Eomes, Havcr2 (TIM-3), Id2, and Pdcd1 (PD-1), were upregulated in Lin28Tg CTLs, but
downregulated in Let-7Tg CTLs. These findings suggest that let-7 globally manipulates
the transcriptional signature of CTLs.
To identify and compare the expression of all genes that were either positively or
negatively regulated by let-7 in CTLs, we used the normalized gene expression reads
from WT, Let-7Tg, and Lin28Tg CTL replicate samples to generate a heatmap plot of all
the genes that were differentially expressed at least by 30% (|log2(fold change|= 0.5) in a
statistically significant manner in Let-7Tg and Lin28Tg CTLs, in comparison to WT
CTLs. Heatmaps are bi-dimensional matrices that represent, across comparable samples,
the differences in the expression level of genes, which are ranked according to the extent
of differential expression (Eisen et al., 1998). Under these criteria, we were able to
categorize 177 of these genes into 4 distinct clusters (Figure 3.2C). Cluster I was the
largest and comprised all genes that were negatively regulated by let-7 (n=98), such as
Cd160, Gzmb, Havcr2, and the direct let-7 target Hk2, and were thus downregulated in
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Let-7Tg CTLs, but upregulated in Lin28Tg CTLs, as compared to WT CTLs. Conversely,
cluster II contained all genes that were positively regulated by let-7 (n=70), including
Il7ra, thereby upregulated in Let-7Tg CTLs, but downregulated in Lin28Tg CTLs, in
comparison to WT CTLs. Cluster III and cluster IV were very small and consisted of
genes downregulated (n=2) or upregulated (n=7) in both Let-7Tg and Lin28Tg CTLs,
when compared to WT CTLs, respectively. These results demonstrate that let-7 has both
substantial negative and positive impacts on the CTL transcriptome.
To determine which biological processes the genes significantly downregulated
in Let-7Tg CTLs and upregulated in Lin28Tg CTLs (cluster I), as well as the genes
significantly upregulated in Let-7Tg CTLs and downregulated in Lin28Tg CTLs (cluster
II) belonged to, we performed functional annotation of these genes using the Database
for Annotation, Visualization and Integrated Discovery (DAVID) (Huang et al., 2009).
This analysis determined that cluster I was enriched for functionally-related gene groups
involved in the defense response to viruses and the response to biotic stimulus, whereas
in cluster II, genes implicated in the immune response and the apoptotic signaling
pathway were over-represented (Figure 3.2D). These data indicate that let-7 expression
in CTLs regulates biological processes associated with the immune response and cell
survival, which is consistent with our previous reports on the regulatory role of let-7 in
CTL differentiation (Wells et al., 2017), as well as the role of let-7 in promoting T cell
survival (Pobezinskaya et al., 2019).
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3.2.2 Let-7 expression promotes a memory-like gene signature in CTLs, while also
repressing genes associated with terminal effector differentiation and
exhaustion
Because several memory markers were upregulated in Let-7Tg CTLs and
downregulated in Lin28Tg CTLs, as compared to WT CTLs, and multiple terminaleffector/exhaustion markers followed the opposite expression pattern in the same cells,
we hypothesized that let-7 may regulate memory versus terminal-effector CD8+ T cell
fate determination.
To support our hypothesis that let-7 promotes memory formation in CD8+ T cells,
we employed gene set enrichment analysis (GSEA), which determines whether a defined
set of genes is differentially expressed in a statistically significant manner between two
samples (Subramanian et al., 2005). To do so, we ranked the differential gene expression
data from Let-7Tg-versus-WT, and Lin28Tg-versus-WT CTLs by increasing statistical
significance using the adjusted p-value. We next ran GSEA by subjecting our ranked gene
lists to a memory-associated gene signature (n=56 genes), as well as a terminaleffector/exhaustion-associated gene set (n=62 genes), both of which were generated by
gathering well-defined markers from the literature (Yang et al., 2011; Im et al., 2016;
Schietinger et al., 2016; Yu et al., 2017; Snell et al., 2018; Miller et al., 2019). In fact, the
memory gene signature was significantly enriched in Let-7Tg CTLs (NES=1.458; pvalue<0.001), whereas in Lin28Tg CTLs this gene set was significantly depleted (NES=1.518; p-value<0.001) (Figure 3.3A). In contrast, the terminal-effector/exhaustion gene
signature was over-represented in Lin28Tg CTLs (NES=1.431; p-value=0.118), but
depleted in Let-7Tg CTLs (NES=-1.153; p-value=0.213), although the statistical
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significance threshold was not reached. These findings suggest that let-7 may play a role
in the specification of memory versus terminal-effector/exhausted CD8+ T cell fate.
To define and compare the expression of the genes contained in the gene sets used
in GSEA, we used the normalized gene expression reads from WT, Let-7Tg, and Lin28Tg
CTL replicate samples and we grouped all genes from both signatures examined into
functional categories. We then generated heatmaps of each gene category, namely
transcription factors, effector molecules and receptors, chemokines and chemokine
receptors, co-stimulatory molecules and receptors, and inhibitory receptors (Figure
3.3B). This analysis revealed that Let-7Tg CTLs upregulated the transcription factors
Foxo1, Id3, Lef1, and Tcf7, which drive the memory fate of CD8+ T cells (Zhou et al.,
2010; Gattinoni et al., 2011; Yang et al., 2011; Zhou & Xue, 2012; Hess Michelini et al.,
2013), but also Tbx21 (T-bet) and Zeb2, which promote cytotoxic activity (Dominguez et
al., 2015). Moreover, the secondary lymphoid organ homing receptor Ccr7, as well as the
cell-adhesion molecule Sell (CD62L), which direct the migration of central memory cells
to the lymph nodes, also showed increased expression in Let-7Tg CTLs (Kishimoto et al,
1990; Förster et al., 1999; Sallusto et al., 1999). In addition, Let-7Tg CTLs exhibited high
expression of the cytokine receptors Il7ra (CD127), emblematic of memory precursor
effector cells (MPECs), as well as Il6ra, which is important for memory CD8+ T cell
survival (Brown et al., 2019). Interestingly, Let-7Tg CTLs also upregulated most costimulatory molecules and receptors assessed, including Cd28, Icos, and Ox40, the
engagement of which is particularly important for optimal recall responses of memory
CD8+ T cells (Borowski et al., 2007). Most strikingly, Let-7Tg CTLs expressed high
levels of T memory stem cell markers, including the transcription factor Sox4, the anti-
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apoptotic protein Bcl2, the secondary lymphoid organ homing receptor S1pr1, as well as
the Wnt signaling target Axin2 (Figure 3.3C) (Gattinoni et al., 2009; Gattinoni et al.,
2011). Thus, these data indicate that let-7 directs the fate of CD8+ T cells towards memory
formation.
On the other hand, Lin28Tg CTLs showed increased expression of the
transcription factors Eomes, Id2, Ikzf2 (Helios), and Prdm1 (Blimp-1), which are highly
expressed in terminally-differentiated effectors and exhausted CD8+ T cells (Wherry,
2007; Shin et al., 2009). Besides, Eomes and Ikzf2 are direct let-7 targets (Agarwal et al.,
2015; Wells et al., 2017). Moreover, most effector molecules and cytokines, including
GzmA, GzmB, Prf1, Ifng, Tnf, and Fasl, were upregulated in Lin28Tg CTLs. In addition,
these cells also expressed high levels of the immunosuppressive cytokine Il10, which, in
addition to being directly targeted by let-7, is also abundantly expressed in exhausted
cells CD8+ T cells (Wilson et al., 2011). Furthermore, numerous pro-inflammatory
chemokines, including Ccl3, Ccl4, Ccl5, as well as the chemokine receptors Cx3cr1 and
Cxcr1, were highly expressed in Lin28Tg CTLs. In contrast, these cells showed enhanced
expression of only a few co-stimulatory molecules and receptors, namely Tnfrsf9 (41BB), its ligand Tnfsf9 (4-1BBL), and Tnfrsf8 (CD30). Most remarkably, Lin28Tg CTLs
showed upregulation of numerous co-inhibitory receptors, including Pdcd1 (PD-1),
Havcr2 (TIM-3), Cd160, and Cd244a (2B4), as well as the short-lived effector cell
(SLEC) marker Klrg1. Therefore, these results suggest that let-7 deficiency leads to
terminal-effector differentiation, which renders CD8+ T cells susceptible to exhaustion
upon engagement with their cognate ligands, which can be found in immunosuppressive
conditions such as the tumor microenvironment.
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To test whether let-7 expression influences the memory potential of
differentiating CD8+ T cells, we injected 2x104 P14Rag2KO WT or P14Rag2KO
Lin28Tg naive CD8+ T cells into congenic CD45.1+ recipient mice which were
subsequently infected with 6x106 colony-forming units (cfu) of a strain of the bacterium
Listeria monocytogenes, a well-established model for the study of memory T cell
responses (Khan & Badovinac, 2015), that expresses the LCMV gp33-41 peptide antigen
(Lm-gp33). Strikingly, the frequencies of donor CD8+ T cells in the spleen of mice that
received Lin28Tg cells were dramatically diminished, and the proportions of effectormemory (CD44hiCD62Llo) to central-memory cells (CD44hiCD62Lhi) were increased, in
comparison to mice that received WT cells (Figure 3.3D). These results demonstrate that
the formation of memory CD8+ T cells is compromised in the absence of let-7 miRNAs,
and that in these conditions the cells that survive contraction preferentially generate
effector-memory cells. Overall, our results strongly indicate that let-7 plays a regulatory
role in the fate determination of CD8+ T cells into memory and terminally-differentiated
cells.

3.2.3 Let-7 expression primes CD8+ T cells towards the memory fate early upon
antigen encounter by negatively regulating T-cell receptor signaling
pathways
The asymmetric-cell-fate model and the signal-strength model propose that the
memory CD8 + T cell fate is specified following antigen encounter (Kaech & Cui, 2012).
To determine whether let-7 can direct the fate of CD8+ T cells towards memory formation
early during activation, we performed RNA-Seq on P14Rag2KO WT, Let-7Tg, and
Lin28Tg naive CD8+ T cells, as well as CD8+ T cells activated in vitro for 12 hours.
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To examine whether let-7 expression has an impact on the gene signatures of
CD8+ T cells at early stages of differentiation, PCA analysis was run on normalized
expression reads of naive and 12h-activated CD8+ T cells. Again, the output data
demonstrated that the transcriptomes of WT, Let-7Tg, and Lin28Tg CD8+ T cells
clustered separately both at the naive and 12h-activated stage, as shown by the shift of
samples from different genotypes along PC1 (accounting for 61% and 57% of the total
variance in naive and 12h-activated, respectively) and PC2 (accounting for 21% and 22%
of the total variance in naive and 12h-activated, respectively), as well as by the grouping
of all samples from the same genotype into non-overlapping clusters (Figure 3.4A and
3.4B). These results demonstrate that let-7 expression induces transcriptional changes
early during CD8+ T cell differentiation.
To assess the magnitude of let-7 influence on the transcriptome of naive and 12hactivated CD8+ T cells, we analyzed the differential gene expression between WT and
Let-7Tg or Lin28Tg CD8+ T cells at these two time points. In naive CD8+ T cells, 220
genes were downregulated and 131 genes were upregulated in Let-7Tg cells, whereas in
Lin28Tg cells 1,687 genes were downregulated, and 2,718 genes were upregulated
(Figure 3.4C). The same analysis in 12h-activated CD8+ T cells revealed that 357 genes
were downregulated and 241 genes were upregulated in Let-7Tg cells, while in Lin28Tg
cells 580 genes were downregulated and 1,177 genes were upregulated. These findings
demonstrate that let-7 expression already has a substantial impact on the transcriptome of
CD8+ T cells at early stages of differentiation (Figure 3.4D).
To determine which genes were significantly controlled by let-7 early during
CD8+ T cell differentiation, heatmap clusters representing the same 4 trends as in our
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CTL bioinformatics studies were generated using all genes exhibiting at least a 30%
change in expression (|log2(fold change)|= 0.5) in Let-7Tg and Lin28Tg CD8+ T cells, as
compared to WT cells, at the naive and 12h-activated stage. In naive cells, 148 of these
genes could be incorporated in these 4 clusters (Figure 3.4E), whereas in 12h-activated
cells, 224 of these genes could be included (Figure 3.4F). Cluster I, which contained
genes repressed by let-7, was again the largest for both time points assessed, especially
in 12h-activated cells. In this cluster, there were 63 genes from the naive stage, including
the let-7 target genes Cdc34, Efhd2, Gng5, Hk2, and Nme4, as well as the proliferating
cell nuclear antigen Pcna. At the 12h-activated time point, cluster I comprised 157 genes,
including additional targets of let-7, such as Arid3a, Arid3b, and Ero1l, but also numerous
genes involved in cell cycle regulation, including Ccna2, Cdc25a, and Mki67, consistent
with the inhibitory role of let-7 in CD8+ T cell proliferation (Wells et al., 2017).
Moreover, this cluster contained T cell activation-associated genes, such as Jund, and
Notch2, as well as the effector molecule Ifng, the activation marker Cd44, and the antiapoptotic factor Bcl2l1 (Bcl-xL) (Boise et al., 1993). Cluster II, which contained genes
positively regulated by let-7, was once again the second largest cluster at both stages
tested, and comprised 41 genes from the naive time point, including the co-stimulatory
receptor Cd28, which was consistent with the same cluster in CTLs (Figure 3.2C). At the
12h-activated time point, cluster II contained 47 genes, and comprised the transcription
factor Ets1, which drives the expression of Il7ra (CD127) (Grenningloh et al., 2011), as
well as Il6st, a component of the IL-6 receptor complex, the signaling of which promotes
memory CD8+ T cell survival (Nish et al., 2014; Harker et al., 2015). Cluster III and IV,
which respectively incorporated genes either upregulated or downregulated in both Let-
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7Tg and Lin28Tg CTLs when compared to WT CTLs, were once more the least
represented at both stages assessed. In naive cells, cluster III comprised 24 genes and
cluster IV contained 20 genes while in 12h-activated cells cluster III incorporated 6 genes
and cluster IV contained 14 genes. These results reveal that let-7 has a mostly negative
impact on the transcriptome of CD8+ T cells that gets established very early during T cell
activation.
To identify the biological processes enriched in cluster I in both naive and 12hactivated CD8+ T cells, we ran the DAVID functional gene annotation algorithm. To our
surprise, the output data revealed that, in naive CD8+ T cells, many functionally-related
gene groups from this cluster belonged to processes associated with T cell activation.
These let-7-regulated pathways included signal transduction, protein phosphorylation,
gene expression regulation, cell cycle progression, apoptosis, the immune response, as
well as signaling pathways downstream of TCR signaling, such as Notch, JNK, MAPK,
and ERK1/2 (Figure 3.5A). Consistently, in 12h-activated CD8+ T cells, there was an
over-representation of let-7-inhibited processes that resulted from these pathways, such
as the regulation of gene expression, protein phosphorylation, and cell cycle progression
(Figure 3.5B), which is in agreement with our previously published findings that let-7
represses CD8+ T cell proliferation (Wells et al., 2017). These data indicate that let-7
regulates CD8+ T cell differentiation at early stages of CD8+ T cell activation.
To validate our predictions, we first examined the extent of ERK1/2
phosphorylation (pERK1/2) in 5-minute in vitro-activated P14Rag2KO WT, Let-7Tg,
and Lin28Tg CD8+ T cells. Outstandingly, the levels of pERK1/2 were diminished in Let7Tg cells, while in Lin28Tg cells the amount of pERK1/2 was increased, which suggests
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that let-7 regulates the strength of TCR signaling in CD8+ T cells (Figure 3.5C). These
findings confirm that let-7 controls the differentiation of CD8+ T cells during the very
first minutes following activation by inhibiting early signaling pathways, including the
ERK1/2 pathway.
We next sought to determine whether let-7 controls the fate of CD8+ T cells
through the negative regulation of the Notch signaling pathway, which has already been
reported to promote short-lived effector cell (SLEC) over memory precursor effector cell
(MPEC) generation (Backer et al., 2014). Notch is a transmembrane receptor which, upon
ligand binding on its extracellular portion, undergoes cleavage of its intracellular portion,
Notch intracellular domain (NICD) (Artavanis-Tsakonas et al., 1995). NICD is the active
form of Notch which can participate both in the transcriptional control of gene expression
in the nucleus (canonical Notch signaling) and in signaling pathways in the cytoplasm
(non-canonical Notch signaling) (Nam et al., 2003; Kwon et al., 2011; Minter & Osborne,
2012; Dongre et al., 2014; Shin et al., 2014). We overexpressed NICD, containing either
a nuclear export signal (NES) or a nuclear localization signal (NLS), in P14Rag2KO
CD8+ T cells by transduction using the pMRX-IRES-GFP retroviral vector that contains
a GFP reporter (Saitoh et al., 2002), and assessed their phenotype in vivo. We injected
2x105 of these cells into congenic CD45.1+ recipient mice which were subsequently
infected with Lm-gp33. Surprisingly, both NICD-NES and NICD-NLS overexpression
in CD8+ T cells had a dramatic effect on memory formation in the spleen of these mice
30 days post-infection (dpi) (Figure 3.5D). Specifically, the frequencies of NICD-NES
and NICD-NLS-overexpressing CD8+ T cells were substantially reduced in comparison
with cells that overexpressed the empty vector, as represented by GFP expression, which
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demonstrates that these cells lost their memory potential. Moreover, the percentages of
effector-memory cells were increased, while central-memory cell proportions were
diminished in NICD-NES- and NICD-NLS-overexpressing CD8+ T cells that persisted at
this time point. This was consistent with the diminished frequencies and enhanced
effector-memory to central-memory cell identity ratio of donor P14Rag2KO Lin28Tg
CD8+ T cells present in the spleen of Lm-gp33-challenged CD45.1+ mice at the same time
point (Figure 3.3D). These results suggest that let-7 antagonizes the Notch signaling
pathway that promotes terminal-effector CD8+ T cell differentiation over memory
formation both by participating in signaling pathways and driving gene transcription.
Since we showed that let-7 negatively regulates early T cell activation signaling
pathways, and that we previously demonstrated that let-7 downregulation depends on the
strength of TCR signaling upon CD8+ T cell activation (Wells et al., 2017), we next
sought to examine whether the generation of SLECs and MPECs depended on strong and
weak TCR signals, in accordance with the signal-strength and asymmetric-cell-fate
models. To this end, we took advantage of Nur77-GFP mice, which express a GFP
reporter under the control of the Nr41a (Nur77) promoter, the expression level of which
directly correlates with the strength of TCR signaling received by T cells upon activation
(Moran et al., 2011). We crossed these mice to P14Rag2KO mice to generate
P14Rag2KO Nur77-GFP mice, and we injected 2x104 naive CD8+ T cells from these
mice into CD45.1+ congenic recipient mice that were subsequently challenged with Lmgp33. Remarkably, we observed that, at day 9 dpi, SLECs (KLRG1hiCD127lo) expressed
higher levels of Nur77 than MPECs (KLRG1loCD127hi), as reflected by GFP MFI
(Figure 3.5E). Of note, intermediate cells (KLRG1hiCD127hi) shared similar Nur77
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expression to MPECs. These findings directly validate the signal-strength model of CD8+
T cell fate determination. Moreover, our data suggest that let-7 promotes the memory
CD8+ T cell fate by suppressing the strength of TCR signaling.
These analyses strongly indicate that let-7 negatively regulates CD8+ T cell
differentiation early on by diminishing the strength of TCR signaling, thereby inhibiting
early downstream activation pathways, including ERK1/2 and Notch. These results
coincide with the signal-strength and asymmetric-cell-fate models of CD8+ T cell fate
specification, and thus provide a mechanism for the let-7-mediated regulation of memory
versus terminal-effector CD8+ T cell fate determination.

3.2.4 Let-7 consistently regulates target genes throughout CD8+ T cell
differentiation
To deepen our understanding of the let-7-regulated molecular mechanisms
controlling the fate of CD8+ T cells, we compared all the let-7 target genes contained in
cluster I at all stages of CD8+ T cell differentiation assessed (naive, 12h-activated, and
CTLs). Remarkably, this analysis revealed that multiple genes were negatively regulated
by let-7 throughout CD8+ T cell differentiation (Figure 3.6A). For instance, the ubiquitinconjugating enzyme Cdc34, which is involved in the regulation of the cell cycle, as well
as in the NF-κB and Wnt signaling pathways, was negatively regulated by let-7 in both
naive and 12h-activated CD8+ T cells (Semplici et al., 2002 ; Legesse-Miller et al., 2010;
Wu et al., 2010). Moreover, the expression of the transcription factor Mycn, which
promotes hematopoietic stem cell proliferation, differentiation, survival, was inhibited by
let-7 at both the 12h-activated and CTLs stage of CD8+ T cell differentiation (Laurenti et
al., 2008). Most interestingly, let-7 consistently repressed several target genes at all time
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points tested, namely Efhd2, Gng5, and Hk2. Efhd2, or EF Hand Domain Family Member
D2, is a calcium-binding adapter protein which has been shown to promote CD8+ T cell
cytotoxicity and contribute to PD-1 inhibitory activity (Peled et al., 2018). Gng5 is a G
protein-coupled receptor gamma subunit that participates in chemokine receptor
signaling, which regulates the migration of T cells (Griffith et al., 2014). Hk2 is the
glycolytic enzyme hexokinase 2, which catalyzes the rate-limiting step of glucose
phosphorylation into glucose-6-phosphate, and is highly upregulated in T cells upon
activation as well as in terminal effectors, but gets downregulated in memory CD8+ T
cells (Tan et al., 2017; Sukumar et al., 2013). These results provide candidate let-7 target
genes that may play a role in the regulation of CD8+ T cell fate determination.
To test whether the candidate let-7 target genes identified above contribute to the
regulation of terminal-effector versus memory CD8+ T cell fate specification, we
overexpressed the open reading frame (ORF) of Cdc34, Efhd2, Gng5, Hk2, and Mycn in
CD8+ T cells by transduction using the pMRX-IRES-GFP retroviral vector.
Overexpression of Cdc34 in in vitro-generated Let-7Tg CTLs resulted in a slight increase
in PD-1 expression, and, unexpectedly, in enhanced frequencies of central memory-like
(CD44hiCD62Lhi) cells over effector memory-like (CD44hiCD62Llo) cells (Figure 3.6B).
However, this effect was also observed in cells that were not transduced (GFP-), making
these results inconclusive. To test the biological relevance of the remaining candidate
genes in the fate of CD8+ T cells, P14Rag2KO CD8+ T cells overexpressing the ORF of
Efhd2, Gng5, Hk2, or Mycn were injected into CD45.1+ congenic host mice that were
subsequently infected with Lm-gp33. At 30 dpi, only overexpression of Hk2 and Mycn
had substantial effects on the formation of memory CD8+ T cells in the spleen of these
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mice (Figure 3.6C and 3.6D). In fact, the percentages of Hk2- and Mycn-overexpressing
CD8+ T cells were significantly diminished when compared to cells that overexpressed
the empty vector. Moreover, the frequencies of effector-memory cells were increased,
while central-memory cell proportions were diminished in Hk2- or Mycn- overexpressing
cells that persisted at this time point. These findings are consistent with the phenotype
observed upon Notch NICD overexpression (Figure 3.5D), and are in agreement with
previous reports describing Notch as a positive regulator of glycolysis, and Mycn as a
positive regulator of Notch (Landor et al., 2011; Tong et al., 2019). Thus, these data
demonstrate that Hk2 and Mycn are let-7 target genes that play a role in establishing the
terminal-effector differentiation program and repressing memory formation in CD8+ T
cells.
Taken together, our results demonstrate that let-7 miRNA expression specifies the
fate of CD8+ T cells following antigen encounter towards memory formation while
preventing terminal-effector differentiation, and thus the susceptibility to exhaustion,
thereby solving the in-vitro versus in-vivo paradox of let-7-regulated CTL function.
Specifically, absence of let-7 leads to the upregulation of co-inhibitory receptors that
induce exhaustion upon engagement with their cognate ligands, which are abundantly
expressed in immunosuppressive environments encountered during chronic infections
and cancer. In fact, we show that let-7 alters the CD8+ T cell transcriptome, reduces TCR
signaling strength, and inhibits downstream signaling pathways during early stages of
activation, including ERK1/2 and Notch. Finally, we identified multiple let-7 target genes
that were continuously dysregulated during CD8+ T cell differentiation, and among these
we found that Hk2 and Mycn drive the terminal-effector CD8+ T cell fate, while inhibiting
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the generation of memory cells. Consequently, our discovery that let-7 skews CD8+ T
cell fate towards memory cell generation may lead to the development of novel
therapeutic strategies contributing to substantial advances in the treatment of cancer and
chronic infections.

3.3 Discussion
Our study uncovered a novel post-transcriptional mechanism regulating the fate
of CD8+ T cells towards memory and terminally-differentiated effector cell formation,
using RNA-Seq and bioinformatics analyses as an unbiased approach. Particularly, we
identified let-7 miRNAs as central regulators of this dichotomy, promoting the generation
of memory CD8+ T cells while restraining the terminal effector program early during
CD8+ T cell differentiation, thereby preventing exhaustion in chronic inflammatory
conditions. This discovery elucidates the paradoxical CTL performance in-vitro and invivo, as let-7 deficiency resulted in high expression of co-inhibitory receptors that can
induce exhaustion upon interaction with their cognate ligands, which are upregulated in
immunosuppressive conditions, such as the tumor microenvironment. Most importantly,
our findings directly establishes let-7 has a promising innovative therapeutic means to
treat chronic pathologies such as cancer.
Analysis of the CTL transcriptome showed that let-7 expression significantly
altered the phenotype of these cells, in which many genes were negatively regulated by
let-7. Consistently with the in-vitro phenotype of CTLs, Let-7Tg CTLs upregulated genes
involved in the immune response and the regulation of apoptosis, whereas processes such
as the defense response to viruses and the response to biotic stimuli were over-represented
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in let-7 deficient CTLs. Moreover, let-7 overexpression contributed to the enrichment of
a memory-associated gene signature, whereas in the absence of let-7 a gene set
characteristic of terminally-differentiated CD8+ T cells was over-represented.
Specifically, we found that Let-7Tg CTLs expressed high levels of the well-defined
memory markers Ccr7, Sell (CD62L), Il7ra, Bcl2, Foxo1, Id3, Tcf7, and Lef1, as well as
T stem cell memory markers, including Axin2, S1pr1 and Sox4, but also transcription
factors involved in CTL differentiation, such as Tbx21 (T-bet) and Zeb2 (Gattinoni et al.,
2009; Gattinoni et al., 2011; Dominguez et al., 2015). Additionally, these cells expressed
high levels of co-stimulatory receptors, such as Cd28, Icos, and Ox40, the signaling of
which contributes to efficient memory responses (Borowski et al., 2007). Based on these
results, we could infer that, although they exhibit reduced cytotoxicity in vitro, Let-7Tg
CTLs maintain a central/stem cell-like memory potential and are thus able to elicit the
robust, long-lasting anti-tumor immunity observed in vivo. This is in accordance with our
previously published findings that let-7 preserves the quiescence of naive T cells, as
memory cells are characterized by a return to the quiescent state (Kalia et al., 2015; Wells
et al., 2017). Our predictions are also consistent with another publication in which we
demonstrated that let-7 expression is required for the survival of naive T cells, as Let-7Tg
CTLs had increased expression of the anti-apoptotic genes Bcl2 and Bcl11b (Bcl-xL)
(Pobezinskaya et al., 2019). Thus, let-7 may contribute to the resistance of memory
precursors to the contraction phase and prolonged survival of memory cells through
enhanced Bcl2 expression (Akbar et al., 1993; Grayson et al., 2000; Pobezinskaya et al.,
2019). In contrast, Lin28Tg CTLs preferentially expressed the transcription factors
Eomes, Id2, Ikzf2 (Helios), and Prdm1 (Blimp-1), the co-inhibitory receptors Pdcd1 (PD-
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1), Havcr2 (TIM-3), Cd160, and Cd244a (2B4), effector molecules and cytokines GzmA,
GzmB, Prf1, Ifng, Tnf, and Fasl, as well as the immunosuppressive cytokine Il10, all of
which are highly expressed in terminally-differentiated and exhausted CD8+ T cells
(Wherry, 2007; Blackburn et al., 2009; Shin et al., 2009). These cells also had increased
expression of the co-stimulatory receptor Tnfrsf9 (4-1BB), which has been described as
an exhaustion marker in CD8+ T cells (Williams et al., 2017). Several of these genes were
also direct targets of let-7, namely Eomes, which we previously reported, as well as Ikzf2
and Il10 (Swaminathan et al., 2012; Agarwal et al., 2015; Wells et al., 2017). Our data
indicate that, despite their superior in-vitro cytotoxic activity, Lin28Tg CTLs fail to
control tumor growth in vivo due to the high expression of these co-inhibitory receptors,
which likely interacted with their cognate ligands in the tumor microenvironment,
inducing exhaustion in these cells. We further show experimentally that Lin28Tg CD8+
T cell have a poor memory potential, as only few of these cells persisted after Lm-gp33
clearance, which are skewed towards the effector-memory phenotype. Thus, these results
suggest that absence of let-7 leads to the terminal differentiation of CD8+ T cells, which
renders these cells prone to exhaustion.
In fact, we show that this let-7-mediated-regulation of CD8+ T cell fate
determination occurs soon after antigen encounter, which is consistent with previous
work in our lab that recapitulated the phenotype of Let-7Tg CTLs by inducing the let-7g
transgene only during the first 48h following CD8+ T cell activation in vitro (Figure 3.7).
Specifically, transcriptome analysis of naive CD8+ T cells predicted that numerous
signaling pathways downstream of TCR signaling were negatively regulated by let-7,
including ERK1/2 and Notch, which we experimentally validated. Interestingly, both the
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cytoplasmic (NICD-NES) and nuclear (NICD-NLS) active forms of Notch inhibited
memory CD8+ T cell formation and skewed the persisting memory cells towards effectormemory cell formation at the expense of central-memory cell generation, thereby
showing that both canonical and non-canonical Notch signaling contribute to the
regulation of CD8+ T cell fate. These results indicate that let-7 expression diminishes the
strength of TCR signaling in these cells, thereby specifying the memory CD8+ T cell fate
minutes following antigen encounter. In fact, we show, using P14Rag2KO donor CD8+
T cells that express the Nur77-GFP reporter of TCR signal strength, that SLECs exhibit
a stronger TCR signaling history than MPECs. These data are consistent with previous
work in our lab demonstrating that let-7 inhibits TCR signal strength in in vitro-activated
P14Rag2KO WT, Let-7Tg, and Lin28Tg CD8+ T cells expressing Nur77-GFP (Figure
3.8). Our data are in accordance with the signal-strength and asymmetric-cell-fate models
of CD8+ T cell fate determination, both of which propose that the strength of TCR
signaling received upon T cell activation inversely correlates with the extent of memory
potential (Kaech & Cui, 2012). Our predictions are also consistent with a previously
published report in which we showed that the magnitude of let-7 downregulation upon
CD8+ T cell activation depends on the strength and duration of TCR signaling, where
high let-7 expression negatively regulates CTL differentiation (Wells et al., 2017).
Moreover, examination of the CD8+ T cell transcriptome at both the naive and 12hactivated stage revealed that let-7 inhibited cell cycle progression, which we had already
shown before (Wells et al., 2017). Thus, reduced proliferation, in addition to the enhanced
survival promoted by let-7 in CD8+ T cells, may also contribute to the maintenance of the
quiescent state in these cells, thereby preserving the memory cell pool.
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Even though our study provides strong evidence that let-7 miRNAs promote the
fate of CD8+ T cells towards memory CD8+ T cells while restraining terminal-effector
differentiation and exhaustion, the relative expression of let-7 at these different stages of
CD8+ T cell differentiation in vivo remains to be examined. It would be reasonable to
hypothesize that, because weak TCR signaling induces the retention of let-7 expression,
these cells would adopt the memory fate, while CD8+ T cells receiving strong TCR
signals downregulate let-7 to a greater extent will become terminally-differentiated, and
thus more susceptible to exhaustion. Along these lines, recurrent TCR stimulation during
chronic inflammation due to persisting antigen may gradually cause the loss of let-7
expression in CD8+ T cells, which would progressively direct these cells towards the
exhausted state. In fact, we confirmed, using CD8+ T cells expressing the Nur77-GFP
reporter of TCR signal strength, that SLECs do receive stronger TCR signals than
MPECs, which is in agreement with our hypothesis. In addition, it would be interesting
to test the memory versus terminal-effector differentiation potential of CD8+ T cells
activated in vitro with different strengths of TCR stimulation at the phenotypic and
functional levels.
We also identified multiple direct target genes of let-7 that were consistently
dysregulated throughout CD8+ T cell differentiation, which provided candidates to study
the let-7-mediated mechanisms that inhibit terminal effector differentiation and
exhaustion. The ubiquitin-conjugating enzyme Cdc34 was common to the naive and 12hactivated time points, the oncogenic transcription factor Mycn was found at both the 12hactivated and CTL stages, and the calcium-binding adapter protein Efhd2, the G-protein
gamma subunit Gng5, as well as the rate-limiting glycolytic enzyme Hk2 were negatively
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regulated by let-7 at all stages of CD8+ T cell differentiation examined. Among these, the
rate-limiting glycolytic enzyme Hk2 and the oncogenic transcription factor Mycn were
confirmed to prevent memory CD8+ T cell formation and enhance the effector- to centralmemory cell ratios using the Lm infection model. Since Hk2 and Mycn overexpression
recapitulated the phenotype observed upon overexpression of Notch, and given that
Notch signaling induces glycolysis and is regulated by Mycn, additional overexpression
studies in Let-7Tg CD8+ T cells or knockdown in Lin28Tg cells would determine whether
these factors have redundant or distinct roles in CD8+ T cell fate regulation (Landor et
al., 2011; Tong et al., 2019). Although they were not investigated in this study, we do not
rule out the possibility that genes which are regulated by let-7 at a single stage of CD8+
T cell differentiation may play a role in the regulation of terminal effector differentiation
and memory formation. In fact, previous work in our lab has identified such a role for the
transcription factor Arid3a, the expression of which is inhibited by let-7 at the 12hactivated stage, as well as the transcription factors Eomes and Hmga1, which are both
negatively regulated by let-7 at the CTL stage (Figure 3.9). Thus, together with the early
T cell activation signaling pathways we had identified above, assessing the function of
these genes will advance our knowledge of the molecular mechanisms through which let7 controls the fate of CD8+ T cells.
Although the present study offers significant insights into the let-7-mediated
mechanisms regulating terminal effector versus memory CD8+ T cell differentiation, it
only examined the role of let-7 miRNAs in the fate of CD8+ T cells at the transcriptional
level, and thus provides an incomplete perspective in this regard. Therefore, validating
whether let-7 shapes the proteome of differentiating CD8+ T cells consistently with our
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transcriptomic study will be important. Moreover, because the memory and terminaleffector fates are also regulated at the epigenetic level, whether let-7 performs its
regulatory function by modeling the chromatin state of differentiating CD8+ T cells
remains to be examined (Araki et al., 2009; Crompton et al., 2016; Kakaradov et al., 2017;
Henning et al., 2018). Furthermore, since it is well understood that terminallydifferentiated and memory T cells rely on distinct metabolic processes, investigating
whether let-7 plays a role in modulating these metabolic pathways will be interesting,
especially since we already showed that the expression of glycolytic genes, including
Glut1, Glut3, Hk2, Pfk1, Pkm, and Tpi, were repressed by let-7 (Wells et al., 2017).
Moreover, previous work in our lab showed that, when compared to WT CTLs, Let-7Tg
CTLs exhibit a lower glycolytic rate, while in Lin28Tg CTLs glycolysis is increased
(Figure 3.10), which is in agreement with studies describing that memory CD8+ T cells
preferentially use fatty acid metabolism, whereas glycolysis is used to a higher extent in
terminally-differentiated cells (Araki et al., 2009; Pearce et al., 2009; Michalek &
Rathmell, 2010; Sukumar et al., 2013; Pollizzi et al., 2016). This is also consistent with
our results showing that Hk2-overexpressing CD8+ T cells fail to form memory cells.
Our data emphasize a strong potential for the translation of the let-7-mediated
control of memory CD8+ T cell formation into novel therapies for the treatment of chronic
pathologies such as cancer and persistent infections. Such innovative medical solutions
could consist of let-7 miRNA delivery to CD8+ T cells during the ex vivo T cell expansion
phase of CAR-T cell production for adoptive T cell therapy, during which these cells
would be directed towards the memory fate, and thus would not be as prone to exhaustion
(Ho et al., 2003; Rosenberg et al., 2011). Besides, in the case of anti-cancer therapy,
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delivering let-7 miRNAs directly to tumor cells could also be performed, since let-7 is a
well-known tumor suppressor, and thus may have at least an additive effect on the
outcome of tumor control. Moreover, the combination of these let-7-based therapies with
checkpoint blockade immunotherapy may elicit a superior anti-tumor response.
Furthermore, our study may substantially contribute to advances in vaccine development,
since effective vaccination relies on the generation of memory cells (Lauvau et al., 2001;
Akondy et al., 2017). Finally, although it remains to be tested experimentally, inhibiting
let-7 expression in CD8+ T cells may constitute a promising healthcare solution to treat
CD8+ T cell-driven autoimmune disorders, such as type-1 diabetes, by inducing
exhaustion in these self-reactive cells (McKinney et al., 2015).
Altogether, our study elucidated the paradoxical outcome of let-7 expression on
the in-vitro versus in-vivo activity of CTLs by predicting that let-7 expression regulates
CD8+ T cell differentiation towards the generation of memory cells, while inhibiting the
differentiation of terminal effectors. Additionally, our data establish let-7 miRNA as
novel therapeutic tool for the manipulation of CD8+ T cell function in the contexts of
cancer, persistent infections, and autoimmune diseases.

103

Figure 3.1 Let-7 expression in CTLs results in paradoxical functional outcomes in
vitro and in vivo. (A) Cytotoxicity assay of in vitro-differentiated CTLs from
P14Rag2KO WT, P14Rag2KO Let-7Tg, and P14Rag2KO Lin28Tg mice co-cultured for
4h at the indicated ratios with splenocytes pulsed with either LCMV gp33-41 peptide
(cognate P14 epitope) or LCMV np396 peptide (non-specific epitope). (B) Tumor growth
curves in mice inoculated subcutaneously with 0.25X106 B16gp33 tumor cells. Tumorbearing mice received adoptive transfer of 1.5X106 CTLs generated in vitro from either
P14Rag2KO WT (n=5), P14Rag2KO Let-7Tg (n=5), P14Rag2KO Lin28Tg (n=5) mice.
Some mice did not receive CTLs (n=5). * p < 0.05, ** p < 0.01, and *** p < 0.001,
compared with WT using two-tailed Student’s t-test. Data are from one experiment
representative of three experiments (A; mean and S.E.M of technical triplicates), or from
one experiment representative of two experiments (B; mean and S.E.M. of 5 biological
replicates).
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Figure 3.2 Let-7 miRNAs significantly alter the CTL transcriptome. (A) Principal
component analysis (PCA) on normalized expression read counts from the RNA-Seq data
obtained from in vitro-generated CTLs from P14Rag2KO WT, P14Rag2KO Let-7, and
P14Rag2KO Lin28Tg mice, separated by PC1 (y axis) and PC2 (x axis), which explain
74% and 13% of the total variance between samples, respectively. All replicate samples
from each genotype were clustered by applying 95% confidence ellipses (p <0.05). (B)
Volcano plots displaying differential gene expression in in vitro-differentiated
P14Rag2KO Lin28Tg (left panel) and P14Rag2KO Let-7Tg (right panel) CTLs, as
compared with P14Rag2KO WT CTLs, by the mean expression value of -log10(p-value)
(y axis) and the log2 value of the expression fold change (Log2(Fold Change), x axis).
Each differentially-expressed gene is represented by a gray solid circle, and examples of
upregulated (red solid circles) and downregulated (blue solid circles) associated with CTL
differentiation are indicated in each plot. (C) Heatmap clusters of normalized expression
read counts from the RNA-Seq data showing all genes differentially expressed by
|log2(Fold Change)| ≥ 0.5 in a statistically-significant manner (p<0.05) in in vitrogenerated CTLs from P14Rag2KO WT (center), P14Rag2KO Let-7 (right), and
P14Rag2KO Lin28Tg (left) mice. Downregulated genes are indicated in blue and
upregulated genes are represented in red. Cluster I shows genes downregulated in Let7Tg CTLs and upregulated in Lin28Tg CTLs, cluster II indicates genes upregulated in
Let-7Tg CTLs and downregulated in Lin28Tg CTLs, cluster III represents genes
downregulated in both Let-7Tg and Lin28Tg CTLs, and cluster IV shows genes
upregulated in both Let-7Tg and Lin28Tg CTLs, in comparison with WT CTLs.
Examples of differentially-expressed genes important for CTL differentiation are
indicated. (D) Database for Annotation, Visualization and Integrated Discovery
(DAVID) analysis of gene ontology (GO) biological processes significantly enriched
(p <0.05) in cluster I (red bubbles) and cluster II (blue bubbles) from (C), based on the
over-representation of functionally-related gene groups. Data is presented relative to the
-log10 of the false discovery rate (-Log10(FDR), x axis). The size of the bubbles indicates
the percentage of genes from each cluster contributing to the enriched biological process.
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Figure 3.3 Let-7 miRNA expression promotes a memory gene signature in CTLs,
while let-7 deficiency is characterized by am enrichment in genes associated with
terminal effectors. (A) Gene set enrichment analysis (GSEA) using the adjusted p-valueranked normalized expression read counts from the RNA-Seq data obtained from in vitrogenerated P14Rag2KO Let-7 and P14Rag2KO Lin28Tg CTLs scored against gene sets
containing memory-associated genes (n=56; left panel) and terminal effector-associated
genes (n=62; right panel), and compared to the transcriptome of P14Rag2KO WT CTLs.
Gene signatures were created by gathering well-characterized genes from the literature
(see Materials and methods). Normalized enrichment score (NES), as well as adjusted pvalues, are shown for each analysis. Positive NES values indicate gene signature
enrichment, while negative NES values show gene set under-representation. (B) Heatmap
clusters of normalized expression read counts from the RNA-Seq data showing
differential expression by P14Rag2KO WT (center), Let-7Tg (right), and Lin28Tg (left)
CTLs of the genes used for GSEA in (A) that were classified into heatmap categories.
Downregulated genes are indicated in blue and upregulated genes are represented in red.
Examples of differentially-expressed genes important for memory and terminal effector
differentiation are indicated. (C) Heatmap showing differential expression of T stem cell
memory (Tscm) markers in P14Rag2KO WT (center), Let-7Tg (right), and Lin28Tg (left)
CTLs. Downregulated genes are indicated in blue and upregulated genes are represented
in red. (D) Staining of CD45.2+ donor P14Rag2KO WT (n=3) and P14Rag2KO Lin28Tg
(n=3) CD8+ T cells in the spleen of CD45.1+ host mice for CD44 and CD62L at day 30
post-infection with Lm-gp33. Numbers represent the frequencies of each population on
the indicated gates (left). Quantification of the frequencies of total, effector memory
(CD44hiCD62Llo), and central memory (CD44hiCD62Lhi) CD45.2+ donor P14Rag2KO
CD8+ T cells for each genotype as assessed by flow cytometry (right) * p <0.05, ** p <
0.01, compared with P14Rag2KO WT CD8+ T cells using two-tailed Student’s t-test (D).
Data are from one experiment representative of two experiments (D, mean ± S.E.M. of
each population from all mice).
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Figure 3.4 Let-miRNAs substantially modify the transcriptome of naive and 12hactivated CD8+ T cells. (A and B) Principal component analysis (PCA) on normalized
expression read counts from the RNA-Seq data obtained from P14Rag2KO WT,
P14Rag2KO Let-7, and P14Rag2KO Lin28Tg naive (A) or 12h-activated (B) CD8+ T
cells, separated by PC1 (y axis) and PC2 (x axis), which explain 61% and 21% (naive) or
57% and 22% (12h-activated) of the total variance between samples, respectively. All
replicate samples from each genotype were clustered by applying 95% confidence
ellipses (p<0.05). (C and D) Volcano plots displaying differential gene expression in
naive (C) and 12h-activated (D) P14Rag2KO Lin28Tg (left panel) and P14Rag2KO Let7Tg (right panel) CD8+ T cells, as compared with P14Rag2KO WT CD8+ T cells, by the
mean expression value of -log10(p-value) (y axis) and the log2 value of the expression fold
change (Log2(Fold Change), x axis). Each differentially-expressed gene is represented
by a gray solid circle, and significantly upregulated and downregulated genes are
indicated in red and blue, respectively. (E and F) Heatmap clusters of normalized
expression read counts from the RNA-Seq data showing all genes differentially expressed
by |log2(Fold Change)| ≥ 0.5 in a statistically-significant manner (p<0.05) in naive (E)
and 12h-activated (F) P14Rag2KO WT (center), P14Rag2KO Let-7 (right), and
P14Rag2KO Lin28Tg (left) mice. Downregulated genes are indicated in blue and
upregulated genes are represented in red. Cluster I shows genes downregulated in Let7Tg CD8+ T cells and upregulated in Lin28Tg cells, cluster II indicates genes upregulated
in Let-7Tg CD8+ T cells and downregulated in Lin28Tg cells, cluster III represents genes
downregulated in both Let-7Tg and Lin28Tg CD8+ T cells, and cluster IV shows genes
upregulated in both Let-7Tg and Lin28Tg cells, in comparison with WT CD8+ T cells.
Examples of differentially-expressed genes important for CD8+ T cell differentiation are
indicated.
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Figure 3.5 Let-7 miRNAs controls the fate of differentiating CD8+ T cells by
suppressing the strength of TCR signaling, thereby inhibiting early signaling
pathways, including ERK1/2 and Notch. Database for Annotation, Visualization
and Integrated Discovery (DAVID) analysis of gene ontology (GO) biological processes
significantly enriched (p <0.05) in cluster I of naive (A) and 12h-activated (B) CD8+ T
cells, based on the over-representation of functionally-related gene groups. Data is
presented relative to the -log10 of the false discovery rate (-Log10(FDR), x axis). The size
of the bubbles indicates the percentage of genes from each cluster contributing to the
enriched biological process. (C) Normalized MFI of phosphor-ERK1/2 (pERK1/2) in
P14Rag2KO WT, P14Rag2KO Let-7Tg, and P14Rag2KO Lin28Tg CD8+ T cells
activated in vitro for 5 minutes with plate-bound anti-CD3e (1 µg/mL) and anti-CD28
mAbs (5 µg/mL). Data is presented relative to results obtained for 5-minute activated
P14Rag2KO WT CD8+ T cells. (D) Staining of CD45.2+ donor P14Rag2KO WT CD8+
T cells transduced with GFP reporter-containing empty retroviral vector (n=3), or
retrovirus expressing Notch intracellular domain (NICD) fused to either a nuclear export
signal (NES, n=3) or a nuclear localization signal (NLS, n=3) in the spleen of CD45.1+
host mice for CD44 and CD62L at day 30 post-infection with Lm-gp33. Numbers
represent the frequencies of each population on the indicated gates (left). Quantification
of the frequencies of total, effector memory (CD44hiCD62Llo), and central memory
(CD44hiCD62Lhi) CD45.2+ donor P14Rag2KO CD8+ T cells for each condition as
assessed by flow cytometry (right). (E) MFI of GFP of P14Rag2KO Nur77-GFP donor
CD8+ SLECs (KLGR1hiCD62Llo) and MPECs (KLRG1loCD127hi) in the blood of
CD45.1+ host mice at day 9 post-infection with Lm-gp33. Data is presented relative to
MFI obtained for control P14Rag2KO WT CD8+ SLECs and MPECs. * p < 0.05; ** p
<0.01, *** p < 0.001, compared with WT using two-tailed Student’s t-test. Data are from
one experiment representative of two experiments (C; mean and S.E.M. of technical
triplicates), or from one experiment (D, E; mean and S.E.M. of each cell population).

112

113

Figure 3.6 Let-7 miRNAs consistently represses the expression of multiple target
genes throughout CD8+ T cell differentiation, and restrain terminal effector
differentiation through inhibiting Hk2 and Mycn expression. (A) Diagram
representing the numbers of let-7 direct targets that are differentially expressed in cluster
I a statistically significant manner at all stages of CD8+ T cell differentiation examined.
(B) Staining of P14Rag2KO Let-7Tg CD8+ T cells transduced with GFP reportercontaining empty retroviral vector or retrovirus expressing Cdc34 and differentiated in
vitro into CTLs for CD44 and CD62L. Numbers represent the frequencies of each
population on the indicated gates (left). Histogram of PD-1 expression in GFPhi cells from
each condition, as assessed by flow cytometry. Numbers represent the MFI of PD-1 for
each condition (right). (C) Staining of CD45.2+ donor P14Rag2KO WT CD8+ T cells
transduced with GFP reporter-containing empty retroviral vector (n=2), or retrovirus
expressing Hk2 (n=3) in the spleen of CD45.1+ host mice for CD44 and CD62L at day
30 post-infection with Lm-gp33. Numbers represent the frequencies of each population
on the indicated gates (left). Quantification of the frequencies of total, effector memory
(CD44hiCD62Llo), and central memory (CD44hiCD62Lhi) CD45.2+ donor P14Rag2KO
CD8+ T cells for each condition as assessed by flow cytometry (right). (D) Staining of
CD45.2+ donor P14Rag2KO WT CD8+ T cells transduced with GFP reporter-containing
empty retroviral vector (n=1), or retrovirus expressing Mycn (n=3) in the spleen of
CD45.1+ host mice for CD44 and CD62L at day 30 post-infection with Lm-gp33.
Numbers represent the frequencies of each population on the indicated gates. * p < 0.05;
** p <0.01, compared with WT using two-tailed Student’s t-test. Data are from one
experiment representative of two experiments (C; mean and S.E.M. of each cell
population), or from one experiment (B, D).
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Figure 3.7 Maintenance of let-7 expression during the first 48h of CTL
differentiation is sufficient to recapitulate the memory phenotype of Let-7Tg CTLs
in vitro. Quantitative RT-PCR analysis of mRNA expression in: Tcf7 (TCF-1), Sell
(CD62L), Ccr7, Id2, Havcr2 (TIM-3), and Cd244 (2B4) in in vitro-differentiated
P14Rag2KO CTLs WT and Let-7Tg CTLs which received doxycycline either prior to
stimulation or during the culture, as indicated (left, blue boxes), presented relative to the
expression of the ribosomal protein Rpl13a. * p < 0.05, ** p < 0.01, *** p < 0.001, ****
p < 0.001 compared with WT cells from matched culture conditions using two-tailed
Student’s t-test. Data are from one experiment representative of two experiments (mean
± S.E.M. of technical triplicates).
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Figure 3.8 Let-7 miRNAs negatively regulate the strength of TCR signaling in CD8+
T cells. MFI of GFP in P14Rag2KO Nur77-GFP WT, P14Rag2KO Nur77-GFP Let-7Tg,
and P14Rag2KO Nur77-GFP Lin28Tg CD8+ T cells activated in vitro for 12h with platebound anti-CD3e and anti-CD28 mAbs (5 µg/mL each). **** p < 0.0001, compared with
WT using two-tailed Student’s t-test. Data are from one experiment representative of two
experiments (mean and S.E.M. of technical triplicates).
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Figure 3.9 Let-7 miRNAs inhibit terminal effector differentiation through a complex
transcriptional mechanism involving Arid3a, Eomes, and Hmga1. Staining of
P14Rag2KO Let-7Tg CD8+ T cells transduced with GFP reporter-containing empty
retroviral vector or retrovirus expressing Arid3a (A), Eomes (B), or Hmga1 (C) and
differentiated in vitro into CTLs for TIM-3, 2B4, CD160, PD-1, and CD62L and
intracellular staining of IFNγ on P14Rag2KO Let-7Tg CD8 T cells transduced with either
GFP-expressing empty vector or Hmga1. Numbers represent either the frequencies of
positive cells (GFP, TIM-3, 2B4, CD160, CD62L), negative cells (CD62L), or mean
fluorescence intensities of protein expression (MFI, PD-1, IFNγ) of each population on
the indicated gates.
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Glycolytic rate assay of in vitro-generated P14Rag2KO CTLs
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Figure 3.10 Let-7 miRNAs regulate glycolysis in CTLs. Glycolytic rate assay of in
vitro-generated P14Rag2KO WT, P14Rag2KO Let-7Tg, and P14Rag2KO Lin28Tg
CTLs. Arrows indicate the times of rotenone/antimycin A (Rot/AA, inhibitor of
mitochondrial activity) and 2-deoxyglucose (2-DG, inhibitor of glycolysis) treatments.
Data from one experiment representative of two experiments (mean ± S.E.M. of
technical triplicates.
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CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTIONS

4.1 Conclusions
Overall, the data presented in this thesis show that let-7 miRNAs are global
regulators of T cell differentiation. We first investigated the role of let-7 in CD4+ T cell
differentiation in the context of autoimmunity, and demonstrated that, as observed in
CD8+ T cells, the expression level of let-7 miRNAs is high in naive CD4+ T cells, but
gets downregulated upon activation, proportionally to both the strength and duration of
TCR signaling. Moreover, we show that this reduction in let-7 expression is required for
the differentiation of pathogenic Th17 cells in EAE, the mouse model of the autoimmune
disease MS. Specifically, maintenance of high levels of let-7 during the differentiation of
these cells resulted in almost complete protection from disease, while absence of let-7 in
pathogenic Th17 cells led to aggravated EAE. In fact, we demonstrated that let-7
negatively regulated the proliferation, IL-1β/IL-23-dependent acquisition of function, and
CCR2/CCR5-dependent migration of these cells to the CNS. This first study thus
established a protective role for let-7 miRNAs in EAE, which has promising therapeutic
implications for the treatment of MS and related autoimmune diseases.
We further predicted a regulatory role of let-7 miRNAs in the fate determination
of CD8+ T cells towards memory cell formation and terminal-effector differentiation
using RNA-Seq and bioinformatics analyses as an unbiased approach, which we validated
through in-vitro and in-vivo experiments. Specifically, we elucidated the paradoxical
outcomes of let-7-mediated regulation of CTL function in-vitro versus in-vivo, during
which we had observed that let-7-deficient CTLs that exhibited superior cytolytic
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function in vitro failed to control tumor growth in vivo. Conversely, overexpression of
let-7 in CTLs in vitro resulted in diminished cytotoxic activity, whereas the same cells
elicited outstanding tumor control in vivo. Transcriptomic analyses of these cells
uncovered that let-7 promoted memory CD8+ T cell differentiation, while inhibiting the
differentiation of terminally-differentiated effectors. Conversely, absence of let-7
resulted in the activation of the terminal-effector differentiation program, characterized,
among others, by the upregulation of co-inhibitory receptors. These receptors may render
let-7-deficient CD8+ T cells susceptible to exhaustion upon engagement with their
cognate ligands, which are upregulated in immunosuppressive conditions, such as the
tumor microenvironment. In fact, we showed that the influence of let-7 miRNAs on CD8+
T cell fate gets established early upon activation, as let-7 dampened the strength of TCR
signaling, which resulted in the inhibition of signaling pathways associated with T cell
activation, including ERK1/2 and Notch. Moreover, we identified direct let-7 target genes
that were dysregulated throughout CD8+ T cell differentiation, among which we validated
the rate-limiting glycolytic enzyme Hk2 and the transcription factor Mycn as drivers of
the terminally-differentiated state in vivo. Thus, we have identified specific genes that are
functionally repressed by let-7 to prevent terminal effector differentiation and maintain
the memory potential of CD8+ T cells.

4.2 Future directions
Even though the discoveries described in this dissertation significantly advance
our knowledge of the let-7-mediated mechanisms regulating T cell differentiation, they
also raise many other questions that remain to be investigated, such as: (1) uncovering
the molecular mechanisms governing let-7 expression in T cells (2) determining the
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common let-7-mediated regulatory mechanisms of T cell differentiation, (3) assessing the
possible role of let-7 in the control of Treg activity, (4) deepening our understanding of
the role of let-7 in the induction of memory T cells, and (5) identifying the function of
Hk2 and Mycn in the differentiation of terminal effector CD8+ T cells.

4.2.1 Determine the molecular mechanisms controlling let-7 expression in T cells
An outstanding question remaining from our studies on the role of let-7 miRNAs
in T cell differentiation is to identify the molecular mechanisms regulating the expression
of let-7 in T cells, especially given the therapeutic potential of modulating let-7
expression in these cells to control T cell responses. We previously demonstrated that let7 miRNAs are abundantly expressed in both naive CD4+ and CD8+ T cells, but get
dramatically downregulated over time upon T cell activation (Wells et al., 2017; Angelou
et al., 2020). Moreover, we showed that the extent of let-7 downregulation following
antigen encounter depends on the strength and duration of TCR signaling, both in CD4+
and CD8+ T cells. Because mature miRNAs are encoded in genes and generated following
a sequence of transcriptional and post-transcriptional steps during biogenesis, it would be
interesting to examine whether the TCR-mediated regulatory mechanisms of let-7
expression are of epigenetic, transcriptional and/or post-transcriptional nature.
To test whether let-7 is regulated at the epigenetic level, the chromatin state at the
distinct let-7 miRNA loci can first be analyzed in naive and activated T cells using
methods such as ATAQ-Seq and bisulfite sequencing. ATAQ-Seq, or assay for
transposase-accessible chromatin with high-throughput sequencing, enables the analysis
of global epigenetic profiles through the construction of a sequencing library using the
hyperactive transposase Tn5, which integrates the Tn5 transposon modified with flanking
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sequencing adapters, at accessible chromatin regions of the genome (Buenrostro et al.,
2013), which can be identified by sequencing. Bisulfite sequencing consists of treating
DNA with bisulfite before sequencing to uncover methylation profiles, particularly of
cytosine residues at the carbon-5 position of CpG dinucleotides, which are found at high
frequencies at gene promoters, and where methylation represses transcriptional activity
(Frommer et al., 1992). The predicted outcomes of such experiments would be that the
genomic loci of let-7 miRNAs in naive T cells consist of open chromatin, and would
therefore be enriched following ATAQ-Seq, but become less accessible to the
transcriptional machinery in activated T cells, in which these loci would not be detected,
or at very low levels, by ATAQ-Seq. Conversely, CpG dinucleotides at let-7 miRNA
promoters in naive T cells would not be marked by methylation, as they are
transcriptionally active, while in activated T cells CpG methylation at these sites would
be increased, as let-7 miRNA transcription is repressed.
To identify the potential transcriptional mechanisms regulating let-7 miRNA
expression in T cells, proteomics of isolated chromatin segments (PICh), can be run on
naive and activated T cells. This technique employs DNA probes that hybridize to
genomic loci of interest and pull these down together with associated proteins, which can
be subsequently identified using mass spectrometry (Déjardin & Kingston, 2009).
Proteins bound to let-7 loci in activated, but not naive T cells, may be responsible for the
negative regulation of let-7 expression following antigen encounter. These candidates can
first be validated by overexpression, where the open-reading frame (ORF) of their
respective genes is cloned into a retroviral vector containing a GFP reporter that gets
transduced in NIH/3T3 fibroblasts, in which let-7 miRNAs are abundantly expressed.
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Candidates that induce a reduction in let-7 expression in this system can then be tested
functionally by transducing activated T cells with specific shRNAs targeting these genes.
Recovery of high let-7 expression upon silencing of these candidates in activated T cells
will confirm their role in the TCR-mediated control of let-7 expression.
Previous work in our lab showed that, while mature let-7 miRNAs, including let7b, let-7c, and let-7g, are depleted in activated T cells, their respective pre-let-7 miRNAs
accumulate, suggesting that a post-transcriptional mechanism controls let-7 expression.
Subsequent mass spectrometry experiments using pre-let-7b pull-down have identified
numerous candidate proteins that bind to pre-let-7b during T cell activation. We have
already tested the potential role of some candidates in the regulation of let-7 expression
by overexpression in NIH/3T3 fibroblasts, using the gain-of-function strategy described
above. Although none of the candidates assessed so far were found to control let-7
expression in this system, more candidates remain to be examined. Once candidates are
validated in NIH/3T3 fibroblasts, their potential role in the regulation of let-7 expression
in T cells can be assessed by silencing the expression of these genes using shRNAs, as
mentioned before. Maintenance of high let-7 miRNA expression upon silencing of these
genes will confirm their role in controlling let-7 expression in T cells.
To further understand how let-7 is regulated at different stages of T cell
differentiation, the experimental approaches proposed above can also be expanded to
SLECs, MPECs, memory, and exhausted T cells. To this end, donor CD8+ T cells
adoptively transferred into congenic recipient mice challenged with Lm or cancer can be
electronically sorted at these differentiation stages. In addition to offering important
insights into the molecular mechanisms regulating the expression of let-7 miRNAs in T
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cells, these findings will provide a therapeutic strategy to modulate let-7 expression to
enhance T cell responses against infections and cancer, and suppress the activity of
autoreactive T cells.

4.2.2 Identify the common let-7-mediated mechanisms regulating T cell
differentiation
We show, in accordance with previous publications (Polikepahad et al., 2010;
Kumar et al., 2011; Swaminathan et al., 2012), that the let-7-mediated suppression of
effector CD4+ T cell differentiation is not limited to the pathogenic Th17 cell subset and
extends to the Th0, Th1, and Th2 lineages. Together with our published data on the
suppressive function of let-7 in the differentiation of effector CD8+ T cells (Wells et al.,
2017), our findings indicate that let-7 plays a global regulatory role in T cell
differentiation, and suggest that common let-7-mediated regulatory mechanisms are
involved in the control of both CD4+ and CD8+ T cell differentiation. Because let-7,
initially highly expressed in naive T cells, is downregulated in both subsets within the
first 48 hours following TCR stimulation, and since both CD4+ and CD8+ T cells undergo
shared early activation signaling pathways downstream of TCR signaling, a major point
to address will be to determine the common genes within these pathways that are
regulated by let-7 during T cell differentiation. A first step in answering this question
would be to perform RNA-Seq on monoclonal WT, Let-7Tg, and Lin28Tg CD4+ and
CD8+ T cells at the naive and early-activated stage, followed by bioinformatics analyses.
Such analyses that will be relevant in identifying the shared signaling pathways regulated
by let-7 in both CD4+ and CD8+ T cells are contained within pathway analysis softwares,
which interact with pathways collections and protein interaction networks databases. The
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algorithm of such softwares will calculate the number of genes from the RNA-Seq data
that are differentially expressed in the pathway collection databases between WT versus
Let-7Tg, and WT versus Lin28Tg activated CD4+ and CD8+ T cells, and generate a list
of predicted let-7-regulated pathways ranked according to the statistical significance of
the overlap between the list of differentially expressed genes and the genes contained in
a given pathway. The pathways that are most probably regulated by let-7 will be the ones
that are shared between the WT-versus-Let-7Tg and WT-versus-Lin28Tg hits in both the
CD4+ and CD8+ T cell samples.
Upon identification of these predicted shared let-7-regulated pathways, and
following validation of these in silico predictions by quantifying the transcript and protein
expression of the direct let-7 target genes contained in the identified pathways in WT,
Let-7Tg, and Lin28Tg activated CD4+ and CD8+ T cells, whether these factors promote
T cell differentiation will be tested using both gain-of-function and loss-of-function
approaches. Gain-of-function can be achieved through transduction of early-activated T
cells with a retroviral overexpression vector containing the open reading frame of these
candidate genes, as well as a reporter such as GFP, upon which cells overexpressing these
factors can be identified through GFP expression. Similarly, loss-of-function can be
accomplished by designing shRNAs capable of inhibiting the expression of the candidate
genes. Implementing these approaches in both in vitro and in vivo experimental strategies,
using the outcome on effector T cell differentiaton as a readout, will enable us to directly
test the hypothesis that let-7 miRNAs negatively regulate both CD4+ and CD8+ T cell
differentiation by mechanistically targeting our candidate genes.
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In vitro, when compared with the same cells overexpressing the empty vector,
recovery of effector T cell phenotype upon overexpression of these genes in Let-7Tg
CD4+ and CD8+ T cells, as well as diminished effector T cell phenotype in WT and
Lin28Tg CD4+ and CD8+ T cells expressing shRNAs targeting these factors, will confirm
that the candidate genes are regulated by let-7, and functionally relevant in both CD4+
and CD8+ T cell differentiation. In vivo models of infection, autoimmunity, and cancer,
can also be used to determine whether these candidate genes control T cell differentiation,
thereby establishing their biological significance. To investigate the potential regulatory
role of these genes in T cell differentiation during acute infection, transduced OT-I
Rag2KO CD8+ T cells, which specifically recognize the OVA257-264 epitope from the
chicken ovalbumin (OVA), or OT-II Rag2KO CD4+ cells, which specifically recognize
the OVA323-339 epitope, can be transferred into congenically-marked recipient mice which
are subsequently challenged with an OVA-expressing Lm strain (Lm-OVA). In
comparison with T cells expressing the empty vector, shRNA-expressing donor WT and
Lin28Tg T cells will become more MPEC-like, resulting in enhanced memory T cell
formation.
To investigate the function of the candidate genes in T cell differentiation during
the anti-cancer immune response, transduced OT-I Rag2KO CD8+ T cells or OT-II
Rag2KO CD4+ cells can be adoptively transferred into recipient mice challenged with
subcutaneous OVA-expressing B16 melanoma tumors (B16-OVA). In the case of CD8+
T cells, it would be predicted that, when compared to the same cells expressing the empty
vector, Let-7Tg T cells overexpressing the candidate genes would divert towards the
terminal-effector state and thus would not be able to control tumor growth, while shRNA-
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expressing donor WT and Lin28Tg T cells would control the tumors more efficaciously,
as they would adopt a memory-like phenotype. For CD4+ T cells, in comparison to empty
vector-expressing cells, donor Let-7Tg T cells overexpressing the candidate genes would
become better helpers and contribute to effective tumor control, while donor WT and
Lin28Tg T cells that express shRNAs would be detrimental to the anti-tumor response,
as their helper capacity would be compromised.
To assess whether the predicted let-7 target genes regulate the differentiation of
both T cell subsets in the context of autoimmunity, T cell transfers in EAE and the RIPmOVA model of diabetes, in which membrane-OVA is expressed under the control of
the rat insulin promoter, can be respectively used as CD4+ and CD8+ T cell-driven
autoimmunity in vivo experimental methods. 2D2Rag2KO donor CD4+ T cells can be
used in EAE, while OT-IRag2KO donor CD8+ T cells can be employed in the diabetes
model. In comparison with T cells expressing the empty vector, Let-7Tg T cells
overexpressing the candidate genes are expected to exhibit enhanced pathogenicity, while
the autoreactive phenotype of shRNA-expressing donor WT and Lin28Tg T cells would
be diminished.
If some candidate genes, in addition to meet our predictions following the abovementioned gain-of-function and loss-of function in vitro and in vivo studies, are not well
characterized in regards to their role in T cell differentiation, it would be interesting to
generate conditional overexpression and knock-out mouse models, in which these factors
are specifically overexpressed or deleted in T cells, respectively. Further crossing of these
mice with TCR-transgenic mice on a Rag2KO background would provide powerful tools
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for the study of the function of these genes in T cell differentiation in vitro and in vivo
using the disease models mentioned before.

4.2.3 Investigating the potential role of let-7 in Treg function
Although we observed substantial suppression of monoclonal 2D2Rag2KO iTreg
differentiation in vitro in Chapter 2, we showed that mice which received 2D2Rag2KO
Let-7Tg CD4+ T cells upon EAE induction did not develop autoimmunity, due to the let7-mediated inhibition of pathogenic effector CD4+ T cells. This global let-7-mediated
inhibition of effector CD4+ T cell differentiation may have masked a potential role of let7 in the regulation of Treg activity, which will be important to determine given that Tregs
are critical regulators of immune responses and are very different from other effector
CD4+ T cell lineages. To study the potential role of let-7 in the regulation of Treg activity,
we could acquire FOXP3-GFP mice, in which only Tregs express the GFP reporter that
is constitutively expressed under the control of the Treg-specific FOXP3 promoter, and
can thus be electronically sorted by gating on GFP+ cells. Breeding FOXP3-GFP mice to
Let-7Tg and Lin28Tg mice will enable the direct investigation of the potential regulatory
role of let-7 miRNAs in the immunosuppressive function of Tregs both in vitro and in
vivo.
To test whether let-7 suppresses Treg activity, an in-vitro suppression assay can
be performed using FACS-sorted FOXP3-GFP (GFP+) WT, Let-7Tg, and Lin28Tg Tregs
co-cultured with CTV-labeled electronically-sorted GFP- naive WT CD4+

T cells

activated in vitro with anti-CD3e mAbs and CD4 T cell-depleted irradiated splenocytes.
In this assay, the extent of GFP- CD4+ T cell proliferation, represented by CTV dilution,
is inversely correlated with the potential of Treg immunosuppressive function. The
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predicted outcome of this assay would be, in comparison to WT Tregs, a diminished
suppressive

capacity

in

Let-7Tg

Tregs,

whereas

in

Lin28Tg

Tregs

the

immunosuppressive potential would be increased.
To confirm the biological significance of let-7 in the negative regulation of Tregmediated immunosuppression in vivo, the T cell transfer model of colitis can be
employed, in which FACS-sorted FOXP3-GFP WT, Let-7Tg, and Lin28Tg Tregs are cotransferred with electronically-sorted GFP- CD45RBhi naive WT CD4+ T cells, which are
pathogenic and induce the disease, into Rag2KO recipient mice. In this model, weight
loss and colon inflammation are inversely correlated with Treg immunosuppressive
capacity and disease control. When compared to WT Tregs, Let-7Tg Tregs would be
expected to show reduced suppressive activity, while Lin28Tg Tregs would exhibit
enhanced disease control.
To investigate the let-7-mediated molecular mechanisms regulating Treg
function, FACS-sorted FOXP3-GFP WT, Let-7Tg, and Lin28Tg Tregs can be subjected
to RNA-Seq, and the transcriptome of these cells can be subsequently analyzed by
bioinformatics analyses. The potential mechanistic role in Treg function of genes that are
negatively regulated by let-7 in Tregs and that are also predicted direct let-7 targets can
be tested by gain-of-function and loss-of-function approaches described before, using invitro suppression assays and colitis.
If the hypothesis that let-7 inhibits Treg-mediated immunosuppression is
validated through the experiments proposed above, let-7 miRNAs may be established as
a novel therapeutic target that could be artificially deleted in Tregs from patients suffering
from autoimmune disorders such as inflammatory bowel disease, transplant rejection, and
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graft-versus-host

disease

to

enhance

Treg-mediated

immunosuppression

of

autoimmunity. On the other hand, let-7 miRNAs could be specifically delivered to Tregs
that populate the the tumor microenvironment of cancer patients to inhibit their
immunosuppressive activity towards the anti-tumor response.

4.2.4 In-vivo assessment of the memory-promoting role of let-7 in T cells
Although we demonstrated in Chapter 3 that the memory potential of let-7deficient CD8+ T cells is compromised in vivo by the adoptive transfer of P14Rag2KO
Lin28Tg naive CD8+ T cells in congenic host mice subsequently challenged with Lmgp33, we did not show that CD8+ memory T cell formation is enhanced when high let-7
expression is maintained by adoptive transfer of Let-7Tg CD8+ T cells in this system.
Despite the fact that this experiment is conceptually feasible, previous work in our lab
revealed that adoptively transferred Let-7Tg cells could not be retrieved from the spleen
of Lm-gp33-challenged host mice at 30 dpi. Because we previously showed that let-7
inhibits CD8+ T cell clonal expansion (Wells et al., 2017), this phenotype could be
explained by impaired proliferation. It was also described that central-memory T cells,
the memory subset which Let-7Tg CTLs shares the most phenotypic attributes with, can
give rise to tissue-resident memory T cells that populate non-lymphoid organs, including
the skin (Osborn et al., 2019). Thus, it will be interesting to test whether the preferential
location of memory Let-7Tg CD8+ T cells is in peripheral tissues, which would provide
an explanation for their absence in lymphoid organs. Moreover, minor differences in the
genetic background of Let-7Tg and host mice exist and could therefore cause allogeneic
rejection of donor Let-7Tg cells. Therefore, whether complete genetic background
matching of Let-7Tg mice with host mice through backcrossing can rescue this technical
130

difficulty would be interesting to assess. A direct solution to this issue that would avoid
the lengthy process of backcrossing would be to clone let-7g into a retroviral vector
containing a GFP reporter, and use this method to overexpress let-7 to the same extent as
in Let-7Tg CD8+ T cells in donor WT CD8+ T cells of the same genetic background as
host mice, which prevents any risk of allogeneic rejection. Using this approach, the role
of let-7 in the formation of memory CD8+ T cells in vivo can be assessed using the Lmgp33 model of infection and compared in the same host mice between let-7goverexpressing (GFP+) and WT (GFP-) donor P14Rag2KO CD8+ T cells. Potential
differences in the preferential anatomical location between these populations can also be
examined by comparing the ratios of GFP+ versus GFP- frequencies in lymphoid and nonlymphoid organs.
The same approach can be used to investigate the potential role of let7 miRNAs
in the control of memory CD4+ T cell generation, which was not addressed in this
dissertation, with the hypothesis that, similarly to CD8+ T cells, let-7 directs the fate of
CD4+ T cells towards memory formation. In fact, we have generated a strain of Lm that
expresses the gp66-81 epitope of LCMV (Lm-gp66), which is specifically recognized by
TCR-transgenic SMARTA CD4+ T cells. Thus, crossing SMARTA mice to WT and
Lin28Tg mice on a Rag2KO background will enable the study of the potential regulatory
role of let-7 miRNA in memory CD4+ T cell generation in vivo by adoptive transfer of
transduced SMARTARag2KO WT CD4+ T cells into congenically-marked host mice
subsequently challenged with Lm-gp66. To investigate the effect of let-7 deficiency on
memory CD4+ T cell formation, donor naive SMARTARag2KO Lin28Tg CD4+ T cells
can be adoptively transferred into congenic recipient mice subsequently infected with
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Lm-gp66 . In comparison with WT (GFP-) CD4+ T cells, let-7-overexpressing (GFP+)
CD4+ T cells would be predicted to show enhanced memory cell formation, while absence
of let-7 would be expected, as in CD8+ T cells, to result in compromised generation of
memory CD4+ T cells.

4.2.5 Determine the function of Hk2 and Mycn in terminal effector CD8+ T cell
differentiation
In Chapter 3, we identified Hk2 and Mycn as let-7 direct targets that functionally
promote the terminal effector fate in CD8+ T cells, using retroviral transduction to
overexpress these genes as a gain-of-function approach. To test whether absence of these
genes results in the specification of CD8+ T cells towards the memory fate, conditional
genetic knock-out mouse models in which these genes would be specifically deleted in
CD8+ T cells could be generated. In fact, Hk2fl/fl and Mycnfl/fl mice were already produced
by other groups (Knoepfler et al., 2002; Patra et al., 2013). Thus, breeding these mice to
mice that express the Cre recombinase under the control of a T cell-specific promoter,
such as CD4 or CD2, will result in the deletion of Hk2 and Mycn only in T cells. These
mouse model will enable the study of the role of these genes in terminal effector CD8+ T
cell differentiation using in-vitro CTL differentiation and the in vivo model of Lm
infection used throughout Chapter 3. It would be expected that, consistently with our
overexpression studies, the generation of memory T cells would be enhanced in CD8+ T
cells deficient in either gene.
Altogether, this dissertation establishes a central role for let-7 miRNAs in the
regulation of T cell differentiation, and highlights the very promising medical potential
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of using let-7 miRNA delivery as a novel therapeutic mean to modulate T cell-mediated
responses for the treatment of pathological conditions, such as autoimmunity and cancer.
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CHAPTER 5
MATERIALS AND METHODS

5.1 Mice
C57BL/6J (WT CD45.2+, stock no. 000664), B6.SJL- PtprcaPepcb/ BoyJ (WT CD45.1+,
stock no. 002014), B6(Cg)-Rag2tm1.1Cgn/J (Rag2KO, stock no. 008449), B6.CgCol1a1tm3(tetO-Mirlet7g/Mir21)Gqda/J (let-7g, stock no. 023912), B6.Cg- Gt(ROSA)26
Sortm1(rtTA*M2)Jae/J

(M2rtTA,

stock

no.

006965),

and

C57BL/6-Tg(Nr4a1-

EGFP/cre)820Khog/J (Nur77-GFP, stock no. 016617) mice were acquired from the
Jackson Laboratory. let-7g and M2rtTA mice were bred to generate Let-7Tg mice. Mice
with a human CD2 promoter-driven Lin28B transgene (Lin28Tg) (Pobezinsky et al.,
2015), as well as B6 Tg(TcrLCMV)327Sdz/JDvs/J (P14) mice were generously provided
by Alfred Singer (NCI, NIH) and C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J (2D2) mice
were a kind gift from Barbara Osborne (UMass Amherst, VASCI). 2D2 mice were
crossed on a Rag2KO background to produce 2D2Rag2KO WT mice. Let-7Tg and 2D2
mice were bred on a Rag2KO background to generate 2D2Rag2KO Let-7Tg mice.
Lin28Tg and 2D2 mice were crossed on a Rag2KO background to produce 2D2Rag2KO
Lin28Tg mice. P14 mice were crossed on a Rag2KO background to produce P14Rag2KO
WT mice. Let-7Tg and P14 mice were bred on a Rag2KO background to generate
P14Rag2KO Let-7Tg mice. Lin28Tg and P14 mice were crossed on a Rag2KO
background to produce P14Rag2KO Lin28Tg mice. Control mice used were either
littermates or age and sex-matched mice. All breedings were maintained at the University
of Massachusetts, Amherst. All experiments were executed according to the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
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National Institutes of Health. All mice were handled in accordance with reviewed and
approved institutional animal care and use committee (IACUC) protocols (#2017-0041,
#2017-0053) of the University of Massachusetts.

5.2 Doxycycline treatment for the induction of let-7 transgene expression
All experimental mice (including controls) were fed with 2 mg/mL doxycycline hyclate
(Sigma) and 10 mg/mL sucrose in drinking water that was replaced once over the course
of 4 days before the start of experiments to induce maximal let-7g expression. For EAE
experiments, doxycycline treatment was maintained throughout disease course analysis,
during which doxycycline-containing water was replaced every other day. For in-vitro
lymphocyte cultures, lymphocyte culture media (see cell sorting and in-vitro culture
below) was complemented with 2 µg/mL doxycycline hyclate.

5.3 Cell sorting and in-vitro culture
Lymph nodes were collected and gently dissociated using sharp-ended forceps to release
lymphocytes. Naive CD4+CD44loCD25-CD8- T cells were either purified using electronic
sorting after removal of B cells from whole-lymphocyte suspensions using α-mouse IgGcoated magnetic beads (BioMAg, Qiagen) or directly isolated from whole-lymphocyte
suspensions using the EasySepTM Mouse Naive CD4+ T Cell Isolation kit (Stem Cell
Technologies) according to the manufacturer’s instructions. Cells were cultured in RPMI
media supplemented with 10% fetal bovine serum, 1% penicillin/streptavidin, 1% Lglutamine, 1% non-essential amino-acids, 1% sodium pyruvate, 1% HEPES and 0.3% βmercaptoethanol. Culture media was supplemented with 2 µg/mL doxycycline, and 100
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µg/mL gentamicin when necessary. Unless otherwise indicated, cells were activated with
plate-bound α-CD3 (clone 2C11, 1 or 5 µg/mL) and α-CD28 (clone 37.51, 5 µg/mL).

5.4 Induction of EAE and disease analysis
EAE was induced by subcutaneous immunization with the MOG35-55 peptide in complete
Freund’s adjuvant (Hooke Laboratories EK-2110) according to the manufacturer’s
instructions. Intraperitoneal injection of 60 ng pertussis toxin (Hooke Laboratories BT0105) was performed 2-4 hours and 26-28 hours post-immunization. For adoptivetransfer experiments, intravenous injection of 2-2.5x106 WT, Let-7Tg or Lin28Tg
2D2Rag2KO naive CD4+ T cells was performed 12 hours prior to immunization with
MOG35-55. EAE symptoms were scored according to standard criteria: 0, asymptomatic;
1, limp tail; 2, hindlimb weakness; 3, hindlimb paralysis; 4, complete hindlimb and partial
frontlimb paralysis; 5, moribund or death.

5.5 Isolation of CNS-infiltrating cells
Experimental mice were sacrificed at the peak of EAE and perfused through the left
cardiac ventricle with PBS containing 1% fetal bovine serum. Brain and spinal cord
tissues were dissociated and digested with 1 mg/mL DNaseI (Roche) and 2.5 mg/mL
collagenase D (Roche) for 30 minutes at 37°C using a gentleMACS dissociator
(Miltenyi), filtered through 100-µm mesh strainers, and centrifuged through a Percoll
density gradient (37% and 70%). Mononuclear cells in the interphase were collected,
washed twice with PBS and resuspended in lymphocyte culture media prior to in-vitro
restimulation.
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5.6 Enzyme-linked immunosorbent assay (ELISA)
Spleens from experimental mice were harvested at the peak of EAE and splenocytes were
released by gentle organ dissociation using sharp-ended forceps. After erythrocyte lysis,
duplicates of 2x107 splenocytes from each mouse were restimulated in lymphocyte
culture media supplemented with either 2.5, 5 or 10 µg/mL MOG35-55 (Hooke
Laboratories DS-0111) in the presence of 2 µg/mL doxycycline hyclate. Cytokine
concentrations were measured in supernatants collected from restimulated cells after 5
days in culture. Concentrations of secreted IL-17, GM-CSF and IFNγ were measured
using matching capture and biotinylated detection mAbs (BD Pharmingen) in a sandwich
ELISA. HRP-conjugated streptavidin and HRP substrate from the TMB ELISA kit
(Pierce) were applied for the quantification of HRP activity at 450 nm using a Synergy™
2 Multi-Mode Microplate Reader (Biotek).

5.7 CTV and CFSE labeling
Naive CD4+ T cells were labeled at 1x106 cells/mL in PBS containing 2.5 µM CTV or 1
µM CFSE, both obtained from Invitrogen, for 15 minutes at 37°C. The labeling reaction
was stopped by washing the cells with lymphocyte culture media prior to use in
experiments.

5.8 In-vitro proliferation assay
CTV-labeled WT, Let-7Tg and Lin28Tg cells were activated with plate-bound α-CD3e
(clone 2C11, 5 µg/mL) and α-CD28 (clone 37.51, 5 µg/mL). Cells were cultured for 3
days prior to CTV dilution profile analysis by flow cytometry.
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5.9 In-vitro differentiation of CD4+ T helper (Th) cells
Naive CD4+ T cells (1x106) were activated with soluble α-CD3 (clone 2C11, 2 µg/mL)
in the presence of irradiated WT splenocytes (5x106) and cultured for 5 days in
lymphocyte culture media. In some experiments, whole-splenocyte suspensions were
depleted of CD4+ and CD8+ T cells using α-mouse CD4 (clone L3T4) and α-mouse CD8
(clone Ly-2) microbeads (Miltenyi) followed by magnetic-activated cell sorting. For
pathogenic Th17 differentiation, culture media was further supplemented with 20 ng/mL
IL-6 (Miltneyi), 10 ng/mL IL-1β (Miltenyi), 10 ng/mL IL-23 (R&D Systems), 10 µg αIFNγ mAbs (clone XMG1.2, BioXCell) and 10 µg/mL α-IL-4 mAbs (clone 11B11,
BioXCell). For Th0 differentiation, culture media was further supplemented with 200
U/mL IL-2 (Peprotech). For Th1 differentiation, culture media was further supplemented
with 200 U/mL IL-2, 10 ng/mL IL-12 (Peprotech) and 10 µg/mL α-IL-4 mAbs (clone
11B11, BioXCell). For Th2 differentiation, culture media was further supplemented with
200 U/mL IL-2, 10 ng/mL IL-4 (Peprotech) and 10 µg/mL α-IFNγ mAbs (clone XMG1.2,
BioXCell). For non-pathogenic Th17 cell differentiation, culture media was further
supplemented with 20 ng/mL IL-6 (Miltenyi), 2 ng/mL TGF-β (Miltenyi), 10 µg/mL αIFNγ mAbs (clone XMG1.2, BioXCell) and 10 µg/mL α-IL-4 mAbs(clone 11B11,
BioXCell). For iTreg differentiation, naive CD4+ T cells were stimulated with 10 µg/mL
soluble α-CD3 (clone 2C11, BD Pharmingen) and culture media was further
supplemented with 100 U/mL IL-2 (Peprotech ) and 5 ng/mL TGF-β (Miltenyi).

5.10 In-vitro differentiation of cytotoxic CD8+ T lymphocytes (CTLs)
Naive CD8+ T cells were stimulated either with irradiated splenocytes loaded with antiCD3e mAbs (10 μg/mL), or plate-bound anti-CD3e mAbs (10 μg/mL) and anti-CD28
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mAbs (5 μg/mL), then differentiated for 5 days in lymphocyte culture media
supplemented with 100 U/mL IL-2 (Peprotech). Culture media was further supplemented
with 2μg/mL doxycycline when necessary.

5.11 Overexpression and retroviral transduction of candidate genes
The open reading frame (ORF) of Ccr2, Ccr5, Cdc34, Hk2, Mycn, NICD-NES, and NICDNLS were cloned into the pMRX-IRES-GFP plasmid, which contain a green fluorescent
protein (GFP) reporter (Saitoh et al., 2002). Empty pMRX-IRES-GFP plasmids were
used as controls. Retrovirus supernatants were produced by transfecting Platinum-E
(Plate-E) retroviral packaging cells (Morita et al., 2000) using Transporter 5 transfection
reagent (Polysciences). Retrovirus supernatants were concentrated 10x in lymphocyte
culture media with PEG-it™ virus concentration reagent (System Biosciences) prior to
cell transduction. T cells were retrovirally transduced 24h after activation with 10xconcentrated retrovirus supernatants by spin-infection (660 xg for 90 minutes at 37°C) in
the presence of polybrene (4 µg/mL). Transduction media was replaced with lymphocyte
culture media appropriately supplemented 4h after spin-infection. Analysis of transduced
cells was performed by gating on the GFP+ cell population.

5.12 Flow cytometry
For analysis of surface markers, live cells were treated with α-CD16/32 Fc block (2.4G2,
BD Pharmingen, RRID:AB_394657) prior to staining with antibodies against surface
markers for 30 minutes at 4°C. For intracellular cytokine staining, cell suspensions were
restimulated in vitro for a total of 4 hours with 50 ng/mL phorbol 12-myristate 13-acetate
(PMA, Sigma) and 1 µM Ionomycin (Sigma) with addition of 2 µM monensin
139

(eBioscience) in the last 2 hours of restimulation to inhibit secretion. After surface marker
staining, cells were stained with the Live/Dead fixable Aqua Dead Cell Stain Kit (Thermo
Fisher Scientific) according to the manufacturer’s instructions. Before intracellular
staining, cells were fixed and permeabilized for 30 minutes at 4°C using the
Cytofix/Cytoperm solution kit (BD Biosciences) for cytokine staining or the Foxp3/
Transcription factor staining buffer set (eBioscience) for transcription factor staining
according to the manufacturer’s instructions. Samples were acquired on a BD LSR
Fortessa flow cytometer (BD Biosciences) and data analysis was performed using FlowJo
software (TreeStar).

5.13 Antibodies
The following monoclonal antibodies were used for flow cytometry: 2B4 (m2B4,
Biolegend), CD4 (RM4-5, Biolegend), CD8a (53-6.7, eBioscience; 5H10, Invitrogen),
CD25 (PC61, Biolegend), CD45.2 (104, BD Pharmingen), CD44 (IM7, BD Pharmingen),
CD62L (MEL-14, Biolegend), CD127 (A7R34, Biolegend), CD160 (CNX46-3,
eBioscience), FOXP3 (FJK-16S, eBioscience), GFP (FM264G, Biolegend), GM-CSF
(MP1-22E9, Biolegend), IFNγ (XMG1.2, Biolegend), IL-4 (11B11, BD Pharmingen), IL17A (17B7, eBioscience), KLRG1 (2F1, BD Pharmingen), PD-1 (29F.A12, Biolegend),
PE-Streptavidin (Biolegend), APC-Streptavidin (Biolegend), TIM-3 (RMT3-23,
Biolegend).

5.14 RNA isolation and quantitative RT-PCR
RNA was isolated using the QIAGEN miRNeasy (QIAGEN) or the Total RNA
Purification kit (Norgen Biotek) according to the manufacturer’s instructions. Genomic
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DNA was eliminated using the DNA-free DNA removal kit (Invitrogen). cDNA of
mRNA-encoded genes was synthesized using the SuperScript III Reverse Transcriptase
kit (Invitrogen) or the SensiFastTM cDNA synthesis kit (Bioline). cDNA of miRNAs was
synthesized using the TaqMan MicroRNA Reverse Transcription kit (Applied
Biosystems). SYBR Green or TaqMan quantitative RT-PCR were executed using the
SensiFastTM SYBR Lo-Rox kit (Bioline) or the SensiFast TM Probe Lo-Rox kit (Bioline),
respectively. The list of specific SYBR Green amplification primers (Integrated DNA
Technologies), TaqMan gene (Integrated DNA Technologies or Thermo Fisher
Scientific) and TaqMan microRNA assays (Thermo Fisher Scientific) used can be found
in Table 5.1. Quantitative RT-PCR data was acquired using a QuantStudio 6 Flex RealTime PCR system and analyzed using QuantStudio Real-Time PCR software (Applied
Biosystems).

5.15 In-silico prediction of let-7 binding sites
Let-7 binding sites were identified by searching for complete or partial continuous
matches to the extended let-7 seed sequence “TACTACCTCA” in the complete mRNA
sequences of the indicated mouse and human genes, and are available in Table 5.2. A 6
bp-long perfect match was considered as minimum requirement for a potential binding
site. Conservation was assessed according to the retention of the binding site position
within corresponding mouse and human mRNA sequences upon optimal GLOBAL
pairwise alignment using BioEdit software (Tom Hall, Ibis Therapeutics).
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5.16 Luciferase reporter assays
NIH/3T3 cells (ATCC) were transfected with the pmirGLO vector (Promega) containing
either the wild-type in-silico predicted let-7-binding sites within Ccr2 and Ccr5 mouse
mRNA, or mutated variants of these binding sites, or either the wild-type or a mutated
variant of the antisense seed sequence of let-7g, using Lipofectamine and Plus Reagent
(Invitrogen). Firefly luciferase activity was measured 48h post-transfection and was
normalized to Renilla luciferase activity, using the Dual-Luciferase Assay Reporter kit
(Promega), on a POLARstar Omega 96-well plate reader (BMG Labtech).

5.17 Motility in collagen matrices
In vitro-differentiated pathogenic Th17 cells from 2D2Rag2KO WT, 2D2Rag2KO Let7Tg and 2D2Rag2KO Lin28Tg mice were harvested at day 5, labeled with CFSE, and
resuspended in RPMI/10% FBS. PureCol EZ Gel (Advanced BioMatrix) was added to
cells in RPMI/10% FBS to obtain a final collagen gel concentration of 1.6 mg/mL with a
final cell concentration of 1.25x106 cells/mL. Collagen gels were allowed to fully
polymerize for 1 hour at 37°C prior to imaging the cells for 20 minutes at 10-second
intervals with a modified inverted epi-fluorescence microscope (Axio Observer.Z1, Carl
Zeiss). Data was analyzed using Imaris software (Bitplane).

5.18 Transwell assay
In vitro-differentiated pathogenic Th17 cells from 2D2Rag2KO WT, 2D2Rag2KO Let7Tg and 2D2Rag2KO Lin28Tg mice were harvested at day 5, washed in RPMI/10% FBS
and resuspended at 5x106 cells/mL in RPMI/10% FBS. Chemotaxis towards 600 µL
control media, Ccl2 and Ccl4 alone (50 ng/mL) or in combination (50 ng/mL or 10 ng/mL
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each) in the lower chamber of a 24-well plate was assessed by incubating 100 µL cell
suspension in the upper chamber of 24-well 6.5 mm transwell inserts with a 5-µm pore
polycarbonate membrane (Corning) at 37°C for 3 hours. Percent chemotaxis was
measured by manually counting the number of cells present in the lower chamber and
normalized to cell counts obtained in control media for each condition.

5.19 Listeria monocytogenes-gp33 (Lm-gp33) infection and adoptive CD8+ T cell
transfer
2x104 CD45.2+ P14Rag2KO donor cells, or 2x105 transduced CD45.2+ P14Rag2KO
donor cells from the indicated mice were transferred intravenously (i.v.) into CD45.1+
congenic hosts. Mice were challenged i.v. with 6x106 colony-forming units (cfu) Lmgp33 grown to log phase in TSB with 50 µg/mL streptomycin the next day, or 1h later,
respectively.

5.20 RNA Sequencing (RNA-Seq) and bioinformatics analyses
20x106 in vitro-generated CTLs were sent out for RNA-Seq. Unless specified, the R
scripting language was used for bioinformatics analyses.

5.20.1 Reads mapping to the reference genome
Reference genome and gene model annotation files were downloaded from genome
website browser (NCBI/UCSC/Ensembl) directly. Indexes of the reference genome were
built using Bowtie v2.0.6 and paired-end clean reads were aligned to the reference
genome using TopHat v2.0.9. Bowtie uses a BWT(Burrows-Wheeler Transformer)
algorithm for mapping reads to the genome and Tophat can generate a database of splice
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junctions based on the gene model annotation file and thus achieve a better mapping result
than other nonsplice mapping tools.

5.20.2 Quantification of gene expression level
HTSeq v0.6.1 was used to count the read numbers mapped of each gene. Reads Per
Kilobase of exon model per Million mapped reads (RPKM), which considers the effect
of sequencing depth and gene length for the reads count at the same time, was calculated
for each gene based on the length of the gene and reads count mapped to this gene.

5.20.3 Differential gene expression analysis
Differential expression analysis between two conditions/groups (three biological
replicates per condition) was performed using the DESeq2 R package (2_1.6.3). DESeq2
provide statistical routines for determining differential expression in digital gene
expression data using a model based on the negative binomial distribution. The resulting
p-values were adjusted using the Benjamini and Hochberg’s approach for controlling the
False Discovery Rate (FDR). Genes with an adjusted p-value <0.05 found by DESeq2
were assigned as differentially expressed.

5.20.4 Plot generation for data visualization
Principal component analysis (PCA) was performed with normalized expression read
counts using the “PCAtools”, “car”, “RColorBrewer”, and “ggplots2” R packages.
Volcano plots were generated with differential gene expression analysis output data using
the “ggplots2” R package. Heatmaps were generated with normalized expression read
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counts using the “ggplots2” and “RColorBrewer” R packages. Bubble plots were
generated using the “ggplots2” R package.

5.20.5 Database for Annotation, Visualization and Integrated Discovery (DAVID)
analysis of gene ontology (GO) biological processes
Lists of genes of interest were subjected to the gene ontology (GO) Functional Annotation
Tool of the Database for Annotation, Visualization and Integrated Discovery (DAVID)
database, which finds functionally-related groups of genes that belong to biological
processes that are enriched in the submitted gene list (Huang et al., 2009). GO terms with
p-value < 0.05 were considered significantly enriched.

5.20.6 Gene set enrichment analysis
The differential gene expression data output was ranked according to the adjusted pvalue. Gene signatures were generated by compiling well-defined memory and terminaleffector/exhaustion markers from the literature (Yang et al., 2011; Im et al., 2016;
Schietinger et al., 2016; Yu et al., 2017; Snell et al., 2018; Miller et al., 2019). The GSEA
software (Broad Institute) was used for data analysis (Mootha et al., 2003; Subramanian
et al., 2005).

5.20.7 Venn diagram
Genes contained in Cluster I at all time points tested were analyzed for predicted let-7
miRNA target genes using the TargetScan database (Agarwal et al., 2015). A Venn
diagram representing the let-7 target genes dysregulated at all stages of CD8+ T cell
differentiation tested was generated using the “ggplots2” R package.
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5.21 Statistics
Data statistical analysis was performed with Prism 7 (GraphPad software) or RStudio
software (RStudio Team). P-values were determined using a two-tailed Student’s t test or
a two-way ANOVA, as indicated on the figure legends. A p value < 0.05 was considered
significant (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
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Table 5.1: Primers and probes used for quantitative RT-PCR
Gene
Bhlhe40
Ccnd2
Ccr2
Ccr5
Cdc25a
Cdc34
Cdk6
Csf2
Gata3
Glut3
Hk2
Il1r1
Il4
Il4ra
Il6ra
Il6st
Il12rb2
Il17a
Il23r
Irf4
Myc
Qars
Rorc
Rpl13a
Stat3
Tfap4
Gene
Ifng
Rpl13a
Ldha
microRNA
hsa-let-7a
hsa-let-7b
hsa-let-7c
hsa-let-7d
hsa-let-7e
hsa-let-7f
hsa-let-7g
hsa-let-7i
U6

SYBR primers
Forward primer (5'-3')
Reverse primer (5'-3')
ACGGAGACCTGTCAGGGATG
GGCAGTTTGTAAGTTTCCTTGC
GAGTGGGAACTGGTAGTGTTG
CGCACAGAGCGATGAAGGT
ATCCACGGCATACTATCAACATC CAAGGCTCACCATCATCGTAG
TTTTCAAGGGTCAGTTCCGAC
GGAAGACCATCATGTTACCCAC
ACAGCAGTCTACAGAGAATGGG GATGAGGTGAAAGGTGTCTTGG
CCCCAACACCTACTATGAGGG
ACATCTTGGTGAACCGGA
GGCGTACCCACAGAAACCATA
AGGTAAGGGCCATCTGAAAACT
TGGAAGCATGTAGAGGCCATCA GCGCCCTTGAGTTTGGTGAAAT
CGAGATGGTACCGGGCACTA
GACAGTTCGCGCAGGATGT
ATGGGGACAACGAAGGTGAC
GTCTCAGGTGCATTGATGACTC
TGATCGCCTGCTTATTCACGG
AACCGCCTAGAAATCTCCAGA
GTGCTACTGGGGCTCATTTGT
GGAGTAAGAGGACACTTGCGAAT
GGTCTCAACCCCCAGCTAGT
GCCGATGATCTCTCTCAAGTGAT
TCTGCATCCCGTTGTTTTGC
GCACCTGTGCATCCTGAATG
CCTGAGACTCAAGCAGAAATGG AGAAGGAAGGTCGGCTTCAGT
CCGTGTGGTTACATCTACCCT
CGTGGTTCTGTTGATGACAGTG
AGAGAATGCTCATTGGCACTTC AACTGGGATAATGTGAACAGCC
TTTAACTCCCTTGGCGCAAAA
CTTTCCCTCCGCATTGACAC
TTCAGATGGGCATGAATGTTTCT CCAAATCCGAGCTGTTGTTCTAT
TCCGACAGTGGTTGATCGAC
CCTCACGATTGTAGTCCTGCTT
AGTGCTGCATGAGGAGACAC
GGTTTGCCTCTTCTCCACAG
CCTTGGCCTTAGCGAGAACAA
TGTCGATGGTAGAACCCAGAATC
GACCCACACCTCACAAATTGA
AGTAGGCCACATTACACTGCT
CGAGGCATGCTGCCCCACAA
AGCAGGGACCACCATCCGCT
AGCTGGACACACGCTACCT
AGGAATCGGCTATATTGCTGGT
GGAGAAGCTAGAGCGGGAAC
TTTTGCCGGGATGTAGAGAC
TaqMan probes
Assay ID
Source
Mm.PT.58.30096391
Integrated DNA Technologies
Mm.PT.58.43547045.g
Integrated DNA Technologies
Mm01612132_g1
Thermo Fisher Scientific
TaqMan microRNA assays
Assay ID
Source
00377
Thermo Fisher Scientific
00378
Thermo Fisher Scientific
00379
Thermo Fisher Scientific
02283
Thermo Fisher Scientific
02406
Thermo Fisher Scientific
00382
Thermo Fisher Scientific
02282
Thermo Fisher Scientific
02221
Thermo Fisher Scientific
01973
Thermo Fisher Scientific
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Table 5.2: Let-7-binding sites identified in mouse and human Ccr2 and Ccr5
mRNA sequences

Species Receptor Accession number Binding site Sequence
1
TACCTCA
Ccr2
NM_009915.2
2
ACCTCA
Mouse
1
CTACCT
Ccr5
NM_009917.5
2
ACTACC
1
ACCTCA
CCR2 NM_001123396.2
2
CTACCTC
Human
3
ACCTCA
1
CTACCT
CCR5
NM_000579.3
2
ACTACCTC
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Positon
153-159
2025-2030
311-316
356-361
211-216
360-366
1679-1684
558-563
1274-1281
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